

**The long-term respiratory health  
effects of the herbicide, paraquat,  
among Western Cape workers**

**Mohamed Aqiel Dalvie**

The University of Cape Town has been given  
the right to reproduce this thesis in whole  
or in part. Copyright is held by the author.

The copyright of this thesis vests in the author. No quotation from it or information derived from it is to be published without full acknowledgement of the source. The thesis is to be used for private study or non-commercial research purposes only.

Published by the University of Cape Town (UCT) in terms of the non-exclusive license granted to UCT by the author.

The long-term respiratory health effects of the herbicide,  
paraquat, among Western Cape farm workers

Mohamed Aqiel Dalvie

BSc (Physiology, Chemistry); BSc Med Hons (Sportscience)

This thesis is presented in fulfilment of the requirements for the degree of Masters in Community Health (Msc) in the Department of Community Health, Faculty of Medicine, University of Cape Town, 1996. The work on which this thesis is based is original research and has not, in whole or in part, been submitted towards another degree, at this University or elsewhere. The University is empowered to reproduce either the whole or any portion of the contents for purposes of research.

August 1996

## ABSTRACT

**Objective:** Paraquat is a commonly used herbicide worldwide and is a well documented cause of pulmonary fibrosis in studies of laboratory animals and in humans following high dose exposure (usually accidental or as parasuicide). The respiratory effects of long-term, low dose paraquat exposure have not been fully evaluated. We set out to evaluate the possible effects of paraquat spraying among deciduous fruit farm workers in the Western Cape, South Africa.

**Methods:** A cross-sectional study of 126 workers was performed. Administered questionnaires generated information on exposure, respiratory symptoms and confounding variables. Spirometry and gas transfer were measured and chest radiographs performed. Oxygen desaturation on exercise testing was by oximetry during a modified stage one exercise test.

**Results:** No association was found between long-term paraquat exposure and reported symptoms, spirometry (FVC, FEV1, FEV1/FVC) and gas transfer ( $T_{L\infty}$  and  $K_{\infty}$ ) or chest radiography. Multivariate analysis showed a significant relationship between measures of long-term paraquat exposure and arterial oxygen desaturation during exercise ( $p < 0.05$ ).

**Conclusion:** Previous studies have also not shown a significant relationship between measures of paraquat exposure and standard



tests of lung function. Arterial oxygen desaturation during exercise represents a more sensitive test. Our findings indicate that working with paraquat under usual field conditions for a long period is associated with abnormal exercise physiology in a dose dependant fashion.

## ACKNOWLEDGEMENTS

I wish to thank The International Research and Development Centre (IDRC), Medical Research Council of South Africa and the Guy Elliot Fellowship in the Department of Medicine UCT for their financial support for the project.

To Marcus Medical for lending the lung function apparatus and providing technical staff for the setting up of the equipment.

To Ceres Hospital for providing the space and involving personnel during data collection.

To Dr Neil White for his important contributions in the planning and execution of the project and for his constructive comments and sound advice during co-supervision of the thesis.

To Professor Johnny Myers for his invaluable guidance, insights and advice during the execution of the project and co-supervision of the thesis.

To Dr Ricky Rain for his supervision of and advice on the clinical respiratory health measurements in the study.

To Professor Dave Christiani for his worthwhile comments on the project.

To the farmers and farm workers of the Kouebokkeveld for

participating in the project.

To all the staff of the research project including interviewers, technologists and technicians for working hard and efficiently during data collection. In particular, Aneleh Midgely, for her competent administration and quality control of the data. And to Hanlie van Heerden and Mandy Vorster for their difficult roles as liaison person and lung function technologist, respectively. Also to Eddie Langeveld and his wife, Pat for their hospitality and assistance with the interviewers.

To Dr Leslie London for his inestimable assistance during the project which stemmed from his investigation of organo-phosphate pesticides.

To Mary Lou Thompson for her advice on statistical analysis.

To the staff of the Department of Community Health for providing a pleasant working environment. In particular, Dot Manly who was always willing to be of assistance.

## SUMMARY OF CONTENTS

|            |  |      |
|------------|--|------|
| CHAPTER 1  | A REVIEW OF PARAQUAT AND AN OUTLINE OF<br>THE OBJECTIVES OF THIS STUDY | 1    |
| CHAPTER 2  | MEASUREMENT OF RESPIRATORY HEALTH USING<br>EXERCISE OXIMETRY           | 20   |
| CHAPTER 3  | METHODS  | 29   |
| CHAPTER 4  | RESULTS  | 59   |
| CHAPTER 5  | DISCUSSION   | 84   |
| Appendix 1 | Questionnaires   | A1-1 |
| Appendix 2 | Lung Function Report Sheet   | A2-1 |
| Appendix 3 | Examples of Saturation and Heart Traces<br>recorded during exercise    | A3-1 |
| Appendix 4 | Glossary of variables  | A4-1 |
| Appendix 5 | Supplementary Results  | A5-1 |

## CONTENTS

|  |      |
|--|------|
| ABSTRACT   | I    |
| ACKNOWLEDGEMENTS   | III  |
| LIST OF TABLES   | XI   |
| LIST OF FIGURES  | XIII |
| LIST OF APPENDICES   | XIV  |
| CHAPTER 1 A REVIEW OF PARAQUAT AND AN OUTLINE OF<br>THE OBJECTIVES OF THIS STUDY | 1    |
| 1.1 Introduction   | 1    |
| 1.2 Paraquat   | 2    |
| 1.2.1 Physical and chemical properties of paraquat                               | 3    |
| 1.2.2 Classification of paraquat toxicity  | 5    |
| 1.2.3 Environmental effects  | 5    |
| 1.2.4 Agricultural application   | 5    |
| 1.2.5 Occupational exposure and absorption                                       | 6    |
| 1.2.6 Acute effects  | 7    |
| 1.2.7 Long term effects  | 11   |
| 1.3 Aims and objectives of the current study                                     | 15   |
| 1.4 References   | 17   |

|  |    |
|--|----|
| CHAPTER 2 MEASUREMENT OF RESPIRATORY HEALTH USING<br>EXERCISE OXIMETRY | 21 |
| 2.1 Significance of measuring exercise health                          | 21 |
| 2.1.1 The exercise test  | 21 |
| 2.1.2 Exercise gas exchange in the healthy                             | 22 |
| 2.1.3 Exercise gas exchange in the diseased                            | 22 |
| 2.2 Oximetry   | 24 |
| 2.2.1 Oxygen Saturation  | 24 |
| 2.2.2 Apparatus  | 24 |
| 2.2.3 Principles of operation  | 25 |
| 2.2.4 Limitations  | 25 |
| 2.2.5 Validity of exercise oximetry to estimate<br>respiratory health  | 26 |
| 2.3 References   | 27 |
| CHAPTER 3 METHODS  | 30 |
| 3.1 Design   | 30 |
| 3.2 Population and Sampling  | 30 |
| 3.2.1 Sample size calculations   | 33 |

|   |    |
|---|----|
| 3.3 Measurement of Exposure                             | 35 |
| 3.3.1 Estimation of occupational exposure to pesticides | 35 |
| 3.3.2 Exposure questionnaire                            | 38 |
| 3.3.3 Calculation of variables                          | 39 |
| 3.4 Measurement of Respiratory Health                   | 41 |
| 3.4.1 Medical Examination                               | 41 |
| 3.4.2 Respiratory Questionnaire                         | 41 |
| 3.4.3 Lung function                                     | 42 |
| 3.4.4 Radiography                                       | 45 |
| 3.4.5 Exercise Testing                                  | 45 |
| 3.5 Possible confounders and effect modifiers           | 47 |
| 3.6 Field work  | 48 |
| 3.7 Ethical considerations                              | 49 |
| 3.8 Data management                                     | 49 |
| 3.9 Statistical Analysis                                | 49 |
| 3.9.1 Univariate analysis                               | 49 |
| 3.9.2 Bivariate analysis                                | 50 |
| 3.9.3 Multivariate Analysis                             | 52 |
| 3.10 References   | 56 |

|  |           |
|--|-----------|
| <b>CHAPTER 4 RESULTS</b>                                   | <b>60</b> |
| <b>4.1 Univariate Analysis</b>                             | <b>60</b> |
| 4.1.1 Sample participation, demographics and anthropometry | 60        |
| 4.1.2 Respiratory symptoms and illnesses                   | 61        |
| 4.1.3 Radiography  | 63        |
| 4.1.4 Respiratory Function                                 | 63        |
| 4.1.5 Exercise Test  | 66        |
| 4.1.6 Life style factors                                   | 68        |
| 4.1.7 Exposure   | 69        |
| <b>4.2 Bivariate analyses</b>                              | <b>70</b> |
| <b>4.3 Multivariate Analysis</b>                           | <b>71</b> |
| 4.3.1 Radiographic results                                 | 72        |
| 4.3.2 Respiratory Symptoms                                 | 73        |
| 4.3.3 Respiratory Function Tests                           | 73        |
| 4.3.4 Exercise Test Results                                | 76        |
| 4.3.5 Relationship between lung function and oximetry      | 84        |
| <b>4.4 References</b>                                      | <b>85</b> |
| <b>CHAPTER 5 DISCUSSION</b>                                | <b>86</b> |
| <b>5.1 The basic finding</b>                               | <b>86</b> |



|   |            |
|---|------------|
| <b>5.2 Biological mechanism</b>                       | <b>86</b>  |
| <b>5.3 Validity of oximetry</b>                       | <b>87</b>  |
| <b>5.4 Clinical significance of the basic finding</b> | <b>87</b>  |
| <b>5.5 Previous studies</b>                           | <b>90</b>  |
| <b>5.6 Selection biases</b>                           | <b>91</b>  |
| <b>5.7 Misclassification</b>                          | <b>92</b>  |
| <b>5.8 Recall bias</b>                                | <b>93</b>  |
| <b>5.9 Generalisability</b>                           | <b>94</b>  |
| <b>5.10 Validation of field oximetry</b>              | <b>95</b>  |
| <b>5.11 Other findings in the study</b>               | <b>97</b>  |
| <b>5.12 Bradford-Hill Criteria</b>                    | <b>99</b>  |
| <b>5.13 Recommendations</b>                           | <b>100</b> |
| <b>5.14 Conclusions</b>                               | <b>101</b> |
| <b>5.15 References</b>                                | <b>102</b> |

## LIST OF TABLES

Table 1.1 Summary of herbicide and paraquat usage patterns in South Africa

Table 1.2 Summary of epidemiological studies which investigated the long term effects of paraquat exposure.

Table 3.1 Sample size estimation for different outcome measures

Table 3.2 Summary of bivariate tests performed

Table 3.3 Associations examined

Table 4.1 Anthropometric results in the study sample

Table 4.2 Respiratory symptom prevalences

Table 4.3 History of Respiratory illness

Table 4.4 Lung Function values

Table 4.5 Exercise test results

Table 4.6 Exposure univariate results

Table 4.7 Full model regression equations for spirometry when including a) only significant predictors found in our study and b) only height and age

Table 4.8 Two multiple linear regression models for the effect of total average intensity of paraquat exposure on exercise oxygen desaturation

Table 4.9 Summary of linear regression associations of exercise oximetry with exposure variables

Table 4.10 The effect of changing cutpoints for dichotomised exercise desaturation in relation to dichotomised total lifetime cumulative paraquat exposure

Table 4.11 The effect of changing cutpoints for dichotomised total lifetime cumulative paraquat exposure in relation to dichotomised exercise desaturation

Table 5.1 The effect of different levels of total cumulative paraquat exposure on exercise oxygen desaturation

## LIST OF FIGURES

Figure 1.1 The proposed biological mechanism of paraquat lung toxicity

Figure 3.1 The manner in which the study sample was obtained.

## LIST OF APPENDICES

|  |       |
|--|-------|
| Appendix 1 Questionnaires  | A1-1  |
| Appendix 1.1 Questionnaire 1   | A1-1  |
| Appendix 1.2 Exposure Questionnaire 1  | A1-29 |
| Appendix 1.3 Exposure Questionnaire 2  | A1-36 |
| Appendix 1.4 Respiratory Health Questionnaire  | A1-38 |
| Appendix 2 Lung Function Report Sheet  | A2-1  |
| Appendix 3 Examples of Saturation and Heart Traces<br>recorded during exercise   | A3-1  |
| Appendix 4 Glossary of variables   | A4-1  |
| Appendix 5 Supplementary Results   | A5-1  |
| Appendix 5.1 Univariate Results  | A5-1  |
| Appendix 5.2 Significant Bivariate associations  | A5-6  |
| Appendix 5.3 Summary of linear regression analysis of<br>the effect of total long-term cumulative<br>paraquat exposure on radiology                          | A5-8  |
| Appendix 5.4 Summary of logistic regression analysis of<br>the effect of long-term total cumulative<br>paraquat exposure on reported respiratory<br>symptoms | A5-9  |

**Appendix 5.5 Summary of linear regression analysis of the  
effect of total long-term cumulative  
paraquat exposure on respiratory function      A5-22**

**Appendix 5.6 Summary of linear regression analysis of the  
effect of long-term total cumulative paraquat  
exposure on the maximum workload achieved in  
exercise testing (MAXWL).      A5-24**

**Appendix 5.7 Correlation matrix of variables in the model  
describing the relationship between  
total average intensity of paraquat  
exposure and exercise oxygen desaturation      A5-25**

**Appendix 5.8 Multivariate analysis of the effect of  
paraquat exposure on exercise oxygen  
desaturation.      A5-26**

## CHAPTER 1 A REVIEW OF PARAQUAT AND AN OUTLINE OF THE OBJECTIVES OF THIS STUDY

### 1.1 Introduction

Pesticides can simply be described as substances used to combat unwanted living organisms (pests), although there are more formal definitions given by institutions such as the FAO, the Codex Alimentarius Commission (Codex) and the Council of Europe. Pesticides are used in vector control programmes, horticulture, forestry and livestock production and refer mostly to chemicals that are used in agriculture for the control of pests, weeds, or plant diseases (agro-chemicals). These include insecticides, herbicides, fungicides, fumigants and molluscicides.

The industrial production of pesticides has increased substantially since the Second World War and in 1985 over 3 million tones of formulated pesticides were produced globally (1). Awareness of the environmental and public health impacts of pesticides has increased since the 1960's when the dangers of DDT and other organochlorine pesticides became apparent and more legislative controls were introduced in first world countries. Pesticide use is presently still increasing, particularly in Third World countries. New pesticides are continually being formulated to increase agricultural productivity.

Agriculture is one of the biggest sources of employment in South

Africa. The use of pesticides in this country has increased at a similar rate as that of developing countries, as reflected by total expenditure on pesticides in 1978-79 (2) and 1990 (4). Over 24 000 tons of pesticides were sold in South Africa in 1978-79.

The Western Cape is an important agricultural region in South Africa (market research shows that more than 7000 tons of pesticides were sold in the Southern region of South Africa in 1989, 4). More than 150 000 workers were employed in this region in 1991 (5). Although maize farming is the largest agricultural activity in South Africa, deciduous fruit farming is most important in the Western Cape where the nature of agricultural production differs from the rest of the country.

Working and living conditions of farm workers and rural populations, are generally poor (6).

## 1.2 Paraquat

Paraquat was introduced commercially in 1961 and is globally one of the two most widely used herbicides (used in more than 130 countries) (7). Its use is banned in Finland, Sweden and Austria, restricted in Hungary and the United States and cancelled in Norway; it has limited registration in Germany and The European Council is currently reviewing paraquat for registration (7).



Paraquat has been one of the most commonly used herbicides in South Africa for the last twenty two years. It is used in all forms of fruit farming (8).

Available information on herbicide and paraquat usage patterns in South Africa are summarised in table 1.1

#### 1.2.1 Physical and chemical properties of paraquat

Paraquat is a bipyridylium compound (1,1'-dimethyl-4,4'-bipyridylium dichloride or 1,1'-dimethyl-4,4'-bipyridylium dimethylsulfate). In aqueous solution it is non-explosive, non-flammable, non - volatile and corrosive.

Paraquat readily undergoes a single-electron reduction to the cation radical which is important for its herbicidal activity and toxic effects.

Analytical methods for detection of paraquat in soil, water, air, biological tissues and plants include spectrophotometry, gas chromatography and radio-immuno-assay. The most sensitive measurement on biological tissues is gas chromatography with detection limits of 0.025 ug/ml (9).

**Table 1.1 Summary of herbicide and paraquat usage patterns in South Africa**

|                             | <b>SA*</b> | <b>Southern Region*</b> |
|-----------------------------|------------|-------------------------|
| <b>Herbicides :</b>         |            |                         |
| Weight (metric tons)        | 6083       | 713                     |
| % of total pesticides       | 24.7%      | 10%                     |
| BEU* (10 <sup>6</sup> x kg) | /          | 1001                    |
| % of total pesticides       | /          | 2.4%                    |
| Sales (R million)           | 282        | 51                      |
| % of total pesticides       | 46%        | 29%                     |
| <b>Paraquat:</b>            |            |                         |
| Weight (metric tons)        | 129        | 59                      |
| % of total herbicides       | 2%         | 8%                      |
| BEU* (10 <sup>6</sup> x kg) | /          | 390                     |
| % of total herbicides       | /          | 39 %                    |

\* Annual pesticide use in the Republic of South Africa in 1978 - 1979 (2); Sales figures are for 1990 (8)

\* Agrochemical usage patterns in the southern region of South Africa (Western and Eastern Cape; 4, 8); based on market research data of 1990

\* BEU: biological equivalent units (method used for weighting usage by relative toxicity)

### 1.2.2 Classification of toxicity

South Africa uses the WHO toxicity classification, which is based on individual acute LD<sub>50</sub>'s (lowest dosage that kills 50% of test animals) for pesticides. According to this classification paraquat, that has an oral LD<sub>50</sub> of 150 mg/kg body weight and a dermal LD<sub>50</sub> of 236 mg/kg body weight, is a group 2 toxin<sup>1</sup>. According to current legislation, paraquat<sup>2</sup> is safe under normal production conditions and has no chronic effects on sprayers.

### 1.2.3 Environmental effects

Unlike pesticides such as DDT, paraquat is not persistent in the environment. It is degraded by soil micro-organisms, is inactivated by becoming strongly bound to clay particles and is adsorbed on aquatic weeds. Paraquat is also not volatile following spraying.

Its low cost relative to other herbicides on the market has been an additional favourable factor governing its use.

### 1.2.4 Agricultural application

Paraquat is a non-selective, broad spectrum, contact herbicide and is also used as a desiccant or cotton defoliant(9).

---

<sup>1</sup> The second highest toxicity category out of 4

<sup>2</sup> Registered under Act 36 with no restrictions

In South Africa, several formulations (granules or liquid concentrates) which include paraquat, preeglone and gramoxone are available. The paraquat content in these products, which are highly toxic and corrosive in their concentrated forms, may vary from 10% to 20 % (W/V, V/V). The final working concentration ranges between 1 to 5 grams/litre active ingredient in water (ICI - Kynoch Spray Programmes, Agrochemicals, 1991).

#### 1.2.5 Occupational exposure and absorption

Herbicides are used in lesser quantities than other pesticides because they require fewer applications (2-3 times per year) and are expensive. They are applied to the ground in the deciduous fruit sector in the Western Cape because spraying has to be directed downwards on to weeds. Usually a tractor is used for spraying. The herbicide is dispensed by a low boom or through hand held sprayguns or rubber hoses. Spraying also occurs from a backpack through a hand-held nozzle.

Regular exposure to a highly toxic compound such as paraquat might present an occupational hazard to workers. This is particularly important in conditions where there is a lack of product knowledge and safety awareness as is the case in South Africa. Previously reported total (respiratory and skin) exposures of 12-170 mg/kg bodyweight/hour of knapsack sprayers (10) are higher than paraquat doses which cause chronic injury in animals (11-14). Long term skin exposure to paraquat may be an important route of exposure (15). Healthy human skin has been

found to have low absorption values to paraquat at working concentrations (16), but there is still uncertainty about the level of paraquat in plasma. Workplace exposures measured previously (10, 17) did not include high exposure tasks such as mixing. Long term skin contact in humans may cause blisters and ulcers, which might increase paraquat absorption (18) particularly in applicators and mixers.

#### 1.2.6 Acute effects

Acute effects are well documented in the literature from both animal studies and case reports of accidental and suicidal paraquat poisoning. Large oral doses of paraquat (more than 10 mg/kg body weight) cause multi-organ acute injuries especially to kidneys and lungs, which are the organs with maximal tissue dose with respect to both intensity and duration. Poisoning is often fatal at high doses (9,11,18).

Lower sublethal doses of paraquat administered as a bolus (less than 10 mg/kg body weight) result mainly in chronic lung injury in laboratory animals (11-14) including effects on lung compliance and arterial oxygen levels in sheep (12), radiological and histological changes in cynomolgous monkeys, (13) and histological changes in rats (11). Acute toxicity is believed to occur when paraquat, for which lung cells have a high affinity, becomes absorbed and damages alveolar epithelial cells leading to inflammation (alveolitis) and eventually fibrosis (11). The effect on lung function seems to occur gradually over a period


of several weeks.

The mechanism by which paraquat causes injury is most commonly believed to occur through its reaction with oxygen to form toxic oxygen radicals (9). The primary biochemical mechanism of paraquat cell toxicity is currently believed to occur by the cyclic redox reactions of paraquat with reducing equivalents and oxygen in the cell leading to the consumption of NADPH and the production of superoxides (19). There is still uncertainty about subsequent events. Either the consumption of NADPH could lead to cell death or the production of superoxides could initiate a series of events causing toxicity. Figure 1.1 Summarises the primary biochemical mechanism of paraquat cell toxicity.

Human case reports post sublethal acute poisoning effects (20-22) have indicated similar events where lung damage may occur in the form of interstitial fibrosis and medial arteriolar hypertrophy. The first detectable change reported associated with such exposures has been an asymptomatic reduction in transfer factor for carbon monoxide. Pulmonary toxicity may be progressive months after exposures has taken place. Symptoms are predominantly dyspnoea and the chest radiograph shows linear shadowing. Subsequent events appear to be related to the dose responsible for initial poisoning. Either lung damage proceeds to pulmonary fibrosis and death, or there is a gradual improvement with some residual fibrosis and/or pulmonary hypertension.

Community exposure to paraquat drift sprayed by helicopter have increased 2-wk self reported respiratory symptoms which included coughing, trouble breathing, unusual tiredness and wheezing (23).

Figure 1.1 The proposed biological mechanism of paraquat lung toxicity





### 1.2.7 Long term effects

The respiratory effects of long term low dose exposure to paraquat have not been studied extensively although studies have been performed on industrial and farm workers (table 1.2). Gutierrez et al. (personal communication with C. Hogstedt) investigated Nicaraguan banana plantation workers and found an effect on reported respiratory disease symptoms but on spirometry. Other studies (17,24.1, 25, 26,27) have used standard respiratory function tests including spirometry and gas transfer, and have also not found a relationship between paraquat exposure and functional or clinical abnormalities. Although standard respiratory function tests would normally be regarded as being adequate to indicate restrictive abnormalities in pulmonary fibrosis, it is still not clear whether these tests are sensitive enough to measure the abnormalities suggested by the symptoms in the Nicaraguan study.

Another factor which might explain the negative results of previous studies is insensitive exposure measurements. In most studies performed, lifetime cumulative days of exposure estimated from work history was the only method of estimating long-term paraquat exposure. The Nicaraguan study used symptoms of paraquat usage to identify a high exposure group and which was found to have a respiratory defect. No previous study incorporated job history variables other than duration in

exposure calculations. This might have resulted in non differential exposure misclassification which might have diluted or missed exposure-response relationships.

Reduced compliance and increased alveolar - arterial oxygen tension difference have, previously been documented in sheep with long term low dose parenteral exposure to paraquat and subsequent development of chronic lung disease (12).

**Table 1.2 Summary of epidemiological studies which investigated the long term effects of paraquat exposure.**

| <b>Authors</b>     | <b>Study sample</b>                             | <b>Year</b> | <b>Methods</b>                                     | <b>Assc</b>   |
|--------------------|---|-------------|--|---------------|
| Swan               | Malaysian rubber workers (n = 38)               | 1969        | Radiography<br>(trial)                             | none          |
| Howard             | English, Malaysian formulation workers (n = 36) | 1979        | Health records<br>(incl. respi-<br>ratory symptoms | none          |
| Howard             | Malaysian formulation workers (n = 24)          | 1981        | Spirometry<br>Transfer factor                      | none<br>none  |
| Gutierrez*<br>etal | Nicaraguan banana plantation workers (n= 136)   | 1988        | Respiratory<br>symptoms<br>Spirometry              | +<br><br>none |
| Senanayake<br>etal | Sri Lankan sprayers (n= 85)                     | 1993        | Spirometry<br>Transfer factor                      | none<br>none  |

**Assc: + = positive association, none = no association**

**\* Unpublished**

In South Africa, the long-term health effects of paraquat have not been subjected to systematic epidemiological study. Over 1,2 million workers are currently employed in the agricultural sector in South Africa (28). An unknown percentage are exposed to herbicides. Farm workers work in poor safety conditions and the incidence of environmentally related respiratory disease is likely to be high in this population. Increased prevalences of respiratory disorders including symptoms and chronic obstructive pulmonary disorders (COPD) have been well documented among European and North American farm workers. There is no comparable information about South African farm workers. However, it may be anticipated that respiratory hazards including infections, tuberculosis, indoor smoke and fume exposures, and other environmental effects are more prevalent in less developed societies.

In addition to the standard respiratory function tests used in previous paraquat studies (17, 24.1, 26, 27) this study aimed to measure one aspect of respiratory reserve in the form of exercise oximetry. The latter is notionally a more sensitive test of respiratory health. A subsidiary aim was to evaluate this test, which is a modified standard clinical exercise test and involves the measurement of oxygen saturation during exercise with oximetry, as an epidemiological tool for field use.

New information on paraquat in South Africa, given that its use is banned in some countries, has important policy implications.

These considerations led to the current study whose aims and objectives are outlined below.

### 1.3 Aims and objectives of the current study

#### AIM

To investigate the respiratory health effects of long - term low dose paraquat exposure under usual application conditions among Western Cape farm workers, independently of current acute effects of exposure or sequelae of past poisoning episodes.

#### OBJECTIVES

1. Measurement of workers' exposure to paraquat including long-term and acute recent exposure using a job exposure matrix, as well as acute poisoning events.
2. Measurement of the respiratory health of workers by means of:
  - i) chest radiograph
  - ii) symptom questionnaire
  - iii) brief clinical examination
  - iv) spirometry
  - v) gas transfer factor
  - vi) exercise performance - oxygen saturation

3. Measurement of potential confounding or effect modifying variables (eg. tuberculosis , other respiratory disorders, smoking)
4. Determination of associations between exposure to paraquat and adverse respiratory outcomes mentioned adjusting, for measured confounders and/or effect modifying factors.
5. Comparison of the sensitivity of the various measurements in detecting paraquat-related effects.
6. Assessment of the field utility of exercise oximetry.

#### 1.4 References

1. Mowbray, DL. Pesticide use in the South Pacific. Nairobi: UNEP (UNEP Regional Seas Reports and Studies, No. 89)1988
2. Fourie HO. Toxicological consequences of pesticidal use in the Republic of South Africa [PhD Thesis]. Cape Town: Department of Community Health. University of Cape Town, 1986.
3. London L. Agrochemical Hazards in the South African farming sector. South African Medical Journal 1992a; 481: 560 - 564
4. London L, Myers J. Agrochemical usage patterns and workplace exposure in the major farming sectors in the southern region of South Africa. South African Journal of Science 1995; 91: 515 - 522
5. Central Statistical Services (CSS). Statistical News Release P1101 - Agricultural Survey. Pretoria: CSS 1991.
6. London L. An investigation into the neurological and neurobehavioural effects of long-term agrochemical exposure among deciduous fruit farm workers in the Western Cape, South Africa, 1994 [MD Thesis]. Cape Town: Department of Community Health. University of Cape Town, 1995.

7. Active ingredient fact sheet; paraquat. Pesticide News 1996;  
32: 20 - 21
8. London L, Myers J. General patterns of agricultural usage  
in the southern region of South Africa. South African  
Journal of Science 1995; 91: 509 - 514
9. World Health Organisation. Paraquat and Diquat.  
Geneva: WHO 1984; IPCS environmental health criteria 39
10. Chester G, Woolen BH. Studies of the occupational  
exposure of Malaysian plantation workers to paraquat.  
British Journal of Industrial Medicine 1982; 38: 23 -33
11. Smith P, Heath D, Kay JM. The pathogenesis and structure  
of paraquat - induced pulmonary fibrosis in rats. The  
Journal of Pathology 1974; 114(2): 57-67
12. Shinozaki S, Bobayashi T, Kubo K, Sekigushi M. Pulmonary  
hemodynamics and lung function during chronic paraquat  
poisoning in sheep. American Review of Respiratory Disease  
1992; 146: 775 - 780
13. Schoenberger CI, Rennard SI, Bitterman PB, Fukuda Y,  
Ferrans Vj, Crystal RG. Paraquat - induced pulmonary  
fibrosis. American Review of Respiratory Disease 1984;  
129: 168 - 173



14. Butler C. Pulmonary interstitial fibrosis from paraquat in the hamster. *Archives of Pathology* 1975; 99: 503 - 7
15. Smith TJ. Exposure assessment for occupational epidemiology. *American Journal of Industrial Medicine* 1987; 12: 249 - 268
16. Walker M, Dugard PH, Scott RC. Absorption through human and laboratory skin: in vitro comparison. *Acta Pharmaceutica Suecica* 1983; 20: 52 - 53.
17. Swan AAB. Exposure of spray operators to paraquat. *British Journal of Industrial Medicine* 1969; 26: 322 - 329
18. Bernardini P. Paraquat and diquat: toxicological aspects and occupational hazards; *Archivio di Scienze del Lavoro* 1986; 331(2): 117 - 123
19. Smith LL. The response of the lung to foreign compounds that produce free radicals. *Annual Review of Physiology*. 1986; 48: 681 - 692.
20. Rebello G, Mason JK. Pulmonary histological appearances in fatal paraquat poisoning. *Histopathology* 1978; 2: 53 - 66
21. Hudson M, Patel SB, Ewen SWB, Smith LL, Friend JAR. Paraquat induced pulmonary fibrosis in three survivors. *Thorax*

22. Levin PJ, Klauff LJ, Rose AG, Ferguson AD. Pulmonary effects of contact exposure to paraquat: a clinical and experimental study. *Thorax* 1991; 46: 201 - 204
23. Ames RG, Howd RA, Doherty L. Community exposure to a paraquat drift. *Archives of Environmental Health* 1993; 48(1): 47 - 49.
24. Howard JK. A clinical survey of paraquat formulation workers. *British Journal of Industrial Medicine* 1979; 24.136: 220 - 223
25. Lings S. Pesticide lung: A pilot investigation of fruitgrowers and farmers during the spraying season. *British Journal of Industrial Medicine*. 1982; 39: 370 - 376
26. Howard JK, Sabapathy NN, Whitehead PA. A study of the health of Malaysian plantation workers occupationally exposed to paraquat. *British Journal of Industrial Medicine*. 1981; 38: 110 - 116
27. Senanayake N, Gurunathan G, Hart TB, Amerisinghe P, Babapulle M, Ellapolla SB, Udupihille M, Basanayake V. An epidemiological study of the health of Sri Lankan tea plantation workers associated with long term exposure to paraquat. *British Journal of Industrial Medicine* 1993; 50: 257 -263
28. Central Statistical Services (CSS). Agricultural survey, CSS. Statistical News Release 1990; p.1101

## CHAPTER 2 MEASUREMENT OF RESPIRATORY HEALTH USING EXERCISE OXIMETRY

### 2.1 Significance of measuring exercise health

During exercise physiological demands are increased due to increased energy demands thus requiring the body to use its physiological reserve. The biological significance of measuring exercise health is to test the body's physiologic reserve which might be altered in diseased persons, representing the earliest disturbances in function which may not be detected at rest.

#### 2.1.1. The exercise test

Standard clinical exercise testing is based on the procedures developed by Jones and Campbell (1), and involves exercise (usually running or cycling) against resistance while measurements are made to assess respiratory health. These measurements which include methods for assessing ventilation, cardiac status, and gas exchange vary in sophistication depending on the type of test. Four stages test series can be performed. The stage one test involves incremental exercise to exhaustion and include basic measurements (heart rate, blood pressure, electrocardiogram, ventilation, mixed expired oxygen and carbon dioxide concentrations,  $O_2$  saturation by oximetry and post-exercise plasma lactate concentration. The stage 2-4 tests are

performed at steady state exercise based on measurements obtained in the stage one tests and include measurements of increasing complexity to obtain more precise information from the subject.

#### **2.1.2. Exercise gas exchange in the healthy**

During exercise oxygen delivery is enhanced by increased ventilation and cardiac output. The pulmonary demands during exercise revolve around the maintenance of the arterial oxygen level above 11.4 kPa to ensure adequate supply of oxygen to exercising muscles. In normal lungs, increased pulmonary ventilation and diffusion are adequate to prevent hypoxemia as evidenced by normal values for a number of indices when compared to resting values (2-5). Invasive blood gas analysis has shown that the arterial end-tidal difference in CO<sub>2</sub> tension ( > 0 kPa) and dead-space/tidal-volume ratio ( > 0.3) which indicate wasted ventilation, as well as arterial O<sub>2</sub> tension ( > 11.4 kPa) and alveolar O<sub>2</sub> difference ( > 5 kPa) which measure hypoxemia remain normal during exercise in healthy persons (2-5).

#### **2.1.3. Exercise gas exchange in the diseased**

Respiratory diseases results in gas exchange abnormalities such as an increase in the amount of left to right shunting, a decrease in the oxygen concentration in mixed venous blood, maldistribution of ventilation-perfusion ratio and diffusion limitations. Despite these limitations, pulmonary reserve ensure that resting PaO<sub>2</sub> in the diseased subject remains normal (5, 6).

Under exercise conditions, however, pulmonary reserve is not sufficient to prevent hypoxemia (5-9).

Paraquat toxicity is associated with interstitial pulmonary alveolar disease which is a disease that results in damage to the alveolar membrane causing fibrosis and a decrease in inspiratory capacity due to stiffening of the lungs. This results in a reduction in lung volume as evidenced by the reduced tidal volumes measured in patients with restrictive defects (5). At rest a tidal volume of sufficient size can be maintained or the breathing rate could be increased to maintain adequate ventilation. During exercise increase in ventilation is limited by the tidal volume. If this cannot be increased the amount of unventilated area in the lung increases resulting in a reduction in the ventilation-perfusion ratio and eventually hypoxemia.

Damage to the alveolar capillary could also result in a diffusion limitation by decreasing the time for diffusion of oxygen from the alveoli into blood. At rest the transit time of a red bloodcell in the pulmonary capillary is about 0.7 seconds and is sufficient for equilibration of arterial  $O_2$  with alveolar  $O_2$  in both diseased and healthy persons. During exercise however the transit time of red blood cells is reduced to 0.25 seconds due to increased blood flow. This is adequate for diffusion of oxygen in healthy persons but not in diseased persons.

## 2.2. Oximetry

Oximetry is a method which uses absorption spectroscopy to measure arterial oxygen saturation ( $\text{SaO}_2$ ) in blood.

### 2.2.1. Oxygen Saturation

Oxygen in blood, binds to haemoglobin to form oxyhaemoglobin. Ninety nine percent of oxygen in blood is transported by binding to haemoglobin and the oxygen content of blood can in fact be determined by the concentration of haemoglobin (approximately 15 g/100 ml), the oxygen binding capacity of haemoglobin and the oxygen saturation of haemoglobin (percentage of total blood haemoglobin bound). The binding of oxygen to haemoglobin increases in a sigmoidal fashion as more oxygen becomes bound. This means that at venous oxygen levels (5.7 kPa) the affinity of oxygen for haemoglobin is low when compared to arterial blood ( $>$  than 14.3 kPa). Factors such as a reduced pH, increased temperature, increased carbon monoxide levels and increased diphosphoglyceride levels shift the dissociation curve to the right because of a reduced affinity of haemoglobin for  $\text{O}_2$ .

### 2.2.2. Apparatus

The basic measuring equipment used in oximetry consists of a probe which is connected to a recording device. The probe is made up of a light source, that emits light at known red and infrared band wavelengths, and a sensor (photodetector) which is

placed across a pulsatile vascular bed (of the finger or ear).

### 2.2.3. Principles of operation

During oximetry the absorbance of oxygenated and reduced haemoglobin in arterial blood are measured usually at 640 (red band) and 940 nm (infrared band) respectively in order to calculate the ratio of oxygenated over total haemoglobin (oxygen saturation). Absorbance is measured continuously to detect fluctuations during the cardiac cycle. In this way background absorbances due to connective tissue, bone and venous blood which are constant during this time, are cancelled out.

### 2.2.4. Limitations

Since  $\text{SaO}_2$  is related to  $\text{PaO}_2$  by the oxyhemoglobin dissociation curve, factors that shift the curve will affect this relationship. Because of the shape of the curve, relatively large changes in  $\text{PaO}_2$  will result in small changes in saturation in the plateau region (14.3 - 10.7 kPa), whereas bigger changes in saturation, for small changes in  $\text{PaO}_2$ , occur at lower  $\text{PaO}_2$  levels.

Other species of haemoglobin such as carboxyhaemoglobin (haemoglobin bound to carbon monoxide) and methaemoglobin can affect absorbances (10 - 11). Previous studies have found pulse oximetry to be highly correlated to CO-oximetry (regarded as the gold standard in oximetry because it incorporates measurements

from other haemoglobin species) at 70 -100 percent saturation levels (10, 12, 13), but a poor correlation at low saturation levels (14).

Factors such as dyes, low perfusion, anaemia, venous pulsations, and excessive light could also interfere with oximeter accuracy (10). Skin pigmentation does not interfere with oximetry readings (15).

#### 2.2.5. Validity of exercise oximetry to estimate respiratory health

Watters (16) has shown that changes in alveolar-arterial oxygen tension and changes in saturation measured with ear oximetry correlated better with histopathologic and histologic changes than subjective clinical assessments, spirometry, diffusion capacity and radiography in patients with pulmonary fibrosis. Sue found spirometry and diffusion capacity at rest to be insensitive predictors of abnormal gas exchange when compared to changes that occurred in arterial blood gases during exercise(7). Powers subsequently showed a high (0.82 - 0.93) correlation between invasively measured oxygen saturation and pulse oximetry, thus validating the use of oximetry for measuring respiratory health (17).



## 2.3 References

1. Jones NL, Campbell EJM . Clinical exercise testing. 2nd ed. Philadelphia: W.B Saunders, 1982.
2. Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing. American Review of Respiratory Disease 1984; 129: Suppl: S49 - S55
3. Sue DY. Normal values in adult exercise testing. Clinic in Chest Medicine. 1984; 5: 89 - 98.
4. Jones NL, McHardy GJR, Naimark A, Campbell EJM. Physiological dead space and alveolar-arterial gas pressure differences during exercise. Clinical Science 1966;31: 19-49
5. Wasserman K, Whipp BJ. Exercise physiology in health and disease. American Review of Respiratory Disease 1985; 132; 612-8
6. Ward JC, Harper, Popovich J. Diffusion capacity predicts arterial oxygen desaturation in patients with lung disease of multiple etiologies. Chest 1986; 89: 514S.abstract.
7. Sue D Y, Oren A, Hansen JE, Wasserman K. Diffusion capacity for carbon monoxide as a predictor of gas exchange during exercise. New England Journal of Medicine 1987; 316: 1301 - 6

8. Risk C, Epler GR, Gaensler EA. Exercise alveolar-arterial oxygen pressure difference in Interstitial lung disease. Chest 1984; 85 69 - 74
9. Keogh BA, Lakatos E, Price D, Crystal GR. Importance of the lower respiratory tract in oxygen transfer. American Review of Respiratory Disease 1984; Suppl S76 - S80
10. Schnapp LM, Cohen HN. Pulse oximetry. Uses and abuses. Chest 1990; 98: 1244 - 50.
11. Taylor M.B., Whitwam J.G. The current status of pulse oximetry. Anaesthesia 1986; 41: 943-9.
12. Yelderman M, New W. Evaluation of pulse oximetry. Anesthesiology 1983; 59: 349 -52.
13. New W. Pulse oximetry. Journal of Clinical Monitoring 1985; 1: 126-31
14. Severinghaus J, Naifeh K. Accuracy of response of six pulse oximeters to profound hypoxia. Anaesthesiology 1987; 67: 551 - 58
15. Bothma PA, Joynt GM, Lipman J, Hon H, Mathala B, Scribante J, Kromberg J. Accuracy of pulse oximetry in pigmented patients. South African Medical Journal 1996; 86(5) : 594 - 596

16. Watters C, King TE, Swharz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. American Review of Respiratory Disease 1986; 133: 97 -103
17. Powers SK, Dodd S, Freeman J, Ayers GD, Samson H, Mcknight T. Accuracy of pulse oximetry to estimate HbO<sub>2</sub> fraction of total Hb during exercise. Journal of Applied Physiology. 67(1): 300 - 304

## CHAPTER 3 METHODS

### 3.1 Design

A cross-sectional analytic study was performed.

### 3.2 Population and Sampling

Ceres is an agricultural district in the Western Cape Province, South Africa. The Koue Bokkeveld is one of the two major fruit producing regions in Ceres comprising of 118 registered farms. Deciduous fruit farming is predominant.

#### *Sampling in the core study:*

In a previous study (1) 113 farms linked to the two major co-operatives in the region were contacted and of these farms 77 participated. A random sample of non-participating farms indicated that a high percentage (39.2%) were small farms (less than 25 hectares).


#### *Sampling in the current study:*

The 77 farms that participated in the core study were contacted. Forty-one farms agreed to participate in the current study. All current herbicide sprayers on these farms (62 sprayers) were selected. Every sprayer was matched for age, overall body size and education with one or two controls (workers not currently

spraying herbicides) from the same farm with the assistance of the farmer. A total of 132 farm workers including 70 controls were selected. Figure 3.1 outlines the manner in which the study sample was obtained.

Selection was done on current spraying status in order to achieve optimal exposure contrast in the population under study.

Figure 3.1 The manner in which the study sample was obtained.



### 3.2.1 Sample size calculations

Table 3.1 lists the sample sizes required in order to detect differences for respiratory symptoms, spirometry, diffusion capacity and exercise oximetry measurements at the 95% confidence level with 80% power. The differences between the exposed and control groups were obtained by estimating the smallest possible expected difference for the different outcome measures in the study. The estimated differences are subclinical (below the values regarded as clinically relevant by physicians and usually 2 standard deviations from the mean of the population). The sample size calculations indicated that the size of the study sample was sufficient to detect significant differences in group outcomes for exercise oximetry (2% difference) and gas transfer factor (0.4 ml/minute/kPa). Oximetry was expected to require the smallest numbers compared to the other outcome measures in the study.

**Table 3.1 Sample size estimation for different outcome measures**

| Outcome (units)              | Estimated *<br>difference | SD † | n per group ‡ |
|------------------------------|---------------------------|------|---------------|
| Respiratory                  | 50                        |      | 82            |
| Symptoms (%)                 | 100                       |      | 26            |
| FVC (l)                      | 0.2                       | 0.55 | 95            |
|                              | 0.3                       | 0.55 | 42            |
| K <sub>co</sub> (ml/min/kPa) | 0.4                       | 0.73 | 42            |
| Desaturation (%)             | 2                         | 2    | 17            |

\* Estimated difference in means or risk ratio between control and exposed groups.

† Standard deviation (used for both control and exposed groups) estimated from the literature.

‡ Two sample one sided estimation



### 3.3 Measurement of Exposure

#### 3.3.1 Estimation of occupational exposure to pesticides

Documentation of past exposures to specific pesticides in South Africa are not available. Data on pesticides sales are not good proxies for usage patterns due to different costs of pesticides. Data on the amounts of pesticides sold and bio-equivalents are difficult to extrapolate to individual levels due to a lack of information on the number of sprayers and the different ways in which sprayers might be exposed in an occupational setting. Detailed industrial hygiene measurements of workplace chemicals in the working environment or biological monitoring data are absent.

#### *Estimation of exposure by means of job exposure matrices*

A number of researchers have developed the concept of a job exposure matrix (JEM) as a low cost and systematic method for estimating individual exposures to chemicals (2, 3). This concept has been refined and applied to agricultural settings (4-7). A job exposure matrix is based on job history variables which are used to calculate individual chemical exposures of workers. The job history variables include aspects of job activity such as job title or calendar year, which can be used to estimate chemical exposures, for example different calendar periods can represent different degrees of exposure according to

the history of chemical usage patterns in the area. JEMs are used in combination with job duration to calculate long term exposure. A JEM has value in an agricultural setting where the subjects's recall of job activity exceeds their ability to recall specific chemical exposure information (4-5). This is particularly true where education levels are low.

Recently, Daures (6) used an agricultural JEM based on calender year of spraying activity and farm location to estimate pesticide exposure amongst French vine farmers. The JEM was combined with agrochemical-specific data on application method, duration of application, hectarage and applied quantities to estimate cumulative exposure to a specific agrochemical. In another study, Migli (5) used a similar JEM which also included the type of crop production. The JEMs in both studies were validated against an assessment by agricultural experts. However, both researchers indicated the need for further validation with methods which measured pesticide exposure directly. Later studies used personal protective equipment (7), method of application (7) and the type of crop production in JEM's to estimate pesticide exposure (4).

#### ***The JEM in the core study :***

The core study (1) drew on the above models to develop a JEM based on specific activities performed in a particular job and crop sector (pomefruit, stone fruit, etc) to estimate exposure to organophosphate pesticides. The highest exposure activity

(indoor mixing) was weighted 1 and other less exposed activities (such as outdoor mixing, back - and hand spraying and tractor spraying) were weighted relative to this exposure. Indoor mixing was considered to be the most exposed job activity because of exposures to concentrated pesticide solutions indoors. Spraying activities were weighted lower due to exposure to less concentrated solutions. This information was obtained from extensive interviews with industry (1) and the job rating was "validated" by consulting key informants in the industry using the Delphi technique. Crop sector weights were based on the concentration of organophosphates per hectare applied in that sector.

***The JEM in the current study:***

Because of the predominance of pome fruit farming in the core study, farming was assumed to be in one crop for this study. Less environmental exposure results from herbicide spraying which is directed downward compared to insecticide spraying which is directed upward and therefore the JEM used in the core study which concerned organophosphate (insecticide) exposure was modified for use in the current study which concerned paraquat (herbicide) exposure. The modifications were:

- i) a reduction in the number of exposure activities
- ii) the weighting of tractor driving less than hand- and backspaying.

The JEM used for the calculation of individual paraquat exposures provided the following exposure intensity weights expressed relative to a maximum value of 1 for the highest possible job exposure:

|                                |      |
|--------------------------------|------|
| mixing indoors:                | 1.0  |
| mixing outdoors :              | 0.8  |
| backspray or handspray :       | 0.7  |
| tractor driving:               | 0.5  |
| repair of herbicide equipment: | 0.2  |
| gardening:                     | 0.05 |
| other exposures                | 0.05 |

### 3.3.2 Exposure Questionnaire (refer to appendix 1.2 and 1.3):

The job history questionnaires, which were specially developed, included separate exposure items for each agricultural job performed (the last 10 agricultural jobs performed). This included the type of farming product, employment period and type, and exposure mechanism (mixing, tractor spraying, hand spraying, back spraying, repair of spray equipment, gardening. The worker was asked to estimate the duration of specific exposure activities (refer to table A in appendix 1.2). The direction of spraying upwards or downwards, indicated insecticide spraying or herbicide spraying respectively.<sup>1</sup> Paraquat exposure was specifically recorded including information about skin burns, and

---

<sup>1</sup> Items marked "A" in appendix 1.2 and 1.3

specific product brandnames (paraquat, gramazone and preeglone).<sup>2</sup> Short-term exposure was measured from exposure in the previous 13 months (one season)<sup>3</sup>. Previous pesticide poisoning occurrence and severity history was obtained<sup>4</sup>.

### 3.3.3 Calculation of variables

Total long term cumulative exposure indices for herbicides (HERBACE, those spraying herbicides in general) and paraquat (PARACE, those who sprayed paraquat as the herbicide) were calculated by multiplying the total number of days accumulated in individual exposure tasks by the weight for that task from the JEM and summing all exposures across all jobs. A simple example:

A worker was employed as a paraquat backpack sprayer and mixer (indoors) for 5 years, working on average for 6 months per year and 5 days a week (660 days), in his first job. In his second job he worked for 2 years, 5 months per year and 3 days per week as a tractor sprayer of paraquat (126 days). His total cumulative paraquat exposure during the two jobs is:

1st job mixing :

660 days X 1 (JEM weight for indoor mixing) = 660 JEM days

---

<sup>2</sup> Items marked "B" in appendix 1.3

<sup>3</sup> Table marked "C" in appendix 1.3

<sup>4</sup> Item marked "D" in appendix 1.2

1st job spraying:

660 days X 0.7 (JEM weight for spraying) = 462 JEM days

2nd job spraying:

126 days X 0.5 (JEM weight for tractor spraying) = 63 JEM days

Total cumulative paraquat exposure for 2 jobs

= 660 + 462 + 63 JEM days

Since workers may be involved in different activities in different, and even the same farm jobs, exposures may be summed over time to derive cumulative and average lifetime intensity exposure estimates (8).

Lifetime average intensity of herbicide (HERBINT) and paraquat exposure (PARINT) were calculated by dividing total cumulative exposure indices by the total period of employment.

Short-term exposure (SHERBACE, SPARACE) indices were calculated from exposure in the previous 13 months. Pure long-term exposure variables (PARACE2, HERBACE2, PARINT2, HERBINT2) were calculated by subtracting short-term exposure from long-term cumulative exposure (for example PARACE2 = PARACE - SPARACE).

Short- and long- term exposure were dichotomised to form a number of categorical exposure variables using different cutpoints (0,25th,50th and 75th percentiles). An ordinal long-term exposure variable with 4 categories (variable EXGRAD listed in

glossary, appendix 4) was created based on the dichotomised exposure variables.

Current exposure status used for sampling was thus not used in the analysis of the data.

### **3.4 Measurement of Respiratory Health**

#### **3.4.1 Medical Examination**

A directed medical examination including chest radiography was carried out by a doctor to exclude cases of tuberculosis. One subject was diagnosed as having tuberculosis and therefore did not perform the clinical tests.

#### **3.4.2 Respiratory Questionnaire**

Respiratory symptoms were measured using a vernacular version of the American Thoracic Society (ATS) respiratory symptoms questionnaire modified for SA conditions (9, appendix 1.4). The items included in the questionnaire were coughing, production of phlegm, shortness of breath, wheezing and chest-tightness in increasing degrees of severity, as well as past history of respiratory illness including bronchitis, pneumonia, hayfever, sinus problems, asthma and tuberculosis.

The ATS questionnaire has been found to be more detailed than the questionnaires developed by the British Medical Research Council

and The American National Heart and Lung Institute while eliciting similar response rates and symptom prevalences (10, 11). The questionnaire has also been found to be valid (10), and correlates with spirometric measurements (12). It can be used to predict both restrictive and obstructive defects.

### 3.4.3 Lung function

Lung function testing included spirometry for the detection of ventilatory impairment, and measurement of the transfer factor for the detection of impairment at the gas exchange level.

#### *Spirometry:*

Spirometry involves the measurement of dynamic lung volumes and flow rates during forced inspiration and expiration or forced breathing when maximal effort is applied throughout the manoeuvre. The information is mostly obtained in terms of the relationships of inspired or expired volumes to time which are described by the volume time curve or relationship of maximal flow rate to lung volume described by flow-volume curve (the lung function report sheet in appendix 2 include an example of the flow-volume curve).

#### *Transfer factor:*

The test is used to assess the transfer of gases between the alveoli and the capillaries. The high permeability of the



intervening membrane to carbon monoxide and the similar molecular weight of CO and O<sub>2</sub>, makes this gas suitable for this measurement.

The test is based on measuring the difference in carbon monoxide concentration in inspired and expired air before and after a 10 second breathhold. A test gas which is low in carbon monoxide and includes an inert gas not normally present in the body (eg helium) is inhaled at nearly full functional capacity and held in the lungs for 10 seconds. A sample of alveolar gas is obtained during exhalation and analyzed for both gases. The dilution factor for helium is then used to calculate the initial carbon monoxide concentration in alveolar gas and to estimate alveolar volume.

The transfer factor is determined mostly by the diffusing capacity of CO and its binding to haemoglobin.

Equation used for the calculation of transfer factor:

$$T_{LCO} = VA \text{ (STPD)} \times 60/t \times 1/(PB-47) \times \ln COA/COE$$

$$T_{LCO} = \text{Single breathe diffusing capacity for CO}$$

$$K_{CO} = T_{LCO}/VA$$

VA = Alveolar volume (STPD) at which breath was held  
(Calculated from helium dilution)

t = Breathe holding time in seconds

PB = Barometric pressure

COA & COE = Initial and expired alveolar [CO]

(Initial alveolar [CO] calculated from helium dilution)

*Measurement of lung function:*

Spirometry and carbon monoxide gas transfer measurement were performed using the Medical Graphics PF/D/x Pulmonary Functions Test System (Medical Graphics Corporation, USA). The tests were performed by a trained respiratory health technologist according to ATS criteria (9). The equipment was recalibrated after each work session. Parameters (refer to appendix 2) included height, weight, body surface area, forced expired vital capacity (FVC), forced one second expiratory volume (FEV1), the ratio of FEV1 to FVC (FEV1/FVC), forced maximum expired flow rate (FEFMAX), and transfer factor uncorrected  $T_{L_{CO}}$  and corrected for alveolar volume ( $K_{CO}$ ). Transfer factor was not corrected for haemoglobin because the procedure involving this measurement is invasive and this might have affected participation of subjects in the study. The small amount of bias which might have resulted from this is expected to be non-differential.

Predicted and percentage of predicted values were calculated for spirometry and transfer factor from the European Community for Coal and Steel standard reference values (13) because:

- i) they are recommended by the ATS
- ii) they have values for a number of important parameters that could be measured in addition to spirometry
- iii) they are widely available on software

iv) with experience we have some idea of how they relate to RSA.

#### 3.4.4 Radiography

Standard PA chest radiographs were taken by two trained radiographers at Ceres Hospital and were read by a doctor<sup>5</sup> according to the standard in the International Labour Organisation (ILO) International Classification of radiographs of pneumoconioses (1980) (14).

#### 3.4.5 Exercise Testing

A modified standard clinical stage one exercise test was performed by myself. This involved the measurement of arterial oxygen saturation by means of oximetry (Ohmeda Biox 3700) during an incremental exercise test performed to exhaustion on a mechanical Monark cycle ergometer.

The exercise test involved cycling at 50 cycles per minute (following the sound of a metronome) while the work rate was increased every minute by 100 kilopondmetres per min (kpm/min, 1 kilopondmetre = 9.8 Joules), starting at 600 kpm/min after an initial 1-2 minute warm-up. Earlobe oximetry was predominantly used, but in two cases finger oximetry was used because earlobe oximetry was unsuccessful. Vaso-dilating ointment (Salicylic acid) was applied to improve blood circulation and improve

---

<sup>5</sup> Neil White

measurement by the oximeter. The oximeter was connected by serial connection to an IBM compatible computer which captured data every two seconds after subjects' resting saturation levels stabilised. Pulse rate was also recorded. Workloads performed by subjects, exercise durations, as well as pre- and post-exercise saturation and pulse rate were also recorded.

Traces of pulse-rate and saturation against time were plotted from the recorded values (Appendix 3). The starting time of exercise relative to the point at which computer recording started was indicated by the increase in heart-rate from resting values (the duration of the warm up as indicated by the traces was confirmed by manual records) and the end of exercise was indicated by the drop in heart rate after exercise (confirmed by manual records). Heart rate and saturation levels at specific work loads could thus be determined. Irregular and inconsistent heart and saturation traces were considered to be uninterpretable and were therefore excluded from the analysis. Appendix 3 shows examples of interpretable and uninterpretable traces.

Desaturation was calculated as the difference between resting and maximum exercise saturation levels. Desaturation was dichotomised to form a number of categorical outcome variables using different cutpoints ( $\geq 1\%$ ,  $\geq 2\%$ ,  $\geq 3\%$ ,  $\geq 4\%$  and  $\geq 5\%$ ). Predictions of heart rate and workload used were those of Campbell and Jones (15):

Maximum predicted heartrate (beats/min) =  $210 - (0.65 \times \text{age})$

Maximum predicted workload (MPW):

$$\text{MPW (kpm/min)} = \{[(60 - 0.55 \times \text{age})\text{weight}] - (3.5 \times \text{weight})\} / 2$$

Conversion of workload (WL) to oxygen consumption (V02):

$$\text{V02 (ml/min)} = (\text{WL} \times 2) + (3.5 \times \text{weight})$$

\* Units: WL - kpm/min; age - years; weight - kg

### 3.5 Possible confounders or effect modifiers

Age, smoking, gender, social class and body size are known predictors of respiratory health measured by spirometry, diffusion capacity and oximetry (17-24). All subjects in the study sample were males. Social class was considered to be homogeneous in the study sample because all subjects could be classified as belonging to the same income group. The study also included measurements of weight and height (performed before lung function testing) which could be used as indices of body size. The study included measurement of alcohol because of the history of high consumption levels in rural areas. Alcohol has been linked to survival from severe paraquat intoxication in heavy drinkers (25). Education could influence the workers ability to performance in tests and answer questions.

Education history, alcohol consumption and smoking history were obtained by questionnaire (appendix 1.1).

Years of schooling was used as proxy for education.

Life time alcohol consumption (grams) was determined from daily

drinking patterns, lifetime period of drinking and the amount of alcohol consumed. Quantities and qualities of beverages and tobacco were obtained from sample containers on display. Smoking was measured in 20 cigarette pack-year equivalents. Smoking and alcohol were dichotomised to form categorical confounder variables (listed in glossary, appendix 4).

### 3.6 Field work

All questionnaires were tested in a pilot of 10 subjects.

Data was collected at the Ceres Hospital during the last two weeks of May 1994. Subjects were directed to various measurement stations (X-ray, interview, pulmonary function and exercise test) by two supervisors. Quality control included a checklist on envelopes, colour coding of questionnaires and the checking of completed questionnaires by the supervisors. The recording of exposure information was performed before the pulmonary function tests, exercise tests and administration of the respiratory symptom questionnaires and observers for each station were blind to the results from other stations.

All questionnaires were in Afrikaans (vernacular language) and administered by trained interviewers.

### **3.7 Ethical considerations**

All workers who participated in the study gave written consent after full explanation of the purpose and methods of the investigation. This was done in accordance with the Declaration of Helsinki of the 25th World Medical Assembly (WHO, 1982), and transacted in Afrikaans, the first language of the subjects.

Full confidentiality was observed for the subjects.

### **3.8 Data management**

Data was encoded by one person and double punched by the University of Cape Town data capture service. Statistical analysis was conducted on a mainframe VAX computer at UCT using SAS 6.09.

### **3.9 Statistical Analysis**

#### **3.9.1 Univariate analysis**

The data was cleaned by inspecting outliers using the PROC FREQ and PROC UNIVARIATE procedures in SAS.

The distributions of all the continuous variables included in the analyses were examined for normality by running the PROC UNIVARIATE PROCEDURE in SAS and this included inspection for symmetry using stem-and-leaf and box-plots, observation of the

closeness of the mean to the median and by the Shapiro-Wilk test for normality. Non-normally distributed variables were transformed where appropriate for purposes of bivariate and multivariate analyses.

### 3.9.2 Bivariate analysis

Bivariate analyses were used to explore associations between relevant outcome and predictor variables and to assess likely confounding with a view to building models for multivariate analysis which included multiple linear and logistic regression techniques.

Table 3.2 summarises the bivariate tests used for detecting associations and table 3.3 summarises the associations examined.



**Table 3.2 Summary of bivariate tests performed**

| <b>variable type</b> | <b>categorical</b>         | <b>continuous</b>  |
|----------------------|----------------------------|--|
| <b>categorical</b>   | <b>Chi-square<br/>Test</b> | <b>T-test (parametric)<br/>Wilcoxon Test (non-<br/>parametric)</b>   |
| <b>continuous</b>    |                            | <b>Pearson correlation<br/>Coefficient (parametric)<br/>Spearman Rank Correlation<br/>Coefficient (non-parametric)</b> |

**Table 3.3 Associations examined**

| <b>variable</b> | <b>outcome</b>                                     | <b>exposure</b>                                  | <b>possible<br/>confounders<br/>and effect<br/>modifiers</b>          |
|-----------------|--|--|---|
| <b>outcome</b>  | <b>association<br/>of outcome<br/>measurements</b> | <b>Measures of<br/>effect</b>                    | <b>independent<br/>predictors of<br/>outcome</b>                      |
| <b>exposure</b> | <b>Measures of<br/>effect</b>                      | <b>association<br/>of exposure<br/>variables</b> | <b>correlation<br/>of potential<br/>confounders<br/>with exposure</b> |

### 3.9.3 Multivariate Analysis

Multivariate analysis included multiple linear regression and multiple logistic regression procedures. A model was constructed for each outcome. Regression diagnostics were performed to ensure that the assumptions underlying linear regression were met. Models results were examined for homoscedasticity of residuals and any obviously non linear relationships.

#### *Model Selection:*

Multivariate models included a priori variables known or thought likely to be associated with outcomes of interest.

i) Age, height and weight, smoking and alcohol consumption were included in all outcome/exposure models as possible confounders. Both height and weight were included in most models as proxies of body size, but for statistical stability, only one (the strongest bivariate and multivariate predictor) was included where the number of data points were below 100.

For exercise desaturation, difference in post exercise and resting heartrate were included to control for exercise exertion.

ii) Other variables found in the bivariate analysis to be associated (p-value = 0.2) with the outcome or with important exposure or a priori variables (potential confounders) were also included.

Collinearity between selected variables was examined in order to prevent simultaneous inclusion of strongly correlated variables in the model. Variables showing strong collinearity ( $r \geq 0.8$ ) were run independently in the model and the variable with the strongest association was included in the model.

Individual predictors rather than ratios of predictors were included in models, for example FEV1 and FVC rather than the FEV1/FVC ratio were analyzed as outcomes, and weight and height were included individually rather than the body mass index ratio.

#### ***Modelling procedures:***

Regression was performed using the PROC REG AND PROC LOGISTIC procedures in SAS. Significant associations between variables were assessed from full model procedures. For lung function and exercise oximetry the best explanatory models were assessed by running stepwise, forward and backward stepping and the  $C_p$  (based on Mallows  $C_p$  statistic) procedures in SAS.

#### ***Descriptions of selection procedures:***

Full model procedure: All predictors are forced in the model.

Forward selection procedure: Selected predictors are added one by one to the model in the order of the magnitude of their contribution (F to enter statistic corresponding to  $p < 0.1$ ) to the model. Variables are not included if they do not exceed a specified F to enter - statistic. Variables stay in the model once they are included.

#### Backward Procedure:

The backward procedure involves the elimination of individual predictors from the full model starting with the variable with the lowest contribution to the model. Elimination stops when the remaining model exceeds a specified model statistic (F to enter statistic corresponding to  $p < 0.1$ ).

#### The Stepwise Procedure:

This is a modification of the Forward Selection Procedure. Variables are included in the model as in Forward Selection but at each inclusion the contributions of all the variables in the model at that stage is assessed and elimination occurs as in the Backward Procedure.

#### The $C_p$ procedure:

All possible subsets are listed in order of ascending  $C_p$  statistic values. The  $C_p$  statistic (24) gives an indication of the loss in predictive power of models. The model with the

lowest  $C_p$  value and explaining most of the variance (high model  $r^2$ ) is the best explanatory model.

All datapoints including outliers were analyzed.

#### *Possible effect modification*

Possible effect modification was studied by including interaction variables (exposure X effect modifier) as predictors in models. The full model and all stepwise procedures were used. A variable was considered an effect modifier if the interaction variable was a significant predictor in the full model of the outcome of interest.

#### *Relationship between lung function and oximetry*

The relationship between lung function and oximetry was investigated by including desaturation as a predictor in the linear regression models for FEV1, FVC, and diffusion capacity.

### 3.10 References

1. London L, An investigation into the neurological and neurobehavioural effects of long-term agrochemical exposure among deciduous fruit farm workers in the Western Cape, South Africa, 1994 [MD Thesis]. Cape Town: Department of Community Health. University of Cape Town, 1994.
2. Hoar SK, Morrison AS, Cole P, Silverman, DT. An occupational and exposure linkage system for the study of occupational carcinogenesis. *Journal of Occupational Medicine* 1980; 22: 722-725
3. Pannet B, Coggon D, Acheson ED. A job-exposure matrix for use in populations based studies in England and Wales. *British Journal of Medicine* 1985; 42: 777 - 783
4. Nanni O, Ricci M, Lugaresi C, Amadori D, Falcini F, Buiatti E. Interactive use of a priori exposure matrix to improve the characterisation of chemical exposures in agricultural work studies. *Scandinavian Journal of Work and Environmental Health* 1993; 19: 191 - 199
5. Migli L, Settimi L, Masala G, Maiozzi P, Alberghini Maltoni S, Seniori Constantini A, Vineis P. Pesticide exposure assessment: a crop exposure matrix. *International Journal of Epidemiology*. 1993; 2(6) Suppl 2: S42 - 45

6. Daures JP, Momas I, Bernon J, Gremy F. A vine-growing exposure matrix in the Herault Area of France. *International Journal of Epidemiology* 1993; 22(6) Suppl 2: S36 - 41
7. Brouwer DH, Brouwer EJ, Van Hemmen JJ. Estimation of long-term exposure to pesticides. *American Journal of Industrial Medicine*. 1994; 25: 573 - 588
8. Checkoway H, Pearce N, Crawford - Brown DJ. Research methods in occupational epidemiology. Oxford University Press 1989. Oxford
9. Ferris GB. Epidemiology Standardization Project. *American Review of Respiratory Disease* 1978; 118: 1-35
10. Helsing J K, Comstock GW, Speizer FE, Ferris BG, Lebowitz MD, Tockman, Burrows B. Respiratory symptoms. *American Review of Respir Disease* 1979; 120; 1221 - 1230
11. Comstock G, Tockman MS, Helsing JK, Hennesy KM. Comparison of the old and the new. *American Review of Respiratory Disease* 1979; 119; 45 - 51
12. Brodtkin CA, Barnhart S, Anderson G, Checkoway H, Omenn GS, Rosenstock L. Correlation between respiratory symptoms and pulmonary function in asbestos-exposed workers. *American Review of respiratory Disease* 1993; 148: 32 - 37

13. European Community for Coal and Steel.  
Bulletin European de Physiopathologie Respiratoire 1983;  
19 Suppl 5: 7-95.
14. White N, Ehrlich R, Rees D. A guide to spirometry as  
applied to occupational health. South African Medical  
Journal 1996; 86: 807 - 813
15. International Labor Office: Guidelines for the use of ILO  
international classification of radiographs of  
pneumoconioses. Geneva: International Labour Office, 1980
16. Jones NL, Campbell EJM. Clinical exercise testing. 2nd  
ed. Philadelphia: W.B Saunders, 1982.
17. Samet JM, Schrag SD, Howard CA, Key RC, Pathak RD.  
Respiratory disease in a New Mexico Population sample of  
Hispanic and non-Hispanic whites. American Review of  
Respiratory Disease 1982; 125: 152 - 157
18. Beck G, Doyle CA, Schachter EN. Smoking and lung function.  
American Review of Respiratory Disease 1981; 123: 149 - 155
19. Senthilselvan A, Chen Y, Dosman JA. Predictors of asthma  
and wheezing in adults: grain farming, sex, and smoking.  
American Review of Respiratory Disease 1993; 148: 667 - 70
20. Iversen M, Dahl R, Korsgaard J, Hallas T, Jensen EJ.



Respiratory symptoms in Danish farmers: an epidemiological study of risk factors. Thorax 1988; 43: 872 - 877

21. White NW, Hanley JH, Lalloo UG, Becklake MR. Review and analysis of variation between spirometric values reported in 29 studies of healthy African Adults. American Journal of Respiratory and Critical Care Medicine 1994; 150:358 - 55
22. Gamsky TE, Mccurdy SA, Samuels SJ, Schenker MB. Reduced FVC among California grape workers. American Review of Repiratory Desease 1992; 145: 257 - 262.
23. Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing. American Review of Respiratory Desease 1984; 129 Suppl: S49 -S55
24. Comstock GW, Meyer B, Helsing KJ, Tockman MS. Respiratory effects of household exposures to tobacco smoke and gas cooking. American Review of Repiratory Desease 1981; 124: 143 -148
25. Ragoucy-Sengler C, Pileire B, Daijardin JB. Survival from severe paraquat intoxication in heavy drinkers. Lancet 1991; 338: 1461.
25. Mallows CL. Some Comments on C<sup>p</sup>. Technometrics 1973; 15 : 661 - 675

## CHAPTER 4 RESULTS

### 4.1 Univariate Analysis

#### 4.1.1 Sample participation, demographics and anthropometry

Of farms agreeing to participate when contacted, 41 (100%) were studied. This represents 34.7% of the farms in the study region. Of workers selected, 126 (95%) including all current herbicide sprayers (62) were studied.

Table 4.1 shows a low education level ( $7.2 \pm 3.57$  years) with 12.7% never attending school. Height and weight measurements (Table 4.1) were low compared with ECCS reference populations (1)

Table 4.1 Anthropometric results in the study sample

| Variables<br>(units) | Mean  | SD   | n   | Range     |
|----------------------|-------|------|-----|-----------|
| Education<br>(yrs)   | 7.2   | 3.57 | 126 | 0-14      |
| Weight (Kg)          | 56.1  | 8.9  | 125 | 35 - 85   |
| Height (cm)          | 163.6 | 6.9  | 125 | 147 - 177 |
| Age (years)          | 34.2  | 9.9  | 126 | 18 - 65   |

Note: n = 126 where information was obtained for all subjects, but n = 125 where tuberculosis case was excluded.

#### 4.1.2 Respiratory symptoms and illnesses

A summary of important respiratory symptom prevalences is shown in table 4.2 (Appendix 5.1, table 2 lists all respiratory symptom prevalences measured).

Table 4.2

## Respiratory symptom prevalences

| Variable                                   | Prevalence<br>(%) n=126 |
|--|-------------------------|
| Regular coughing                           | 57.1                    |
| > 3 mnths                                  | 11.9                    |
| > 2 years                                  | 7.9                     |
| Production of phlegm during coughing       | 32.5                    |
| > 3 mnths                                  | 10.3                    |
| > 2 yrs                                    | 7.9                     |
| Coughing and phlegm > 3wks                 | 23.8                    |
| > 2 years                                  | 21.4                    |
| Wheezing in past year                      | 46.8                    |
| Shortness of breath during wheezing (SOBW) | 25.4                    |
| Awake in morning due to SOBW               | 7.9                     |
| Attack of SOBW                             | 8                       |
| Medication received for SOBW               | 2.4                     |
| Wheezing for > 2 years                     | 22.2                    |
| Dyspnea during fast or incline walking     | 40.5                    |
| Slower walk than people of same age        | 15.9                    |
| Dyspnea during level walking               | 7.9                     |
| Dyspnea during level walking for 100m      | 7.1                     |
| Get colds in chest                         | 75.4                    |
| Severe chest colds in past 3 yrs           | 15.9                    |
| Phlegm during chest colds                  | 11.9                    |

Table 4.3 shows a summary of important respiratory illness prevalences (Appendix 5.1, table 2 lists a all respiratory illness prevalences measured).

**Table 4.3**  
**History of Respiratory illness**

| Variable                | Prevalence<br>(%) n=126 |
|-------------------------|-------------------------|
| Lung problems before 16 | 9.5                     |
| Bronchitis              | 16.7                    |
| Pneumonia               | 21.4                    |
| Hayfever                | 14.3                    |
| Sinus problems          | 19.0                    |
| Tuberculosis            | 7.9                     |
| Asthma                  | 2.4                     |

#### 4.1.3 Radiography

The prevalence of past and present x-ray evidence of tuberculosis was 5.6%. Prevalence of small opacities ( $\leq 1/0$ ), was 17.6%, with 1/0 being the highest score.

#### 4.1.4 Respiratory Function

A summary of important respiratory function test results are given in table 4.4 (Appendix 5.1, table 1 gives a summary of all

respiratory function results). Lung capacities are consistently 10 - 15% lower than ECCS reference values, while lung diffusion capacities are higher than ECCS reference values (All lung function values were significantly different from ECCS reference values [1]).

**Table 4.4**  
**Lung Function values**

| Outcome (units)                                  | Mean               | SD   | n                | % of ECCS<br>reference |
|--|--------------------|------|------------------|------------------------|
| Forced Vital Capacity<br>(FVC,l)                 | 3.73 <sup>†</sup>  | 0.61 | 125              | 89.24                  |
| Forced 1-second<br>Expiratory Volume<br>(FEV1,l) | 3.06 <sup>†</sup>  | 0.57 | 125              | 86.11                  |
| FEV1/FVC(%)                                      | 82.03 <sup>†</sup> | 9.84 | 125              | 96.85                  |
| Forced expiratory<br>flowrate (l/sec)            | 7.73 <sup>†</sup>  | 1.91 | 125              | 89.23                  |
| Transfer factor ( $T_{L\infty}$ ,<br>ml/min/kPa) | 4.10 <sup>†</sup>  | 0.75 | 107 <sup>*</sup> | 106.4                  |
| $T_{L\infty}$ /alveolar volume<br>(ml/min/kPa/l) | 0.78 <sup>†</sup>  | 0.14 | 107 <sup>*</sup> | 117.12                 |

\* n = 107 for measurement of transfer factor due to breakdown of gas analyzers on day 6 of fieldwork.

<sup>†</sup> Mean is significantly ( $p < 0.05$ ) different from ECCS reference value (1).

#### 4.1.5 Exercise Test

A summary of important exercise test outcomes are shown in table 4.5 (Appendix 5.1, table 1 gives all the univariate exercise test results).



Table 4.5  
Exercise test results

| Outcome (units)                         | Median | Mean   | SD     | n*  | Range       |
|---|--------|--------|--------|-----|-------------|
| Maximum work Load<br>(MWL, Kpm/min)     |        | 1080.3 | 164.46 | 122 | 700 - 1500  |
| % predicted MWL                         |        | 103.45 | 19.80  | 122 | 59 - 170    |
| Resting saturation<br>(%)               |        | 98.3   | 1.5    | 90  | 95 - 100    |
| Saturation at<br>MWL (%)                |        | 95.8   | 2.7    | 90  | 86 - 100    |
| Difference in<br>saturation(%)          |        | 2.54   | 2.36   | 90  | -1 - 10     |
| Rest. heart rate<br>(beats/min)         | 65     | 68.8   | 15.2   | 122 | 60 - 120    |
| Maximum heart rate<br>(beats/min)       | 170    | 168.7  | 12.2   | 122 | 137 - 200   |
| Difference in heart<br>rate (beats/min) | 101.5  | 99.9   | 16.52  | 122 | 32 - 132    |
| % of predicted<br>maximum heart rate    |        | 89.6   | 6.65   | 122 | 73 - 104    |
| VO <sub>2</sub> MAX (ml/min)            |        | 2357.9 | 335.6  | 122 | 1582 - 3210 |

Medians are given for non-normally distributed variables

\* n = 122 for total exercise tests completed; n = 90 for number of

One hundred and twenty - two subjects performed the exercise test and 90 saturation traces in this group were considered interpretable. The proportion of traces that were considered uninterpretable was 28.6%. This group of subjects did not differ significantly from the group with interpretable traces with respect to age, schooling years, maximum heartrate, smoking history, alcohol consumption and lifetime paraquat exposure, but was found to be significantly shorter and lighter ( $p < 0.05$ ). This group also had significantly lower prevalences of chest illnesses and colds ( $p < 0.05$ ).

The prevalence of desaturation at different cut-off levels was 73.3% for  $\geq 1\%$ , 32.2% for  $\geq 4\%$  and 18.8% for  $\geq 5\%$  cut-off levels.

Table 4.5 shows the average maximum workload attained to be 1080.3 kpm/min or 103.5% of predicted, corresponding to a  $V_{O2max}$  of 2.36 l/min. This suggests that most of the subjects where exercising at their true maximal potential. The average maximum pulse rate was 89.6% of predicted values.

#### 4.1.6 Life style factors

Median 20 cigarette pack-years was 7.5 (range = 0-94.5). Lifetime alcohol consumption was 148.8 kg (range = 0-1298.7). Prevalences of lifetime alcohol (92.9 % more than 1 gram) and smoking (84.8% smoked more than 1 cigarette pack-year) consumption are high. Smoking information for one subject was

excluded due to inconsistent questionnaire responses.

#### 4.1.7 Exposure

Table 4.6 shows a summary of important exposure indices (Appendix 5.1 table 1 gives a full summary of exposure values).

Table 4.6  
Exposure univariate results

| Exposure (units)  | Median | n   | Range         |
|---|--------|-----|---------------|
| Employment (years)  | 16.0   | 126 | 3.0 - 54.0    |
| Lifetime average intensity of<br>paraquat exposure (days/yr,<br>JEM* units) | 12.81  | 68' | 0.07 - 192.36 |
| Total cumulative lifetime<br>paraquat exposure (JEM* days)                  | 190.3  | 68' | 1.8 - 5196    |
| Short-term exposure<br>(JEM* days)  | 45.0   | 41' | 0.7 - 135     |

\* JEM = Job Exposure Matrix (see methods)

' n of those exposed > 0 JEM days (numbers < 126)

The average total cumulative exposure of the paraquat exposed workers in the study was found to be approximately 0.52 JEM year-equivalents. The average number of years employed in exposed jobs in this particular group of workers was 11.5 years (range 1 to 47).

No subject reported having been previously poisoned by paraquat.

Only four subjects, of whom 3 had interpretable saturation traces in exercise testing, reported past history of skin burns (back, hands or other) due to paraquat use. The average desaturation in these subjects was  $4.67 \pm 5.03\%$ .

#### 4.2 Bivariate analyses

All categorical and continuous variables (listed in glossary in Appendix 4) were used to explore associations of interest (based on table 3.3 in Methods) using the appropriate statistical tests.

Appendix 5.2 lists the significant associations found in bivariate analysis. For simplicity, only the associations of effect involving total cumulative exposure as index for long term exposure are shown. Similar associations were found for average lifetime intensity indices.

##### *Important associations:*

##### i) Exposure effects on different outcomes:

Oximetry (associations marked "a" in appendix 5.2):

The degree of desaturation was positively associated with highly exposed (EXPA700, EXPPA700) and recently exposed (EXPS, EXPP, SPARACE, SHERBACE) subjects.

Reported respiratory health (associations marked "b" in appendix 5.2):

Past history of phlegm production and episodes of coughing and phlegm were associated with exposure (EXPA0, EXPA50, EXPA100, EXPPA100, EXPPA250), and wheezing with highly exposed subjects (EXPA700, EXPPA700).

ii) Associations between potential confounders and outcome indices:

Smoking (NICCAT) was associated positively with past history of coughing (associations marked "c" in appendix 5.2).

Age (AGE), weight (WEIGHTKG) and height (HEIGHTCM) were associated with most lung function indices (associations marked "d" in appendix 5.2).

iii) As expected, exposure (EXPA700) was positively associated with age (association marked "e" in appendix 5.2). Exposure (EXPPA250, EXPPA700) was also positively associated with alcohol consumption (association marked "f" in appendix 5.2).

#### 4.3 Multivariate Analysis

Bivariate analysis of the study data did not produce additional variables for inclusion in multivariate models in addition to those already included on theoretical grounds.

Smoking and alcohol were treated as continuous variables in all models, because of the low prevalence of non-smokers and non-alcohol users (refer to univariate results).

Long-term exposure variables were run in separate models due to collinearity ( $> 0.9$ ). Short-term exposure was run i) alone as an independent exposure variable in models and ii) together with total long-term exposure as separate predictors in models. The effects of all exposure indices on all outcomes were analyzed.

Because of the similarity of results for radiography, respiratory symptoms and lung function when a) using total long-term measures (includes short-term exposure for example PARACE) for herbicides or paraquat b) using pure long-term measures (long-term exposure after subtraction of short-term component for example PARACE2) and c) including short-term exposure measures in models as described above, the results of only one exposure index (total cumulative exposure) is illustrated below for each outcome.

#### **4.3.1 Radiographic results**

No significant associations were found between small opacity profusion score and age, weight, height, alcohol, smoking and exposure (table 1 in appendix 5.3 summarises the full models when using total cumulative paraquat exposure as an exposure index).

#### 4.3.2 Respiratory Symptoms

None of the reported respiratory symptoms were significantly related to paraquat exposure, neither were they consistently related to any of the other predictors in models which included age, weight, height, education, smoking and alcohol (Appendix 5.4 Table 1 summarises the full models when using total cumulative paraquat exposure as an exposure index).

#### 4.3.3 Respiratory Function Tests

Appendix 5.5, table 1 summarises the linear regression analysis for lung function when using total cumulative paraquat exposure as an exposure index.

Height, weight and age were significant predictors explaining most of the variance for most respiratory function outcomes and were the variables included in the models with the lowest  $C_p$ . Alcohol (adjusted  $\beta = 5.4 \times 10^{-6}$  % per g,  $SE(\beta) = 2.5 \times 10^{-6}$  % per g,  $p = 0.03$ ) was found to be a significant predictor of diffusion capacity and was included in the model with the lowest  $C_p$ .

Smoking was not a consistent predictor and exposure did not significantly affect respiratory function. Only maximum expiratory flow-rate (FEFMAX) was significantly associated with exposure ( $\beta = 5.2 \times 10^{-4}$  l/sec,  $SE(\beta) = 2.4 \times 10^{-4}$  l/sec,  $p = 0.031$ ).

Table 4.7 lists full model regression equations for spirometry in which a) significant predictors found in our study are listed and b) for comparison with the literature only height and weight are included.



Table 4.7

Full model regression equations for spirometry when including  
a) only significant predictors found in our study and b) only height and age

| Equation   | R <sub>2</sub> | p-value |
|--|----------------|---------|
| a) FVC = -2.62 - 0.021 AGE + 0.08 WEIGHT + 0.04 HEIGHT     | 0.3            | 0.0001  |
| b) FVC = -3.25 - 0.019 AGE + 0.047 HEIGHT                  | 0.3            | 0.0001  |
| a) FEV1 = -0.069 - 0.029 AGE + 0.017 WEIGHT + 0.019 HEIGHT | 0.39           | 0.0001  |
| b) FEV1 = -1.35 -0.025 AGE + 0.03 HEIGHT                   | 0.34           | 0.0001  |

#### 4.3.4 Exercise Test Results

Weight, age and difference between post- and pre-exercise heart rate were significant predictors for maximum work load (MAXWL) achieved in exercise testing in a model that also included smoking, alcohol, oxygen saturation at rest and total cumulative paraquat exposure. (Appendix 5.6, table 1 summarises multivariate results).

#### *Exercise oxygen desaturation*

Diagnostics for linear regression and procedure of multivariate analysis:

The Shapiro-Wilk test (a stringent test) for normality indicated that the residuals were not normal. A number of attempted transformations did not improve normality. Stem and leaf and box plots, however did indicate near-normality and because of its robustness, multiple linear regression (statistical notes: Department of Statistics, UCT) was used for exercise desaturation models. Model results were examined for homoscedasticity of residuals and any obviously non linear relationships. Additionally, the nature of potential associations were examined by logistic regression. For logistic regression, dichotomised outcome variables (listed in glossary, appendix 4) were modelled with continuous and dichotomised paraquat exposure variables.

### Correlation matrix:

The correlation matrix of the full model (Appendix 5.7) indicated that collinearity between variables was not a problem (all  $r < 0.8$ ).

### Variables selected:

Table 4.8a summarises the full model results for the relationship between exercise oxygen desaturation and long-term paraquat exposure, using lifetime average intensity of exposure, which had the strongest effect, as an exposure index. Long-term paraquat exposure (partial  $r^2 = 0.0652$ ;  $p = 0.019$ ) and weight (partial  $r^2 = 0.0431$ ;  $p = 0.027$ ) were significant predictors of exercise oxygen desaturation although this explained only a small proportion of the variance. The unadjusted regression coefficients were :

WEIGHTKG:  $-0.0459$  % desaturation/kg ( $r^2 = 0.0326$ ,  $p = 0.0887$ )

PARINT:  $0.0176$  % desaturation/JEM day/yr ( $r^2 = 0.057$ ,  $p = 0.0232$ )

Exposure and weight were also the only variables selected in stepwise procedures and in the model with the lowest  $C_p$  (Table 4.8b)

Table 4.8 Two multiple linear regression models for the effect of lifetime average intensity of paraquat exposure on exercise oxygen desaturation.

a) Full Model ( $n = 90$ ,  $C_p = 7.000$ )

| Predictor        | B                      | SE(B)                 | P-value | Partial.<br>R <sup>2</sup> |
|------------------|------------------------|-----------------------|---------|----------------------------|
| AGE (yrs)        | 0.0350                 | 0.03033               | 0.252   | 0.0007                     |
| WEIGHT (kg)      | -0.0620                | 0.02760               | 0.027   | 0.0431                     |
| SMOKE (pckyrs)   | 0.0067                 | 0.01787               | 0.710   | 0.0012                     |
| ALCOHOL (kg)     | $-6.74 \times 10^{-6}$ | $1.55 \times 10^{-6}$ | 0.666   | 0.0026                     |
| DIFFHR (bts/min) | 0.01499                | 0.01754               | 0.395   | 0.0140                     |
| PARINT (days/yr) | 0.0194                 | 0.00811               | 0.0190  | 0.0652                     |

Model  $R^2 = 0.1222$  (DF=6,  $p = 0.090$ )

b) Best Model resulting from stepping and Cp procedures in SAS ( $n = 90$ ,  $C_p = 0.894$ )

| Predictor | B       | SE(B)  | P-value | Partial<br>R <sup>2</sup> |
|-----------|---------|--------|---------|---------------------------|
| WEIGHT    | -0.0514 | 0.0260 | 0.051   | 0.0408                    |
| PARINT    | 0.0186  | 0.0075 | 0.015   | 0.0611                    |

Model  $R^2 = 0.1019$  (DF = 2,  $p = 0.010$ )

Similar results were found when using a) total long-term exposure measures including lifetime average intensity and lifetime cumulative herbicide or paraquat exposure b) pure long-term exposure measures. Average intensity of exposure was the strongest predictor. PARINT which is a measure of total long-term exposure was used for illustrative purposes in table 4.8. Table 4.9 which gives a summary of linear regression associations with exposure variables, illustrates these effects. The linear regression exposure results were also supported by logistic regression results of the same relationships as well as that between dichotomised exposure and dichotomised oxygen desaturation.

Short-term exposure weakened the effect of total long-term exposure by a small degree when both exposure variables were forced in full models, for example  $\beta(\text{PARINT}) = 0.0180$ ;  $p = 0.062$  when including SPARACE, compared to  $\beta(\text{PARINT}) = 0.0194$ ;  $p = 0.019$  when excluding SPARACE. In these models total long-term exposure was selected in stepwise procedures and the model with the lowest  $C^p$ . Short-term exposure was however, not significant when included as the only exposure variable in the model (SPARACE in table 4.9) and because of the fact that the effect of long-term exposure remained after subtracting the short-term component (PARACE2, PARINT2 in table 4.9), long-term exposure can be considered to have an effect which is independent of short-term exposure.

Appendix 5.8 (tables 1 and 2) gives a full summary of these results.

A distinction could not be made between herbicide exposure and paraquat specific exposure. Both variables were not included in the regression model due to high collinearity ( $r = 0.99$ ).

**Table 4.9 Summary of linear regression associations of exercise oximetry with exposure variables.**

| Predictor | $\beta$ | SE( $\beta$ ) | P-value | Partial $R^2$ | Model $R^2$ |
|-----------|---------|---------------|---------|---------------|-------------|
| PARACE    | 0.00114 | 0.00056       | 0.0464  | 0.0474        | 0.106       |
| PARINT    | 0.01941 | 0.00812       | 0.0190  | 0.0652        | 0.122       |
| SPARACE   | 0.01198 | 0.00826       | 0.1506  | 0.0250        | 0.084       |
| HERBACE   | 0.00116 | 0.00056       | 0.0391  | 0.0508        | 0.109       |
| HERBINT   | 0.01938 | 0.00810       | 0.0192  | 0.0650        | 0.123       |
| PARACE2   | 0.00126 | 0.00058       | 0.0504  | 0.0458        | 0.104       |
| PARINT2   | 0.01984 | 0.00849       | 0.0219  | 0.0624        | 0.120       |

- a) Total lifetime average intensity of paraquat (PARINT) or herbicide (HERBINT) exposure as well as cumulative paraquat (PARACE) and herbicide (HERBACE) exposure are significant predictors ( $p < 0.05$ )
- b) Pure long-term measures (PARACE2, PARINT2) are also strongly associated.
- c) SPARACE is not a significant predictor ( $p = 0.1506$ ).
- d) Average intensity was the strongest predictor.

Odds ratios are shown in table 4.10 for multiple logistic regression analysis of a dichotomous oximetry outcome based on different desaturation cutpoints.

Odds ratios are also shown in table 4.11 for multiple logistic regression analyses of a dichotomous oximetry outcome and dichotomous long-term exposure indices based on different cutpoints.

Alcohol consumption did not modify the effect of paraquat.

The prevalence of skin burns due to paraquat use was not significantly related to exercise oxygen desaturation (t-test, Fisher's Exact test and Logistic Regression) nor did it modify the effect of paraquat.

Reported asthma and tuberculosis prevalences did not have an effect on exposure-outcome relationships. There were no obvious differences between those with earlobe versus finger oximetry.

Table 4.10 The effect of changing cutpoints for dichotomised exercise desaturation in relation to dichotomised total lifetime cumulative paraquat exposure.

| Desaturation<br>cutpoint | Odds Ratio | 95% CI       |
|--------------------------|------------|--------------|
| ≥ 2%                     | 2.09       | 0.49 - 8.92  |
| ≥ 3%                     | 2.79       | 0.75 - 10.31 |
| ≥ 4%                     | 5.66       | 1.39 - 23.06 |
| ≥ 5%                     | 4.76       | 0.94 - 24.16 |

The cut-off level for exposure was 516 JEM days (75th percentile for the exposed group). The strength of the relationship tends to increase as the cutpoint for desaturation is increased.



Table 4.11 The effect of changing cutpoints for dichotomised total lifetime cumulative paraquat exposure in relation to dichotomised exercise desaturation.

| Exposure<br>cutpoint | Odds Ratio | 95% CI      |
|----------------------|------------|-------------|
| $\geq 250$ JEM* days | 1.09       | 0.97 - 1.21 |
| $\geq 700$ JEM* days | 2.72       | 1.85 - 7.44 |

The cut-off level for desaturation was  $\geq 3\%$ . The strength of the relationship tends to increase as the cutpoint for exposure is increased.

\* JEM = Job Exposure Matrix (see methods)

#### **4.3.5 Relationship between lung function and oximetry**

Exercise desaturation was not significantly associated with lung function including diffusion capacity even after adjusting for long-term exposure, age , height, weight, smoking and alcohol.

#### 4.4 References

1. European Community for Coal and Steel mine. Bulletin  
European de Physiopathologie Respiratoire 1983; 19 Suppl 5:  
7-95.

## **CHAPTER 5 DISCUSSION**

### **5.1 The basic finding**

This study is the first to examine the patho-physiological effect of long term low dose paraquat exposure on exercise oximetry. The main finding is a small but significant effect. This is indicated by the fact that the effect was found consistently despite the use of different exposure indices and different modelling techniques. The effect of long-term paraquat exposure is significant even when accounting for short-term exposure. This suggests that exercise oximetry is a sensitive test for the patho-physiological effect expected and seems suitable for the early detection of respiratory illhealth due to paraquat exposure and possibly exposure to other fibrogenic agents.

### **5.2 Biological mechanism**

The primary biochemical mechanism of acute paraquat toxicity (chapter 1) and the effect of pulmonary fibrosis on lung function (chapter 2) have been described in the first two chapters. Briefly, the cell toxicity of paraquat has been linked to its redox reaction with oxygen and reducing equivalents which initiate a number of proposed toxic reactions inside the cell. Cell death, tissue inflammation and eventually pulmonary fibrosis results. Fibrosis causes a decrease in inspiratory capacity due to a stiffening of the lungs. This reduces ventilatory capacity leading to a decrease in ventilatory-perfusion ratios which could

result in hypoxemia, especially during exercise.

Damage of the alveolar capillary membrane could also cause diffusion limitations between alveoli and blood. This could result in hypoxemia during exercise when oxygen diffusion has to occur rapidly because of increased blood flow.

As mentioned in chapter one, previously reported total (respiratory and skin) paraquat exposures of 12-170 mg/kg body-weight/hour of knapsack sprayers are higher than paraquat doses which cause chronic injury in animals. Long-term low dose paraquat exposure in agrochemical applicators and mixers could result in lung injury, especially in cases where absorption is increased by skin damage.

### 5.3 Validity of exercise oximetry

The validity of exercise oximetry as a method for measuring oxygen saturation and as a respiratory health measurement has been discussed in chapter 2. Briefly, oximetry has been shown to correlate with invasive measurements and has been shown to be a more sensitive predictor of respiratory disorders than subjective clinical assessment, spirometry, diffusion capacity and radiography.

### 5.4 Clinical significance of the basic finding

The regression coefficient of total cumulative exposure (PARACE)

in table 4.9 projects that 12.5 JEM years of cumulative paraquat exposure (equivalent to mixing paraquat every day for 12.5 years) will produce 5% exercise oxygen desaturation, commonly regarded as clinically significant (1). None of the subjects that performed a successful exercise test, had that level of lifetime cumulative paraquat exposure suggesting that exposures in the study sample were too low to produce clinically significant desaturation. This perhaps explains the absence of clinical and subclinical effects on lung function testing. One should be careful, however, in drawing conclusions beyond the range of the data. If the median lifetime average intensity of paraquat exposure (13 JEM days) and the median short-term paraquat exposure (45 JEM days) in the study sample are used to indicate the amount of JEM-days that on average could be accumulated in one calendar year, then 12.5 JEM years translate to a lifetime of paraquat exposure. However, exposures in the study sample seemed to be low.

Table 5.1 shows that the prevalence of clinically significant desaturation increased in a dose-dependent manner with increasing paraquat exposure and that the relative prevalence of the highest exposure category compared to the lowest exposure category was 2.85 while the difference in the mean desaturation was 1.54%.

**Table 5.1 The effect of different levels of total cumulative paraquat exposure on exercise oxygen desaturation**

| <b>Exposure category<br/>(days)</b> | <b>n</b> | <b>Prevalence<br/>of desat.</b> | <b>Mean<br/>desaturation (%)</b> |
|-------------------------------------|----------|---------------------------------|----------------------------------|
| 0                                   | 37       | 10.81                           | 2.08                             |
| > 0 and ≤ 200                       | 27       | 22.22                           | 2.37                             |
| > 200 and ≤ 516                     | 13       | 23.08                           | 3.15                             |
| > 516                               | 13       | 30.77                           | 3.62                             |

**Note: Desaturation > 4%**

## 5.5 Previous studies

Guitierrez et al. (personal communication with C Hogstedt) found a positive relationship between paraquat exposure and reported dyspnea on walking and episodic wheezing accompanied by shortness of breath in Nicaraguan workers. In that study the exposure group was divided into a low exposure group which did not report symptoms of paraquat exposure, and a high exposure group which reported symptoms. Two years of cumulative paraquat exposure was the cut-off level for the exposure groups. The level of exposure in our study is lower when considering that the average exposure in our study (190 JEM days amongst exposed) is lower than the lowest value (2 yrs = 730 days) in the Nicaraguan study. The fact that exposure in the Nicaraguan study was not measured using a JEM does not explain the differences in exposures in the two studies. Reported skin burns due to paraquat usage were also substantially higher in the Nicaraguan study. Long term paraquat use is known to cause skin damage. Low exposures and therefore low prevalences of skin burns could account for the lack of association to respiratory symptoms found in this study.

The presence of symptoms of long-term paraquat usage could be used to identify high exposure groups locally as in the Nicaraguan study. The low prevalence of skin burns precluded its incorporation into exposure calculations and weakened its use as a separate exposure variable and potential effect modifier in this study. Nevertheless, the average oxygen desaturation of the subjects who reported skin burns due to paraquat and who had



interpretable saturation traces (3) was high (4.67 %).

Previous studies (3, 4) also found no effect of paraquat exposure on FEV1, FVC, FEV1/FVC and carbon monoxide transfer factor. Low exposures and a lack of sensitivity in detecting subtle respiratory defects might be factors explaining these results. Sample size calculations indicated that the sample size in this study requires substantially larger exposure effects for oximetry than for respiratory symptoms, spirometry and diffusion capacity measurements. These exposure effects as a percentage of the mean of the respective outcomes are:

FVC : 7% (0.27 ml)

K<sub>co</sub> : 8% (0.34 kPa)

DIFFSAT: 93 % (1.1%)

The fact that despite this, an exposure effect was measured with oximetry, indicates that the measurement of exercise desaturation is a sensitive test for measuring respiratory health. The exposure effect on diffusion capacity was less than originally estimated.

## 5.6 Selection biases

Various selection biases which might have given rise to an underestimation of the paraquat effect include the low response from small farms which might have excluded some relatively highly exposed workers from the study sample and low exposures compared

to other studies. The Healthy Worker Effect (HWE) in this cross-sectional study is not thought to be significant because:

Firstly the nature of adverse effects being sought are subtle and often subclinical, and are unlikely to result in gross disability leading to job loss or to death, and therefore loss to the study population.

Secondly, farm workers in South Africa appear to have limited labour market mobility. Those who lose their jobs, tend to remain as farm workers but on other farms in less demanding jobs (5) and may have appeared in our study as currently non-exposed subjects with a history of past exposure. In our study 6 subjects selected as current non-applicators were former paraquat spraymen.

Another variant of the Healthy Worker Effect, selection of healthy individuals into the farm worker workforce, is also likely to be very limited in the South African agricultural setting, given the lack of alternative employment opportunities, the low levels of unemployment in rural areas relative to urban areas (6) and the low-skill requirements of agricultural labour.

## 5.7 Misclassification

The lack of a gold standard for past paraquat exposure, non-existent agronomic records and very low literacy levels of farmworkers necessitated the use of a Job Exposure Matrix(JEM)

as a best estimate of exposures. The JEM was shown to be reasonably valid and repeatable in a study focusing on organophosphate exposure (7), although formal validation by industrial hygiene studies of workers involved in the job activities used in the JEM, is still required. The inclusion of farming sector in the JEM might have refined exposure dose estimation, although pome fruit farming was found to be the predominant farming sector in the previous study (7). A small proportion of herbicide sprayers also sprayed insecticides in the same job. This means that the herbicide and paraquat exposure estimates contained a small amount of insecticide exposure. Any misclassification arising from this and the use of the JEM would most likely have been non-differential given the blinded nature of exposure estimation. This might be expected to have biased any measured effect towards the null, except in the case of extreme exposure scenarios (8).

Formal validation of the JEMs for the deciduous fruit setting is essential and this requires one or more field industrial hygiene studies of workers involved in the job activities used in the JEM to confirm or adjust the priori estimates.

### 5.8 Recall bias

Recall bias might have been operative for the reporting of respiratory symptoms, but there was probably insufficient understanding by subjects of the effects of paraquat to cause them to over report. Observers in the different aspects of the

study were blind to all other aspects with the exposure questionnaire being administered before recording respiratory outcomes.

It is additionally very difficult for the subject to knowingly interfere with exercise-desaturation relationships in such a way as to bias the exposure-desaturation association away from the null.

### 5.9 Generalisability

Generalisability of these results is limited by the exclusion of females and the fact that it applies only to farm workers from the study. An unknown number of women are being employed in work involving agrochemical spraying in South Africa. Additionally, the study sample was obtained from farms belonging to two large co-operatives which export fruit to international markets. The infrastructure and safety practices on these farms would in general be of a higher standard than on other farms in South Africa. London(7) found the use of personal protective equipment on these farms to be high which could mean that pesticide exposures in this study were probably on the low end of the spectrum. The study population is unlikely to differ substantially from agricultural worker populations in other less developed countries.

## 5.10 Validation of field oximetry

The average resting saturation of 98.3% compares well with laboratory measurements by Taylor (1). The lowest resting oxygen saturation level in the sample of 95% indicates that all starting values in the sample were in the plateau region of the sigmoidal oxygen-haemoglobin dissociation curve, above the recommended cut-off of 94%. The significant predictors of exercise performance in this study (age and weight were significant predictors of the maximum workload achieved during exercise) are consistent with those measured in the literature (9-10). This shows conclusively that exercise oximetry can be used in a field setting.

One limitation of oximetry in general is the high proportion (28.6%) of unusable traces. This is unavoidable as the technique is subject to movement artefact from jerky cycling movements due to subjects straining and flailing their heads. Lack of familiarity with the cycle or the type of ergometer might have caused this, but even people who are very familiar with cycle ergometry and who use more sophisticated cycle ergometers can cause artifacts when approaching their maximum. A Biox type oximeter has been found to have the highest correlation to invasively measured oxygen desaturation in a group of COPD patients of a group of oximeters currently available on the market (11). Measurements could have been improved if the procedures of the exercise test were demonstrated to subjects in groups. This was not focused upon during exercise testing in the current study because of time and logistic constraints. Group

demonstrations and technological advances to reduce noise due to movement artefact in oximeters could substantially reduce the number of uninterpretable traces during exercise oximetry.

The non-significance of smoking and age, which are known risk factors for respiratory disease, as predictors of exercise desaturation in the study must be explained. Smoking was also not a consistent predictor for other outcome measures in the study and this point is discussed later. Age has a greater effect on spirometry than on oximetry which is reliant on the efficiency of gas exchange within the lungs and this is far more dependent upon regional inequalities of ventilation and perfusion due to lung disease. This is the first study that has used exercise oximetry in a field setting and more multivariate studies are required to explore the effect of age on exercise desaturation.

The amount of desaturation did not consistently predict lung function (refer to multivariate results), but this could be expected because exercise oximetry is a more sensitive respiratory health measurement than lung function testing. Sue (12) found diffusion capacity to be an insensitive, but specific marker of respiratory disease. Diffusion capacity and other respiratory health measurements are probably not sensitive tests for the detection of the expected subclinical nature of respiratory defect due to long-term paraquat exposure in this study population.

The high prevalence of desaturation at all cut-off levels (refer to univariate results) indicates the high sensitivity of oximetry. The test is however not specific for paraquat.

#### 5.11 Other findings in the study

An interesting finding was that body weight was an unexpected predictor of exercise desaturation and transfer factor. This association is expected for spirometry where body status is a known predictor (spirometry involves measurement of ventilatory capacity). This indicates that low weight as a marker of poor socio-economic status may predict poor respiratory health. Mean heights and weights of the study group were extremely low, indicating serious nutritional and growth retardation problems manifesting as low weight for age and stunting. This is consistent with the finding in the previous study (6) where low serum albumin predicted poorer neurobehavioral function (vibration sense) in a similar group.

Consistent with other studies on similar populations (13), the lung function values in this study (FVC, FEV1) were lower than ECCS reference values (14). In a review by White (13) on spirometric values of healthy populations of subsaharan ancestry (including 9690 men), considerable variation in standardised spirometric values of individual studies were found. The standardised (age = 38 yrs and height 171 cm) spirometric values for this study calculated using the methods in the review are:



FVC (1): 4.07 (3.85 - 4.29)

FEV1 (1): 2.83 (2.61 - 3.05).

These values are higher than values found in grain mill and control factory workers in Cape Town (15) and lower than textile (16), asbestos (17) and bank workers (18) measured in South Africa, although factors such as calendar year, geographic region and altitude should be considered when comparing measurements from individual populations (13).

This finding and the fact that the FEV1/FVC ratio was significantly below ECCS reference values suggests mild airflow obstruction present in this population. Regression analysis suggest that this is not smoking or paraquat related. The defect might be explained by adverse socio-environmental (SE) factors present in the study population (19).

The prevalence of past history of asthma was low and that of tuberculosis high when compared to that found in textile workers in South Africa (16) with similar anthropometric measurements. The prevalence of past history of tuberculosis seemed to be similar or lower than that found in industrial settings in Cape Town (15, 20).

The significant effects of age, weight, and difference between post- and pre-exercise heart rate on exercise are not unexpected. Weight, as a proxy for body size, and age are known predictors of performance in exercise testing (exercise performance



prediction equations includes age and weight). Heart rate is known to increase with exercise intensity (9).

The inconsistent relationship between smoking and reported respiratory symptoms and lung function is consistent with earlier studies performed on industrial workers (15, 20) and might be due to the low level of smoking (average of 7.5 cigarette pack years) despite the high percentage of smokers. The low percentage of non-smokers (15.2%) in the study might not have provided sufficient information to investigate smoking as a predictor of respiratory health in this study. The 'healthy smoker' effect (phenomenon where healthy individuals tend to take up smoking more than unhealthy individuals) might explain the inconsistent relationships to smoking. There is evidence (22) that this phenomenon is operative in smoking populations.

#### 5.12 Bradford-Hill criteria

Most of the Bradford-Hill criteria used for demonstrating causality, applicable in this study are fulfilled. **Strength** (the effect of paraquat was significant on a group of workers not highly exposed), **dose** (the effect was shown using linear regression and table 5.1 shows dose dependent effect), **biological plausibility** (cell toxicity mechanism involving the production of superoxide radicals) and **experimental evidence** (animal studies have shown paraquat effects in low doses) exists. Although the cross-sectional study design does not demonstrate time ordering, paraquat exposure could be assumed to precede respiratory disease

because there are no known selection effects operative explaining the reverse. Only consistency has not been demonstrated because this is the first study which has shown a long term effect of paraquat. However, this study has used more sensitive methods for measuring exposure and outcome compared to previous studies. Specificity and analogy are not applicable. The evidence could thus be said to be reasonably coherent.

### 5.13 Recommendations

According to current pesticide legislation, paraquat has no chronic health effects and is regarded as being safe for use under normal application conditions. This study has however indicated that long term paraquat exposure under normal application conditions could result in respiratory abnormalities. This result should at least emphasise the need to increase farmers' and farm workers' awareness of the possible health hazards of paraquat by informing them of the chronic health effects in addition to the known acute effects. This could encourage the increased use of protective clothing and safer and reduced application of paraquat. The study has also emphasised the importance of early effective treatment of paraquat burns. The need for further studies performed prospectively and studies performed on women, who might be more highly exposed, is highlighted.

The practicability and usefulness of exercise oximetry as a sensitive test in a field setting holds promise for the

investigation and possibly the early detection and secondary prevention of occupational respiratory disease. Exercise oximetry could be used for screening (biological monitoring) workers.

#### 5.14 Conclusions

Exercise oximetry appears to be a more sensitive measure for subclinical respiratory effects than clinical symptoms or lung function tests. This study demonstrated a clear relationship between long term paraquat exposure and exercise oximetry independently of recent acute effects of exposure or sequelae of past poisoning episodes. Subtle occupational respiratory effects due to other agents should be researched further using this technique.

## 5.15 References

1. Taylor M.B., Whitwam J.G. The current status of pulse oximetry. *Anaesthesia* 1986; 41: 943-9
2. Bernardini P; Paraquat and diquat: toxicological aspects and occupational hazards; *Archives di Scienze del Lavoro*. 1986; 331(2) : 117 - 123
3. Howard JK, Sabapathy NN, Whitehead PA. A study of the health of Malaysian plantation workers occupationally exposed to paraquat. *British Journal of Industrial Medicine*. 1981; 38: 110 - 116
4. Senanayake N, Gurunathan G, Hart TB, Amerisinghe P, Babapulle M, Ellapolla SB, Udupihille M, Basanayake V. An epidemiological study of the health of Sri Lankan tea plantation workers associated with long term exposure to paraquat. *British Journal of Industrial Medicine* 1993; 50: 257 -263
5. Waldman PL. Here you will remain: Adolescent experience on farms in the Western Cape [MA Thesis] Cape Town: Department of Anthropology, University of Cape Towns, 1993
6. Donaldson A, Roux A. Education, employment and income of black South Africans in 1985. *Development South Africa* 1994;

7. London L, An investigation into the neurological and neurobehavioural effects of long-term agrochemical exposure among deciduous fruit farm workers in the Western Cape, South Africa, 1994 [MD Thesis]. Cape Town: Department of Community Health. University of Cape Town, 1994
8. Dosemeci M, Wacholder S, Lubin JH. Does nondifferential misclassification of exposure always bias a true effect towards the null? American Journal of Epidemiology; 132(4): 746-748.
9. Jones NL, Campbell EJM . Clinical exercise testing. 2nd ed. Philadelphia: W.B Saunders, 1982.
10. Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing. American Review of Respiratory Disease 1984; 129 Suppl: S49 -S55
11. Würtemberger G, Muller S, Matthys H, Sokolov I. Accuracy of nine commercially available pulse oximeters in monitoring patients with chronic respiratory insufficiency. Monaldi Arch Chest Dis 1994; 49(4): 348 - 353.
12. Sue D Y, Oren A, Hansen JE, Wasserman K. Diffusion capacity for carbon monoxide as a predictor of gas exchange during exercise. New England Journal of Medicine 1987; 316 : 1301 - 6

13. White NW, Hanley JH, Lalloo UG, Becklake MR. Review and analysis of variation between spirometric values reported in 29 studies of healthy African Adults. American Journal of Respiratory and Critical Care Medicine 1994; 150: 358 - 5
14. European Community for Coal and Steel. Bulletin European Physiopathologie Respiratoire 1983; 19 Suppl 5: 7-95
15. Yach D. Myers J. Bradshaw D. Benatar SR. A respiratory epidemiologic survey of grain mill workers in Cape Town, South Africa. American Review of Respiratory Disease 1985; 131: 505-510
16. White N. Byssinosis in South Africa. A survey of 2411 textile workers. South African Medical Journal 1989; 75: 435-42.
17. Coetzee AM, Becker PJ. Lung function screening in industry. South African Medical Journal 1989; 67: 550 -3
18. Goldin JG. Spirometric and gas transfer measurements among normal adult South African men - an investigation into anthropometric, socio-economic, racial and environmental factors influencing lung function in Cape Town, South Africa [PhD Thesis]. Cape Town: Department of Community Health. University of Cape Town, 1994

19. Steinberg M, Becklake MR. Socio-environmental factors and lung function. South African Medical Journal 1986; 70: 270 - 4.
20. Myers JE, Cornell JE. Respiratory health of brickworkers in Cape Town, South Africa. Scandanavian Journal of Work and Environmental Health 1989; 15: 188-194.
21. Ragoucy-Sengler C, Pileire B, Daijardin JB. Survival from severe paraquat intoxication in heavy drinkers. Lancet 1991; 338: 1461.
22. Becklake MR, Lalloo U. 'The healthy smoker': a phenomenon of health selection? Respiration 1990; 57(3): 137-44.

## **APPENDICES**

### **Appendix 1: Questionnaires**



Appendix 1.1 Questionnaire 1

STUDY NUMBER :

\*\*\*\*\*

GIFSTOFOPNAME - CERES / KOUEBOKKEVELD 1994-

Department of Community Health

University of Cape Town

TOESTEMMING

Ons doen hierdie navorsingsstudie om vas te stel of die aard van u werk enige moontlike effekte op u gesondheid het. Hierdie informasie sal gebruik word om veiligheid in die werksituasie te verbeter.

Vrae sal gevra word, ondersoeke sal gedoen word en bloedtoetse sal geneem word om die studie moontlik te maak.

Enige-iets wat u aan ons vertel en alle resultate van die ondersoeke sal vertroulik hanteer word - dit beteken dat slegs u (en die verpleegster op die plaas) kennis sal dra van die resultate en niemand anders sonder u toestemming daarvan kennis sal kan neem nie.

'n Algemene rapport van die studie sal aan die plase verskaf word, maar individuele resultate sal nie daarin geïdentifiseer kan word nie. Ons sal u resultate aan u stuur, behalwe as u dit nie wil hê nie. Sal u so vriendelik wees om enige van die ondersoekers in kennis te stel indien u die resultate NIE wil hê nie.

Hiermee gee ek my toestemming om aan hierdie studie deel te neem:

..... (handtekening)

## INHOUDSOPGAWE

## Bladsy

|    |                                    |    |
|----|------------------------------------|----|
| A. | INLEIDING                          | 1  |
|    | Vrae 1 - 6                         |    |
| B. | LEWENSGESKIEDENIS                  | 2  |
|    | Vrae 1 - 12                        |    |
| C. | WERKSONDERVINDING                  | 10 |
|    | Vrae 1 - 12                        |    |
| D. | HOUDING TEENOR VEILIGHEIDSMATREËLS | 17 |
|    | Vrae 1 - 6                         |    |
| E. | AKUTE BLOOTSTELLING                | 18 |
|    | Vrae 1 - 3                         |    |
| F. | HUISHOUDELIKE BLOOTSTELLING        | 19 |
|    | Vrae 1 - 4                         |    |
| G. | NEUROLOGIESE SIMPTOME              | 21 |
| H. | ROOKGEWOONTES                      | 22 |
|    | Vrae 1 - 9                         |    |
| I. | ALKOHOLGEBRUIK                     | 24 |
|    | Vrae 1 - 27                        |    |
| J. | EXAMINATION FINDINGS               | 27 |

## A. INLEIDING

DATUM VAN ONDERHOUD: (dd/mm/jj)

NAAM VAN DIE ONDERHOUDVOERDER: .....

PLAASNAAM: .....

## INLIGTING OOR DIE WERKER

1. Die werker se voornaam: .....

2. Die werker se van: .....

3. Werker se geboortedatum: (dd/mm/jj) .....

4. Die werker se Algemene Praktisyn (naam): .....

5. Wat is die hoogste standerd wat u voltooi het? .....

6. Vir hoeveel jaar was u op skool? .....

(Begin skoolgaan: ..... Opgehou: .....)

|    |  |  |  |  |  |  |  |
|----|--|--|--|--|--|--|--|
| 1  |  |  |  |  |  |  |  |
| 5  |  |  |  |  |  |  |  |
| 11 |  |  |  |  |  |  |  |
| 12 |  |  |  |  |  |  |  |
| 15 |  |  |  |  |  |  |  |
| 21 |  |  |  |  |  |  |  |
| 27 |  |  |  |  |  |  |  |
| 33 |  |  |  |  |  |  |  |
| 39 |  |  |  |  |  |  |  |
| 41 |  |  |  |  |  |  |  |
| 43 |  |  |  |  |  |  |  |

B. LEWENSGESKIEDENIS

1. Waar is u gebore?

Naam van die plek:.....

Naam van die distrik:.....

Hoe lank het u daar gewoon?.....

2. Waar het u daarna gewoon?

Naam van die plek:.....

Naam van die distrik:.....

Hoe lank het u daar gewoon?.....

3. Waar het u daarna gewoon?

Naam van die plek:.....

Naam van die distrik:.....

Hoe lank het u daar gewoon?.....

4. Waar het u daarna gewoon?

Naam van die plek:.....

Naam van die distrik:.....

Hoe lank het u daar gewoon?.....

5. Waar het u daarna gewoon?

Naam van die plek:.....

Naam van die distrik:.....

Hoe lank het u daar gewoon?.....

6. Waar het u daarna gewoon?

Naam van die plek:.....

Naam van die distrik:.....

Hoe lank het u daar gewoon?.....

7. Waar het u daarna gewoon?

Naam van die plek:.....

Naam van die distrik:.....

Hoe lank het u daar gewoon?.....

Waar het u daarna gewoon?

Naam van die plek:.....

Naam van die distrik:.....

Hoe lank het u daar gewoon? .....

Waar het u daarna gewoon?

Naam van die plek:.....

Naam van die distrik:.....

Hoe lank het u daar gewoon? .....

0. Waar het u daarna gewoon?

Naam van die plek:.....

Naam van die distrik:.....

Hoe lank het u daar gewoon? .....

TABEL 1: Vir elke woonplek bo, vul die tabel in.

| Tipe plek (sleutel) | Duur  | Losies (Ja/Nee) |
|---------------------|-------|-----------------|
| 1.....              | ..... | .....           |
| 2.....              | ..... | .....           |
| 3.....              | ..... | .....           |
| 4.....              | ..... | .....           |
| 5.....              | ..... | .....           |
| 6.....              | ..... | .....           |
| 7.....              | ..... | .....           |
| 8.....              | ..... | .....           |
| 9.....              | ..... | .....           |
| 10.....             | ..... | .....           |

#### SLEUTEL

1. stad
2. dorp
3. klein dorp
4. plaas
5. plaas en ander plek
6. klein dorp en ander plek
7. ander

# EERSTE PLAAS

PLEKNOMMER: ..... PLEKNAAM: .....

1. Waarmee is daar geboer?

.....

.....

2. Waar was u huis geleë in verhouding met die naaste boord, wingerd of landery (posisie) SLEUTEL (\*)

.....

## SLEUTEL:

- 1.in die landery / boord / wingerd
- 2.langs die landery / boord / wingerd (< 10 m)
- 3.oorkant die pad / rivier

Identifiseer 'n landmerk en vergelyk die afstande met die afstande in die werker se situasie:

- 4.10 - 100 m vanaf die landery / boord / wingerd
- 5.100 - 1000 m vanaf die landery / boord / wingerd
- 6.>1000 m vanaf die landery / boord / wingerd

3. Is die boord, wingerd of landerye met gifstowwe gespuit?

1.JA 2.NEE 3.NIE SEKER

INDIEN JA:

Is die spuitwerk gedoen met behulp van 'n:

\* Rugsak? 1.JA 2.NEE 3.NIE SEKER

\* Trekker? 1.JA 2.NEE 3.NIE SEKER

\* Vliegtuig? 1.JA 2.NEE 3.NIE SEKER

## TWEEDE PLAAS

PLEKNOMMER: ..... PLEKNAAM: .....

1. Waarmee is daar geboer?

.....

.....

2. Waar was u huis geleë in verhouding met die naaste  
boord, wingerd of landery (posisie) SLEUTEL (\*)

.....

3. Is die boord, wingerd of landerye  
met gifstowwe gespuit? 1.JA 2.NEE 3.NIE SEKER

INDIEN JA:

Is die spuitwerk gedoen met behulp van 'n:

\* Rugsak? 1.JA 2.NEE 3.NIE SEKER

\* Trekker? 1.JA 2.NEE 3.NIE SEKER

\* Vliegtuig? 1.JA 2.NEE 3.NIE SEKER

## DERDE PLAAS

PLEKNOMMER: ..... PLEKNAAM: .....

1. Waarmee is daar geboer?

.....

.....

2. Waar was u huis geleë in verhouding met die naaste boord,  
wingerd of landery (posisie) SLEUTEL (\*)

.....

3. Is die boord, wingerd of landerye  
met gifstowwe gespuit? 1.JA 2.NEE 3.NIE SEKER

INDIEN JA:

Is die spuitwerk gedoen met behulp van 'n:

\* Rugsak? 1.JA 2.NEE 3.NIE SEKER

\* Trekker? 1.JA 2.NEE 3.NIE SEKER

\* Vliegtuig? 1.JA 2.NEE 3.NIE SEKER

## VIERDE PLAAS

PLEKNOMMER: ..... PLEKNAAM: .....

1. Waarmee is daar geboer?

.....

.....

2. Waar was u huis geleë in verhouding met die naaste boord,  
wingerd of landery (posisie) SLEUTEL (\*)

.....

3. Is die boord, wingerd of landerye  
met gifstowwe gespuit? 1.JA 2.NEE 3.NIE SEKER

INDIEN JA:

Is die spuitwerk gedoen met behulp van 'n:

\* Rugsak? 1.JA 2.NEE 3.NIE SEKER

\* Trekker? 1.JA 2.NEE 3.NIE SEKER

\* Vliegtuig? 1.JA 2.NEE 3.NIE SEKER

## VYFDE PLAAS

PLEKNOMMER: ..... PLEKNAAM: .....

1. Waarmee is daar geboer?

.....

.....

2. Waar was u huis geleë in verhouding met die naaste boord,  
wingerd of landery (posisie) SLEUTEL (\*)

.....

3. Is die boord, wingerd of landerye  
met gifstowwe gespuit? 1.JA 2.NEE 3.NIE SEKER

INDIEN JA:

Is die spuitwerk gedoen met behulp van 'n:

\* Rugsak? 1.JA 2.NEE 3.NIE SEKER

\* Trekker? 1.JA 2.NEE 3.NIE SEKER

\* Vliegtuig? 1.JA 2.NEE 3.NIE SEKER



# SESDE PLAAS

PLEKNOMMER: ..... PLEKNAAM: .....

1. Waarmee is daar geboer?

34

36

38

40

2. Waar was u huis geleë in verhouding met die naaste  
boord, wingerd of landery (posisie) SLEUTEL (\*)

41

3. Is die boord, wingerd of landerye  
met gifstowwe gespuit? 1.JA 2.NEE 3.NIE SEKER

42

INDIEN JA:

Is die spuitwerk gedoen met behulp van 'n:

\* Rugsak? 1.JA 2.NEE 3.NIE SEKER

43

\* Trekker? 1.JA 2.NEE 3.NIE SEKER

44

\* Vliegtuig? 1.JA 2.NEE 3.NIE SEKER

45

## SEWENDE PLAAS

PLEKNOMMER: ..... PLEKNAAM: .....

46

1. Waarmee is daar geboer?

48

50

52

2. Waar was u huis geleë in verhouding met die naaste boord,  
wingerd of landery (posisie) SLEUTEL (\*)

53

3. Is die boord, wingerd of landerye  
met gifstowwe gespuit? 1.JA 2.NEE 3.NIE SEKER

54

INDIEN JA:

Is die spuitwerk gedoen met behulp van 'n:

\* Rugsak? 1.JA 2.NEE 3.NIE SEKER

55

\* Trekker? 1.JA 2.NEE 3.NIE SEKER

56

\* Vliegtuig? 1.JA 2.NEE 3.NIE SEKER

57

## AGSTE PLAAS

PLEKNOMMER: ..... PLEKNAAM: .....

1. Waarmee is daar geboer?

.....

.....

2. Waar was u huis geleë in verhouding met die naaste boord,  
wingerd of landery (posisie) SLEUTEL (\*)

.....

3. Is die boord, wingerd of landerye  
met gifstowwe gespuit? 1.JA 2.NEE 3.NIE SEKER

INDIEN JA:

Is die spuitwerk gedoen met behulp van 'n:

\* Rugsak? 1.JA 2.NEE 3.NIE SEKER

\* Trekker? 1.JA 2.NEE 3.NIE SEKER

\* Vliegtuig? 1.JA 2.NEE 3.NIE SEKER

## NEGENDE PLAAS

PLEKNOMMER: ..... PLEKNAAM: .....

1. Waarmee is daar geboer?

.....

.....

2. Waar was u huis geleë in verhouding met die naaste boord,  
wingerd of landery (posisie) SLEUTEL (\*)

.....

3. Is die boord, wingerd of landerye  
met gifstowwe gespuit? 1.JA 2.NEE 3.NIE SEKER

INDIEN JA:

Is die spuitwerk gedoen met behulp van 'n:

\* Rugsak? 1.JA 2.NEE 3.NIE SEKER

\* Trekker? 1.JA 2.NEE 3.NIE SEKER

\* Vliegtuig? 1.JA 2.NEE 3.NIE SEKER

# TIENDE PLAAS

PLEKNOMMER: ..... PLEKNAAM: .....

1. Waarmee is daar geboer?

.....

.....

2. Waar was u huis geleë in verhouding met die naaste  
boord, wingerd of landery (posisie) SLEUTEL (\*)

.....

3. Is die boord, wingerd of landerye  
met gifstowwe gespuit? 1.JA 2.NEE 3.NIE SEKER

INDIEN JA:

Is die spuitwerk gedoen met behulp van 'n:

\* Rugsak? 1.JA 2.NEE 3.NIE SEKER

\* Trekker? 1.JA 2.NEE 3.NIE SEKER

\* Vliegtuig? 1.JA 2.NEE 3.NIE SEKER

11. Het u ooit SAAM MET IEMAND in die huis gewoon wat:

a) Vir 'n firma gewerk het waar  
gifstowwe vervaardig is? 1.JA 2.NEE 3.NIE SEKER

INDIEN JA, gee die aantal jare: .....

b) Vir iemand gewerk wat  
gifstowwe versprei het? 1.JA 2.NEE 3.NIE SEKER

INDIEN JA, gee die aantal jare: .....

c) Gifstowwe in geboue teen plaes  
aangewend het? 1.JA 2.NEE 3.NIE SEKER

INDIEN JA, gee die aantal jare: .....

d) Gifstowwe gespuit het op 'n plaas 1.JA 2.NEE  
3.NIE SEKER

INDIEN JA, gee die aantal jare en wie dit gedoen het:

.....

12. Het u ooit naby 'n fabriek wat  
gifstowwe vervaardig gewoon? 1.JA 2.NEE 3.NIE SEKER

INDIEN JA, gee die aantal jare: .....

## C. WERKSONDERVINDING

## 1. EERSTE WERK

1. Wat was u eerste werk? (ook deeltydse werk terwyl op skool of terwyl woonagtig by ouers of seisoenwerk op 'n plaas):

.....

2. Hoe oud was u toe u begin werk het? .....

3. Watter soort werkplek was dit? .....

4. Beskryf die werk wat u gedoen het (wat het u die meeste van die tyd gedoen?):

.....

.....

5. Waar was hierdie werk? .....  
(Pleknaam en distrik)

## 2. TWEDE WERK

1. Watse werk het u daarna gedoen?

.....

2. Hoe oud was u toe u die werk begin het? .....

3. Watter soort werkplek was dit? .....

4. Beskryf die werk: (die meeste van die tyd gedoen?):

.....

.....

5. Waar was hierdie werk? .....  
(Pleknaam en distrik)

## 3. DERDE WERK

1. Watse werk het u daarna gedoen?

.....

2. Hoe oud was u toe u die werk begin het? .....

3. Watter soort werkplek was dit? .....

4. Beskryf die werk: (die meeste van die tyd gedoen?):

.....

5. Waar was hierdie werk? .....  
(Pleknaam en distrik)

4. **VIERDE WERK**

1. Watse werk het u daarna gedoen?

.....

2. Hoe oud was u toe u die werk begin het? ..... 61

3. Watter soort werkplek was dit? ..... 63

4. Beskryf die werk: (die meeste van die tyd gedoen?):

..... 46

.....

5. Waar was hierdie werk? ..... 67  
(Pleknaam en distrik)

5. **VYFDE WERK**

1. Watse werk het u daarna gedoen?

.....

2. Hoe oud was u toe u die werk begin het? ..... 69

3. Watter soort werkplek was dit? ..... 71

4. Beskryf die werk: (die meeste van die tyd gedoen?):

..... 74

.....

5. Waar was hierdie werk? ..... 75  
(Pleknaam en distrik)

6. **SESDE WERK**

1. Watse werk het u daarna gedoen?

.....

2. Hoe oud was u toe u die werk begin het? ..... 7

3. Watter soort werkplek was dit? ..... 7

4. Beskryf die werk: (die meeste van die tyd gedoen?):

..... 12

.....

5. Waar was hierdie werk? ..... 13  
(Pleknaam en distrik)

7. **SEWENDE WERK**

1. Watse werk het u daarna gedoen?

.....

2. Hoe oud was u toe u begin werk het? .....

3. Watter soort werkplek was dit? .....

4. Beskryf die werk wat u gedoen het (wat het u die meeste van die tyd gedoen?):

.....

.....

5. Waar was hierdie werk? .....  
(Pleknaam en distrik)

8. **AGSTE WERK**

1. Watse werk het u daarna gedoen?

.....

2. Hoe oud was u toe u die werk begin het? .....

3. Watter soort werkplek was dit? .....

4. Beskryf die werk: (die meeste van die tyd gedoen?):

.....

.....

5. Waar was hierdie werk? .....  
(Pleknaam en distrik)

9. **NEGENDE WERK**

1. Watse werk het u daarna gedoen?

.....

2. Hoe oud was u toe u die werk begin het? .....

3. Watter soort werkplek was dit? .....

4. Beskryf die werk: (die meeste van die tyd gedoen?):

.....

5. Waar was hierdie werk? .....  
(Pleknaam en distrik)

10. TIENDE WERK

1. Watse werk het u daarna gedoen?

.....
2. Hoe oud was u toe u die werk begin het? .....

39
3. Watter soort werkplek was dit? .....

41
4. Beskryf die werk: (die meeste van die tyd gedoen?):

.....

.....

44
5. Waar was hierdie werk? .....

(Pleknaam en distrik)

45

TABEL 2:

Dui vervolgens aan in watter kategorie elk van die voorafgaande soorte werk val, deur dit A, B, C of D te noem, soos hieronder aangedui:

- Landbou - A
- Bosbou - B
- Gifstofvervaardiging, Fabriek of Vervoer - C
- Munisipaliteit - D

As dit ander werk is - 0

| Kategorie:    | Jaar: |
|---------------|-------|
| WERK 1: ..... | ..... |
| WERK 2: ..... | ..... |
| WERK 3: ..... | ..... |
| WERK 4: ..... | ..... |
| WERK 5: ..... | ..... |
| WERK 6: ..... | ..... |
| WERK 7: ..... | ..... |
| WERK 8: ..... | ..... |
| WERK 9: ..... | ..... |
| WERK 10:..... | ..... |

|  |  |  |    |
|--|--|--|----|
|  |  |  | 48 |
|  |  |  | 51 |
|  |  |  | 54 |
|  |  |  | 57 |
|  |  |  | 60 |
|  |  |  | 63 |
|  |  |  | 66 |
|  |  |  | 69 |
|  |  |  | 72 |
|  |  |  | 75 |

vul nou asb. die ooreenstemmende seksies oor spesifieke bedrywighede in: LANDBOU, BOSBOU, FABRIEK EN VERVOER, MUNISIPALITEIT  
\*(word gevind in die ekstra leërs wat voorsien is)

11. **ANDER WERK**

- \* Is daar enige ander werk wat u voorheen gedoen het, wat u nog nie genoem het nie, waarin u kontak gehad het met gifstowwe?

1.JA 2.NEE 3.NIE SEKER


**INDIEN JA:**

.1 Watter soort werkplek was dit? .....

.2 Beskryf die werk: (wat het u die meeste van die tyd gedoen?):

.....

.....

.3 Waar was hierdie werk? (Dorp of distrik) .....

.4 Vir hoe lank het u die werk gedoen?

Jare: ..... Maande: .....

(Hoe oud was u toe u hierdie werk begin doen het en hoe oud was u toe u met die werk opgehou het)

As die werk een van die volgende bedrywighede is:

LANDBOU, BOSBOU, FABRIEK EN VERVOER, MUNISIPALITEIT

Vul dan die ooreestemmende seksies in (word gevind in die ekstra leërs wat voorsien is)

12. **CHECK VRAAG**

1. Het u ooit vir iemand gewerk:

- |  |            |
|--|------------|
| * wat gifstowwe versprei het                           | 1.JA 2.NEE |
| * wat geboue binne en buite teen pes gespuut het       | 1.JA 2.NEE |
| * waar u betrokke was by die aflewering van plaagdoder | 1.JA 2.NEE |

As die werker ja op enige van bogenoemde vrae beantwoord het:


**VOLTOOI SEKSIE E**

[ MAAR as die werker REEDS die WERK GENOEM HET, ignoreer die vraag en gaan na die volgende vraag 13]



### 13. BESKERMINGMONDERING

1. Het u beskermingsmondering gekry as u gifstowwe hanteer het? 1.JA 2.NEE
2. Watse beskermingsmondering het u gekry as u gifstowwe hanteer het?

|                 | VRYLIK: | SPOOR AAN: | WAARVOOR? |
|-----------------|---------|------------|-----------|
| 1. Handskoene   |         |            |           |
| 2. Masker Tipe: |         |            |           |
| 3. Oorpak       |         |            |           |
| 4. Plastiek     |         |            |           |
| 5. Ander Tipe:  |         |            |           |

18

21

25

28

31

35

3. Hoe gereeld het u die ..... gedra?

|            | 1.ALTYD | 2.MEESTE VAN DIE TYD | 3.SOMS | 4.NOOIT |
|------------|---------|----------------------|--------|---------|
| Handskoene |         |                      |        |         |
| Masker     |         |                      |        |         |
| Oorpak     |         |                      |        |         |
| Plastiek   |         |                      |        |         |
| Ander      |         |                      |        |         |

36

37

38

39

40

4. As u teen die einde van die dag klaargemaak het, wanneer het u die oorpak uitgetrek?

- by die werk, voordat u huis toe is
- nadat u by die huis gekom het of
- net voordat u gaan slaap het?
- ander (spesifiseer) :

41

.....

5. Hoe gereeld het u die oorpak gewas of laat was?

- elke dag
- nie elke dag nie, maar meer as een keer per week
- een keer per week
- minder as een keer per week

42

6. Waar het u die oorpak gewas? .....

43

7. Is daar lopende water by u huis? 1.JA 2.NEE

44

14. **GIF BY DIE HUIS**

\* Het u ooit gifstowwe huis toe geneem om daar te gebruik?  
(bv. in u eie groentetuin) 1.JA 2.NEE

INDIEN JA:

a. Waarvoor? .....

.....

b. Watter soort gif? .....

\* Het u ooit leë gifstofhouers (kanne) huis toe geneem om te gebruik?

1.JA 2.NEE

INDIEN JA, waarvoor?

.....

.....

#### D. HOUDING TEENOR VEILIGHEIDSMATREËLS

1. Hoe belangrik dink u is dit om handskoene te dra as u kontak het met plaagdoder?

1. Baie belangrik
2. Belangrik
3. Maak nie veel van 'n verskil nie
4. Van geen belang nie

53

2. Hoe belangrik dink u is dit om 'n masker te dra as u kontak het met plaagdoder?

1. Baie belangrik
2. Belangrik
3. Maak nie veel van 'n verskil nie
4. Van geen belang nie

54

3. Hoe belangrik dink u is dit om 'n oorpak te dra as u kontak het met plaagdoder?

1. Baie belangrik
2. Belangrik
3. Maak nie veel van 'n verskil nie
4. Van geen belang nie

55

4. Na u mening, wat is die gevaar wanneer u met gifstowwe werk?

57

5. Op watter manier kan 'n mens vergiftiging voorkom?

59

6. Dink u dat die manier waarop ander werkers met gifstowwe werk: (omkring die een wat gekies word)

- 1.veiliger is as u manier
- 2.dieselfde is as u manier
- 3.nie so veilig is soos u manier nie
- 4.kan nie duidelik antwoord gee nie

60

7. Kan 'n mens altyd beskermingsklere maklik gebruik?

Verduidelik verder : .....

62

## E. AKUTE BLOOTSTELLINGSGESKIEDENIS

1. Wanneer laas het u kontak gehad met plaagdoder, in die vorm van spuitwerk, meng of algemene hantering? (die datum of hoeveelheid weke gelede)
- .....

2. Wanneer het u plaagdoder begin spuit, meng of hanteer hierdie seisoen?
- .....

3. Gedurende die seisoen, hoe dikwels het u elke maand gespuit. Begin met die eerste maand van hierdie spuitseisoen:

TABEL 4:

Maand:      Hoeveel weke per maand:      Hoeveel dae per week:

|               |  |  |
|---------------|--|--|
| Januarie      |  |  |
| Februarie     |  |  |
| Maart         |  |  |
| April         |  |  |
| Mei           |  |  |
| Junie         |  |  |
| Julie         |  |  |
| Augustus      |  |  |
| September     |  |  |
| Oktober       |  |  |
| November      |  |  |
| Desember      |  |  |
| Januarie 1993 |  |  |
| Februarie     |  |  |
| Maart         |  |  |

F. HUISHOUDELIKE BLOOTSTELLING

1. Gebruik u enige plaagdoder in u tuin of by die huis? 1.JA 2.NEE

51

INDIEN JA:

1 Hoe lank gebruik u dit reeds?  
Jare.....Maande.....  
2 Wanneer laas het u dit gebruik? .....  
\*Laaste datum  
3 Hoe gereeld het u plaagdoder gebruik in die afgelope 3 maande? .....  
\*Hoeveelheid kere  
4 Wanneer laas het u plaagdoder gekoop? .....  
\*Laaste datum  
5 Wat is die naam van die plaagdoder?  
.....  
6 Is u in die verlede blootgestel aan plaagdoder by die huis?  
1.Gereeld 3.Amper nooit  
2.Soms 4.Nooit

54  
56  
60  
62  
64  
66  
68  
69

2. Het u 'n stokperdjie wat vereis dat u daaglik gebruik vir meer as 'n maand op 'n slag? 1.JA 2.NEE

70

3. Gebruik u enige middels wat hout langer behoue laat bly? (preserveermiddels) 1.JA 2.NEE

71

INDIEN JA:

1 Hoe gereeld gebruik u die preserveermiddels?  
1.Gereeld 2.Soms 3.Amper nooit 4.Nooit  
2 Noem die preserveermiddel wat u die meeste gebruik:  
.....  
3 Vir hoeveel jaar gebruik u die preserveermiddel al?  
Jare ..... Maande .....  
4 Is u voorheen blootgestel aan houtpreserveermiddels by die huis?  
1.Gereeld 3.Amper nooit  
2.Soms 4.Nooit

72  
74  
76  
78  
79

4. Is daar enige iemand by die huis wat met plaagdoder werk? 1.JA 2.NEE 3.NIE SEKER

INDIEN JA:

1 Hoeveel mense by die huis werk met plaagdoder?

.....

2 Ten opsigte van elke persoon, die volgende :

PERSOON 1:

a.Waar werk die persoon? .....

b.Watse werk doen hy/sy? .....

c.Word die oorpak gewas voordat hy/sy huis toe kom elke dag?  
1.JA 2.NEE 3.NIE SEKER

PERSOON 2:

a.Waar werk die persoon? .....

b.Watse werk doen hy/sy? .....

c.Word die oorpak gewas voordat hy/sy huis toe kom elke dag?  
1.JA 2.NEE 3.NIE SEKER

PERSOON 3:

a.Waar werk die persoon? .....

b.Watse werk doen hy/sy? .....

c.Word die oorpak gewas voordat hy/sy huis toe kom elke dag?  
1.JA 2.NEE 3.NIE SEKER

- \* Was u ooit aan gifstowwe blootgestel buite u werk?  
1.JA 2.NEE 3.NIE SEKER

INDIEN JA,

- 1.Gereeld  
2.Somtyds  
3.Amper nooit

\* Was dit:

\* Vir hoe lank was u daaraan blootgestel?

.....jare en/of .....maande

## G. NEUROLOGIESE SIMPTOME:

In die afgelope twee weke, het u enige van die volgende simptome gehad:

|   |            |    |
|---|------------|----|
| * MAAGPYN   | 1.JA 2.NEE | 34 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 35 |
| * GEVOEL DAT U WIL OPGOOI                             | 1.JA 2.NEE | 36 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 37 |
| * LIGHOOFDIGHEID                                      | 1.JA 2.NEE | 38 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 39 |
| * MOEILIK GEVIND OM TE LOOP                           | 1.JA 2.NEE | 40 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 41 |
| * GEVOELLOOSHEID IN HANDE OF VOETE                    | 1.JA 2.NEE | 42 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 43 |
| * PRIKKELSENSASIE IN HANDE OF VOETE                   | 1.JA 2.NEE | 44 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 45 |
| * OORPYN  | 1.JA 2.NEE | 46 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 47 |
| * TAMHEID IN ARMS EN BENE                             | 1.JA 2.NEE | 48 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 49 |
| * PYN IN ARMS EN BENE                                 | 1.JA 2.NEE | 50 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 51 |
| * LOOPNEUS  | 1.JA 2.NEE | 52 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 53 |
| * KOPSEER   | 1.JA 2.NEE | 54 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 55 |
| * LOMERIGHEID   | 1.JA 2.NEE | 56 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 57 |
| * SWAAR GEVOEL OP U BORS                              | 1.JA 2.NEE | 58 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 59 |
| * MOEGHEID  | 1.JA 2.NEE | 60 |
| Indien wel, het dit vir meer as drie maande aangehou? | 1.JA 2.NEE | 61 |

## H. GESKIEDENIS VAN ROOKGEWOONTES

1. Rook u tans?

(gaan na 3.)

1 JA

2 NEE

(gaan na 2.)

2. Het u al ooit voorheen gerook?

1 JA

(gaan na 3.)

2 NEE

(STOP hier)

3. Hoe oud was u toe u begin rook het? ..... jaar

4. Wat rook u / het u gerook?

1. Sigarette

2. Pyp

3. Albei

5. Hoeveel rook u / het u gerook?

- Sigarette per dag:

1. Minder as 10

2. 10 tot 19

3. 20 tot 29

4. 30 en meer

5. Ander:.....

- Pyptabak per week:

1. Klein pakkie

2. Medium pakkie

3. Groot pak

4. Ander:

INDIEN TANS 'N ROKER:

6. Het u in die verlede meer of minder as nou gerook?

1 JA

(gaan na .1)

2 NEE

(gaan na 8.)

.1 Hoeveel het u altyd gerook?

- Sigarette per dag: 1. Minder as 10

2. 10 tot 19

3. 20 tot 29

4. 30 en meer

5. Ander: .....

- Pyptabak per week:

(wys verskillende groottes pakkies: groot, medium en klein)

1. Klein pakkie

2. Medium pakkie

3. Groot pakkie

4. Ander: .....

.2 Vir hoe lank (getal weke, maande of jare)  
het u soveel gerook?

.....



INDIEN 'N ROKER IN DIE VERLEDE:

7. Hoe oud was u toe u ophou rook het?

.....

8. Snuif of pruim u tabak?

- 1. Snuif
- 2. Pruim
- 3. Albei
- 4. Geen

9. Het u al ooit dagga probeer?

1 JA

2 NEE

INDIEN JA:

INDIEN NEE: STOP hier

Rook u nou dagga?

1 JA

2 NEE

INDIEN JA:

INDIEN NEE: STOP hier

a) Hoe gereeld rook u dagga?

- 1.elke dag
- 2.nie elke dag nie, maar meer as een keer per week
- 3.minder as een keer per week
- 4.partykeer, maar minder as een keer per maand
- 5.nooit

b) Het u ooit meer (of minder) as nou gerook?

1 JA

2 NEE

INDIEN JA:

(STOP hier)

\* Hoe gereeld het u dagga gerook?

- 1.elke dag
- 2.minder as elke dag maar meer as een keer per week
- 3.minder as een keer per week
- 4.partykeer, maar minder as een keer per maand
- 5.nooit

\* Vir hoe lank (weke, maande, jare) het u soveel dagga gerook?

.....

## I. GESKIEDENIS VAN ALKOHOLGEBRUIK

1. Neem u tans alkohol?

1 JA

(gaan na 3.)

2 NEE

(gaan na 2.)

2. Het u voorheen alkohol geneem?

JA

(gaan na 3.)

NEE

(stop hier)

3. Hoeveel drink u / het u gedurende die week gedrink?

|                       | Bier  | Wyn   | "Harde hout" | Tuisgebrou |
|-----------------------|-------|-------|--------------|------------|
| Maandag tot Donderdag | ..... | ..... | .....        | .....      |
| Vrydag                | ..... | ..... | .....        | .....      |
| Saterdag              | ..... | ..... | .....        | .....      |
| Sondag                | ..... | ..... | .....        | .....      |

## SLEUTEL:

Bier dumpie: A      Wyn kan: F      Glase: L tot N  
 Bier quart: B      Wyn bottel: G      Beker: P  
 Bier "Pint": C      Boks Wyn (5 liter): H (kraantjie)  
 Bier blik: D      Boks Wyn (2 liter): HH  
 Bier lang blik: E  
 Brandewyn half jack: I      Brandewyn quarter jack: J  
 Brandewyn 750 ml: K      Brandewyn 1 liter: KK

4. Hou oud was u toe u begin drink het? ..... jaar

5. INDIEN HY ALKOHOL SLEGS VOORHEEN GENEEM HET:

\* Hoe oud was u toe u ophou drink het? ..... jaar

\* Hoeveel jaar lank het u gedrink? ..... jaar

\* Hoekom het u opgehou? .....

.....

6.

VIR BEIDE DIE WAT TANS ALKOHOL NEEM EN DIE  
WAT IN DIE VERLEDE ALKOHOL GENEEM HET

\* Wanneer u na 'n vriend toe gaan / gegaan het vir 'n drankie of as u na 'n kroeg toe gaan / gegaan het saam met vriende, hoeveel drankies drink u / het u gedrink?

50

.....

\* Het u (al) ooit gevoel dat u minder moet drink? 1.JA 2.NEE

51

\* Het mense u (al) ooit kwaad gemaak deur u drinkgewoontes te kritiseer? 1.JA 2.NEE

52

\* Het u (al) ooit sleg of skuldig gevoel omdat u drink? 1.JA 2.NEE

53

\* Het u (al) ooit vroeg in die oggend 'n drankie gedrink om u beter te laat voel of om oor u babelaas (hang over) te kom? 1.JA 2.NEE

54

\* Dink u u drinkgewoontes is / was normaal? 1.JA 2.NEE 3.WEET NIE

55

\* Het dit (al) ooit met u gebeur dat u wakkerword in die oggend nadat u die vorige aand gedrink het en nie kan onthou wat als die vorige aand gebeur het nie? 1.JA 2.NEE 3.NIE SEKER

56

\* Kan / kon u maklik ophou drink na een of twee drankies? 1.JA 2.NEE 3.NIE SEKER

57

\* Dink u vriende of familie / het u vriende of familie gedink dat u normale drinkgewoontes het / gehad het? 1.JA 2.NEE 3.NIE SEKER

58

\* Was u (al) ooit in die hospitaal as gevolg van drank? 1.JA 2.NEE

59

\* Het u (al) ooit vriende of 'n meisie verloor as gevolg van drank? 1.JA 2.NEE

60

\* Het u (al) ooit u familie afgeskeep as gevolg van drank? 1.JA 2.NEE

61

\* Het u (al) ooit u verantwoordelikhede (bv. by die werk) afgeskeep as gevolg van drank? 1.JA 2.NEE 3.NIE SEKER

62

\* Het u (al) ooit, agv drank gehalusineer (skimbeelde gesien), of stemme gehoor wat agterna nie daar is / was nie en het u onbeheerbaar gebewe? 1.JA 2.NEE

63

\* Het u (al) ooit na iemand toe gegaan (bv. 'n dokter, verpleegster, 'n vriend of iemand by die werk) om u te help met u drinkgewoontes? 1.JA 2.NEE

64

\* Het u (al) ooit in die moeilikheid gekom by die werk as gevolg van drank? 1.JA 2.NEE

\* Wat dink u is normale drinkgewoontes?

(Getal drankies per dag) .....

\* Wat dink u is abnormale drinkgewoontes? (d.w.s te veel)

(Getal drankies per dag) .....

7. **INDIEN HY TANS ALKOHOL NEEM:**

Het u ooit in die verlede meer (of minder) as nou gedrink?

1 JA

2 NEE

(gaan na a)

(gaan na 8)

a) Hoeveel het u gedurende hierdie periode gedrink?

|                       | Bier  | Wyn   | "Harde hout" | Tuisgebrou |
|-----------------------|-------|-------|--------------|------------|
| Maandag tot Donderdag | ..... | ..... | .....        | .....      |
| Vrydag                | ..... | ..... | .....        | .....      |
| Saterdag              | ..... | ..... | .....        | .....      |
| Sondag                | ..... | ..... | .....        | .....      |

\* Vir hoe lank (weke, maande, jare) het u soveel gedrink?

.....

8. Gedurende die afgelope week, van verlede Woensdag af, het u drinkpatroon verskil van die gewone?

1.JA 2.NEE 3.NIE SEKER

INDIEN JA, beskryf:

|                       | Bier  | Wyn   | "Harde hout" | Tuisgebrou |
|-----------------------|-------|-------|--------------|------------|
| Maandag tot Donderdag | ..... | ..... | .....        | .....      |
| Vrydag                | ..... | ..... | .....        | .....      |
| Saterdag              | ..... | ..... | .....        | .....      |
| Sondag                | ..... | ..... | .....        | .....      |

Werker se naam: .....

Huidige Plaasnaam:.....

1

5

SUBSEKSIE A: LANDBOU

1. Watter werk is nou ter sprake? (die eerste, tweede, derde,....., neende of tiende, soos bo genoem)

7

2. Waarmee is daar geboer op die plaas? (Begin met die belangrikste produkte)

9

11

13

3. Het u permanent of net tydens die seisoen op die plaas gewerk?

14

1) Hoe lank het u hierdie werk gedoen? .....  
(Jare of maande)  
Begin: ..... Ophou: .....

16

18

2) In die werk was daar vir u wyn gegee op die plaas?

19

- 1.Nooit
- 2.Soms
- 3.Elke dag

|   |
|---|
| Werker se naam: .....<br>Huidige Plaasnaam: ..... |
|---|

|   |  |   |
|---|--|---|
| 1 |  |   |
|   |  | 5 |

**SUBSEKSIE A: LANDBOU**

1. Watter werk is nou ter sprake? (die eerste, tweede, derde,....., neende of tiende, soos bo genoem)

|  |  |   |
|--|--|---|
|  |  | 7 |
|--|--|---|

2. Waarmee is daar geboer op die plaas? (Begin met die belangrikste produkte)

|  |  |    |
|--|--|----|
|  |  | 9  |
|  |  | 11 |
|  |  | 13 |

3. Het u permanent of net tydens die seisoen op die plaas gewerk?

|  |  |    |
|--|--|----|
|  |  | 14 |
|--|--|----|

1) Hoe lank het u hierdie werk gedoen? .....  
 (Jare of maande)

Begin: ..... Ophou: .....

|  |  |    |
|--|--|----|
|  |  | 16 |
|  |  | 18 |

2) In die werk was daar vir u wyn gegee op die plaas?

- 1.Nooit
- 2.Soms
- 3.Elke dag

|  |  |    |
|--|--|----|
|  |  | 19 |
|--|--|----|

4. Het u enige van die volgende take gedoen terwyl u hier gewerk het:

1 TREKKER BESTUUR

1.JA 2.NEE

INDIEN JA, het dit enige van die volgende behels:

.1 Gifstowwe met 'n spuitpomp gespuit? 1.JA 2.NEE

Indien Ja, was u die hoofspuitman? 1 JA 2 NEE

.2 Trekker bestuur terwyl ander werkers van agter op die trekker met handspuite gif gespuit het? 1.JA 2.NEE

.3 Gifstowwe buitekant afgemeet of gemeng? 1.JA 2.NEE

.4 Gifstowwe in 'n gebou afgemeet of gemeng? 1.JA 2.NEE

2 GIFSTOWWE SELF AANGEWEND PER HANDSPUIT VAN AGTER OP 'N TREKKER

1.JA 2.NEE

INDIEN JA, sluit dit enige van die volgende in:

.1 Meng of uitmeet van gif in 'n toe kamer? 1.JA 2.NEE

.2 Meng of uitmeet van gif buitekant? 1.JA 2.NEE

.3 Het u insekdoder of onkruidodder of albei gespuit? 1.INSEKD 2.ONKRUIDD 3.ALBEI

As die werker nie kan onthou nie, vra dan:

Het u die gif op die grond gespuit of op die plante?

SLEUTEL:

1.Op die plante: INSEKD  
2.Op die grond: ONKRUIDD

3 GIF GESPUIT MET BEHULP VAN 'N RUGSAK

1.JA 2.NEE

INDIEN JA, het dit enige van die volgende behels:

.1 Meng of uitgooi en afmeet van gif in 'n toe kamer? 1.JA 2.NEE

.2 Meng of uitgooi en afmeet van gif buitekant? 1.JA 2.NEE

.3 Die spuit van insekdoders, onkruiddoders of albei? 1.INSEKD 2.ONKRUIDD 3.ALBEI

As die werker nie kan onthou nie, vra dan:

Het u die gif op die grond gespuit of op die plante?

SLEUTEL:

1.Op die plante: INSEKD  
2.Op die grond: ONKRUIDD

4 GIFSTOWWE GEMENG OF UITGEGOOI EN AFGEMEET  
(Anders as werk 1 tot 3) 1.JA 2.NEE  
INDIEN JA:

.1 Het u dit ooit in 'n toe kamer gedoen? 1.JA 2.NEE  
.2 Het u dit ooit buitekant gedoen? 1.JA 2.NEE

5 'N CHEMIESE MIDDEL - DORMEX - OP BOME OF IN WINGERDE EN  
LANDERYE AANGEWEND MET 'N VERFKWAS OF RUGSAK OF MET 'N  
HANDSPUIT? 1.JA 2.NEE

6 SLEGS GRAANBOERDERYE

AS MERKER GEDIEN HET VIR 'N VliegTUIG WAT DIE LANDERYE  
MET GIF SPUIT? 1.JA 2.NEE

7 AS WERKTUIGKUNDIGE GEWERK MET 'n SPUITPOMP TREKKER  
MET DIE VERANTWOORDELIKHEID OM DIT IN STAND TE HOU  
OF GEREEDSKAP SKOONGEMAAK WAT VIR SPUITWERK GEBRUIK IS.

1 JA 2 NEE

8 SLEGS VRUGTEBOERDERYE

.1 HET U OOIT VRUGTE UITGEDUN? 1.JA 2.NEE  
.2 HET U OOIT AS MONITORPERSOON GEWERK? 1.JA 2.NEE

9 SLEGS WINGERDE

HET U ENIGE VAN DIE VOLGENDE GEDOEN:

.1 Onderhoudswerk in die seisoen? 1.JA 2.NEE  
.2 Met die suier gewerk? 1.JA 2.NEE  
.3 Lote vasgemaak aan rankrame? 1.JA 2.NEE  
.4 Trosse geoes? 1.JA 2.NEE  
.5 Druie uitgedun? 1.JA 2.NEE

10 IN DIE WINGERDE OF BOORDE GEWERK TERWYL DAAR GESPUIT IS?  
(anders as 8 en 9) 1.JA 2.NEE

11 TUINWERK IN DIE BOER SE TUIN GEDOEN? 1.JA 2.NEE

12 VEE GEDIP? 1.JA 2.NEE

13 HET U IN HIERDIE WERK ENIGE ANDER KONTAK MET GIFSTOWWE  
GEHAD? 1.JA 2.NEE

INDIEN JA, spesifiseer:

.....  
.....



INDIEN ENIGE VAN VOORAFGAANDE JA IS, VUL VOLGENDE TABEL IN:

TABEL A:

Hoeveel jaar lank het u hierdie werk gedoen?

Noem die maande van die jaar:

Hoeveel dae per week?

Soort werk:

Jare:

Maande vd jaar:

Dae/week:

1. Spuit  
(trekker)

\*

\*

2. Handspuit

3. Rugsak

\*

\*

4. Meng

\*

\*

5. Dormex

55

|  |  |  |  |
|--|--|--|--|
|  |  |  |  |
|  |  |  |  |

59

|  |  |  |  |
|--|--|--|--|
|  |  |  |  |
|  |  |  |  |

63

|  |  |  |  |
|--|--|--|--|
|  |  |  |  |
|  |  |  |  |

67

|  |  |  |  |
|--|--|--|--|
|  |  |  |  |
|  |  |  |  |

71

|  |  |  |  |
|--|--|--|--|
|  |  |  |  |
|  |  |  |  |

1

|  |  |  |  |
|--|--|--|--|
|  |  |  |  |
|  |  |  |  |

3

|  |  |  |  |
|--|--|--|--|
|  |  |  |  |
|  |  |  |  |

6

|  |  |  |  |
|--|--|--|--|
|  |  |  |  |
|  |  |  |  |

10

|  |  |  |  |
|--|--|--|--|
|  |  |  |  |
|  |  |  |  |

14

|  |  |  |  |
|--|--|--|--|
|  |  |  |  |
|  |  |  |  |

| TABEL A:<br>(vervolg)   |       |                                     |
|---|-------|-------------------------------------|
| Hoeveel jaar lank het u hierdie werk gedoen?  |       |                                     |
| <div> <div>↓</div> <div>Hoelank het u dit in die jaar gedoen?</div> <div>↓</div> </div> |       |                                     |
| Soort werk:   | Jare: | Dae, weke of maande<br>in die jaar: |
| 6. Landmerker   |       |                                     |
| 7. Instandhou-<br>ding van<br>gereedskap  |       |                                     |
| 8. Uitdun   |       |                                     |
| 9. Monitor  |       |                                     |
| 10. Wingerd<br>instandhou-<br>ding  |       |                                     |
| 11. Tuinwerk  |       |                                     |
| 12. Veedip  |       |                                     |
| 13. Ander   |       |                                     |

|  |  |  |  |  |
|--|--|--|--|--|
|  |  |  |  |  |
|--|--|--|--|--|

21

|  |  |  |  |  |
|--|--|--|--|--|
|  |  |  |  |  |
|--|--|--|--|--|

25

|  |  |  |  |  |
|--|--|--|--|--|
|  |  |  |  |  |
|--|--|--|--|--|

29

|  |  |  |  |  |
|--|--|--|--|--|
|  |  |  |  |  |
|--|--|--|--|--|

33

|  |  |  |  |  |
|--|--|--|--|--|
|  |  |  |  |  |
|--|--|--|--|--|

37

|  |  |  |  |  |
|--|--|--|--|--|
|  |  |  |  |  |
|--|--|--|--|--|

41

|  |  |  |  |  |
|--|--|--|--|--|
|  |  |  |  |  |
|--|--|--|--|--|

45

|  |  |  |  |  |
|--|--|--|--|--|
|  |  |  |  |  |
|--|--|--|--|--|

49

### 13. Beskermingsmondering

1. Het u beskermingsmondering gekry in die bogenoemde werk?

1.JA 2.NEE

2. Watse beskermingsmondering het u gekry as u gifstowwe hanteer het?

|                 | VRYLIK: | SPOOR AAN: | WAARVOOR? |
|-----------------|---------|------------|-----------|
| 1. Handskoene   |         |            |           |
| 2. Masker Tipe: |         |            |           |
| 3. Oorpak       |         |            |           |
| 4. Plastiek     |         |            |           |
| 5. Ander Tipe:  |         |            |           |

### VERGIFTIGING IN HIERDIE WERK

15. Het u ooit siek geword van die gifstowwe?

1.JA 2.NEE

#### INDIEN JA:

1. Beskryf die omstandighede en die oorsaak en gevolg:

.....  
.....

2. Het u 'n dokter besoek?

1.JA 2.NEE

3. Is u in die hospitaal opgeneem?

1.JA 2.NEE

INDIEN JA, moes u daar oorbly?

1.JA 2.NEE

HOSPITAAL se naam: .....

4. Moes u uit die werk wegbly?

1.JA 2.NEE

Werker se naam: .....

Huidige Plaasnaam: .....

**1993/94 BLOOTSTELLING AAN ONKRUIDDODERS:**

[Note to the interviewer: Gaan die rekords na vandat die vorige vraelys ingevul is (vraag nommer E: Akute blootstellingsgeskiedenis-bladsy 18) en voeg die volgende informasie daarby:]

1. Wanneer het u laas kontak gehad met gifstowwe, in die vorm van spuitwerk, meng of algemene hantering? (datum of hoeveelheid maande, weke of seisoene gelede)  
.....
2. Weet u wat die naam van die gifstowwe was waarmee u gewerk het?  
 Gramazone: 1. JA 2. NEE  
 Paraquat: 1. JA 2. NEE  
 Ander: .....  
 .....
2. Het u gifstowwe gemeng, hanteer of op die grond gespuit gedurende die afgelope jaar?  
 Gemeng: 1. JA 2. NEE  
 Hanteer: 1. JA 2. NEE  
 Op die grond gespuit: 1. JA 2. NEE
3. Hoe dikwels het u met onkruidodders gewerk vanaf verlede jaar Meimaand tot nou toe? (hetsy meng, hantering of spuit op die grond):

| Maand:         | Hoeveel weke per maand: | Hoeveel dae per week: |
|----------------|-------------------------|-----------------------|
| Mei 1993       |                         |                       |
| Junie 1993     |                         |                       |
| Julie 1993     |                         |                       |
| Augustus 1993  |                         |                       |
| September 1993 |                         |                       |
| Oktober 1993   |                         |                       |
| November 1993  |                         |                       |
| Desember 1993  |                         |                       |
| Januarie 1994  |                         |                       |
| Februarie 1994 |                         |                       |
| Maart 1994     |                         |                       |
| April 1994     |                         |                       |
| Mei 1994       |                         |                       |

# SUBSEKSIE A: LANDBOU

Hierdie vrae verwys na die ..... WERK wat jy genoem het in die vorige opname. (Werksondervinding - bladsy 10 - wit vraelys)

[Note to the interviewer: Indien die werker "Ja" geantwoord het op vrae 1 tot 3 in die vorige (liggroen) vraelys, verwys daarna met die vraag: "Jy het ons laaste keer vertel dat jy gifstowwe aagewend het in hierdie werk, hetsy met 'n handspuit, rugsak of met 'n 'hose gun' agterop die trekker . . . " ]

1. Was die gifstowwe op die grond gespuit of op teen die bome/vrugte?

A { Op die grond: 1. JA 2. NEE  
Op die bome: 1. JA 2. NEE  
Albei: 1. JA 2. NEE

2. Indien jy op die grond gespuit het, het jy enige brandwonde opgedoen op jou rug of hande as gevolg van die gifstof waarmee jy gewerk het?

B { Op die rug: 1. JA 2. NEE  
Hande: 1. JA 2. NEE  
Enige ander: .....

3. Indien jy op die grond gespuit het, weet jy wat die naam van die gifstowwe was wat jy gebruik het?

B { Paraquat Chloride, Gramozone : 1. JA 2. NEE  
Paraquat : 1. JA 2. NEE  
Preeglone : 1. JA 2. NEE  
Ander: .....

[Note to interviewer: Verwys na Tabel A op volgende bladsy van die liggroen vraelys en herhaal die aantal jare, maande en dae wat voorheen ingevul was.]

4. Gedurende die aantal jare wat jy hierdie werk gedoen het, hoeveel van die tyd het jy spandeer om met 'n handspuit/rugsak of 'n "hose gun" agterop die trekker gifstowwe op die grond te spuit?

Maande van die jaar of seisoen: .....

| Jan | Feb | Mar | Apr | Mei | Junie | Julie | Aug | Sept | Okt | Nov | Des |
|-----|-----|-----|-----|-----|-------|-------|-----|------|-----|-----|-----|
|     |     |     |     |     |       |       |     |      |     |     |     |

Hoeveel dae per week: .....

| Maan | Dins | Woens | Donder | Vrydag | Saterdag | Sondag |
|------|------|-------|--------|--------|----------|--------|
|------|------|-------|--------|--------|----------|--------|

5. Wat was die meeste agtereenvolgende dae wat jy ooit onkruidodder gespuit het?

..... dae

6. Hoeveel spanne wat daar wat onkruidodder gespuit het?

..... spanne

FARM WORKERS' HEALTH SURVEY

IDENTIFIKASIE NOMMER : (IDNUM) <idnum> .....

Ondervraer se naam: \_\_\_\_\_

PLAASWERKER SE NAAM : \_\_\_\_\_

PLAASNAAM : \_\_\_\_\_

Hierdie vrae het meestal met die bors en longe te doen.  
Antwoord asseblief JA of NEE waar moontlik.

A. HOES

- A1. Hoes jy nogal baie? (COUGHA1)<Y>  
(Tel die kere wat jy hoes vanaf bv. jou eerste sigaret of <N>  
wanneer jy die eerste keer buitekant toe gaan soggens -  
dit sluit keel skoonmaak of kug uit.)

Indien antwoord NEE , gaan na die volgende bladsy.

- A2. Hoes jy gewoonlik 4 tot 6 keer per dag,  
4 dae of meer in die week? (COUGHA2)<Y>  
<N>
- A3. Hoes jy as jy soggens opstaan of wanneer jy  
in die oggend wakker word? (COUGHA3)<Y>  
<N>
- A4. Hoes jy nogal baie gedurende die res van die  
dag of snags ? (COUGHA4)<Y>  
<N>

Indien JA op enige van die bogenoemde vrae, beantwoord  
Vrae A5 en A6.

Indien NEE op bogenoemde vrae, trek 'n kring om die NEE  
en gaan na die volgende bladsy.

- A5. Hoes jy gewoonlik so baie (soos voorheen beskryf) die  
meeste van die tyd vir 3 maande aaneen of meer as dit  
deur die jaar? (COUGHA5)<Y>  
<N>
- A6. Hoeveel jaar lank het jy al hierdie hoes? (COUGHA6)##  
\_\_\_\_\_j

## B. SLYM

B1. Hoes jy gewoonlik slym uit jou bors op ? {PHLEGMB1}<Y>

&lt;N&gt;

Antwoord JA as dit gebeur met jou eerste sigaret of  
wanneer jy opstaan of as jy die slym insluk.  
Antwoord NEE as dit uit jou neus kom.)

B2. Hoes jy gewoonlik slym op meer as twee keer {PHLEGMB2}<Y>  
per dag, 4 of meer dae per week? <N>

B3. Hoes jy gewoonlik slym op wanneer jy opstaan of {PHLEGMB3}<Y>  
onmiddelik nadat jy wakker word in die oggend? <N>

B4. Hoes jy gewoonlik slym op enige ander tyd PHLEGMB4)<Y>  
gedurende die dag of snags? <N>

Indien JA op enige van die bogenoemde vrae, antwoord B5.

Indien NEE op al die bg., gaan na die volgende bladsy.

B5. Hoes jy slym op soos vantevore beskryf die {PHLEGMB5}<Y>  
meeste van die tyd vir 3 maande aaneen of <N>  
meer as dit gedurende die jaar?

B6. Hoeveel jaar lank het jy al probleme met slym? {PHLEGMB6}##  
(Het jy die probleem met slym al van kinds-  
been af of net in die laaste paar jaar?) \_\_\_\_\_j

## C. EPISODES VAN HOES EN SLYM

C1. Is daar tye van die jaar wanneer jy vir {EPSDEC1}<Y>  
3 weke of langer meer hoes en meer <N>  
probleme met slym ondervind? (Vir persone  
wat gewoonlik hoes en/of slym het)  
(..... byvoorbeeld sekere seisoene?)

Indien JA op C1, beantwoord die volgende:

C2. Vir hoe lank het jy al ten minste een so {EPSDEC2}##  
'n episode per jaar ? \_\_\_\_\_j

## D. HYG NA ASEM (FLUIT IN DIE BORS)

D1. Het jy die afgelope jaar enige fluit-  
of suisgeluid in u bors gehad?

{WHEZD1} <Y>  
<N>

Indien JA, gebeur dit:

D1.1 Wanneer jy verkoue het ?

{WHEZ1D1} <Y>  
<N>

D1.2 Somtyds wanneer jy nie verkoue het nie?

{WHEZ2D1} <Y>  
<N>

D1.3 Die meeste dae of nagte ?

{WHEZ3D1} <Y>  
<N>

Indien 'NEE' gaan na Vraag E ; Indien 'JA':

D1.4 Raak jy ooit kortasem wanneer jy  
hierdie suisgeluid ondervind ?

{WHEZ4D1} <Y>  
<N>

D1.5 Het jy hierdie suis- of fluitgeluid  
ondervind wanneer jy nie verkoue gehad het nie?

{WHEZ5D1} <Y>  
<N>

D1.6 Het jy in die afgelope jaar ooit wakker  
geword met 'n benoude gevoel in die bors?

{WHEZ6D1} <Y>  
<N>

D1.7 Het jy in die afgelope jaar wakker  
geword en gevoel jy kan nie asem kry nie?

{WHEZ7D1} <Y>  
<N>

D2. Hoeveel jaar lank kry jy dit al ?

{WHEEZD2} ##

— j

D3. Het jy al ooit 'n aanval van hyging of fluit  
in die bors gehad wat jou kortasem laat voel het?

{WHEEZD3} <Y>  
<N>

Indien JA op D3, beantwoord die volgende :

D4. Hoe oud was jy toe jy dit die eerste keer  
gekry het?

{WHEEZD4} ##

— j

D5. Het jy dit al twee keer of meer kere gekry ?

{WHEEZD5} <Y>  
<N>

D6. Het jy al ooit behandeling of medisyne  
benodig vir hierdie aanval(le)?

{WHEEZD6} <Y>  
<N>



## E. KORTASEM

- E1. As jy te sleg voel om te loop as gevolg van enige ander siekte behalwe hart- of longsiektes, beskryf asseblief die siekte.

Aard van ongeskiktheid ..... {BREATHE1}

.....

- E2. Raak jy kortasem wanneer jy vinnig op 'n gelykte of teen 'n effense opdraend loop? {BRETHER2}<Y>  
<N>

- E3. Moet jy stadiger stap as ander mense van jou ouderdom omdat jy kortasem is? {BRETHER3}<Y>  
<N>

- E4. Moet jy ooit stilstaan om asem te skep wanneer jy teen jou eie pas op 'n gelykte stap? {BRETHER4}<Y>  
<N>

- E5. Moet jy ooit stilstaan om asem te skep wanneer jy omtrent 100 meter (of na 'n paar minute) op 'n gelykte gestap het? {BRETHER5}<Y>  
<N>

- E6. Is jy te kortasem om uit te gaan of raak jy kortasem wanneer jy aan- en uittrek? {BRETHER6}<Y>  
<N>

## F. BORSVERKOUES EN BORSSIEKTES

- F1. Wanneer jy verkoue kry, kry jy dit gewoonlik in die bors? (gewoonlik beteken meer as die helfte van die tyd). {CHESTF1}<Y>  
<N>

- F2. Het jy gedurende die laaste 3 jaar enige bors-siektes opgedoen wat jou van die werk af gehou of in die huis of in die bed gehou het? {CHESTF2}<Y>  
<N>

Indien JA op F2, beantwoord die volgende:  
Indien NEE, gaan na die volgende bladsy.

- F3. Het jy slym op gehoes met enige van hierdie siektes? {CHESTF3}<Y>  
<N>

- F4. Hoeveel keer die afgelope 3 jaar het jy sulke borskwale gehad (met baie slym), wat 'n week of langer aangehou het? {CHESTF4} ##  
\_\_\_\_\_ keer

## G. SIEKTE GESKIEDENIS

G1. Het jy enige long probleme gehad voor jy 16 jaar oud was? {HISTG1}<Y>  
<N>

G2. Het jy al ooit enige van die volgende siektes gehad:

G2.1 Aanvalle van brongitis ? {G2HIST1A}<Y>  
(Wanneer die hoës soos 'n blaf klink) <N>

Indien JA op G2.1 :

A. Is dit deur 'n dokter bevestig? {G2HIST1B}<Y>  
(Het die dokter gesê dit is brongitis?) <N>

B. Hoe oud was jy toe jy dit vir die eerste keer gekry het? {G2HIST1C}##  
\_\_\_\_\_j

G2.2 Longonsteking (Pneumonie )? {G2HIST2A}<Y>  
(insluitend brongopneumonie) <N>

Indien JA op G2.2 :

A. Is dit deur 'n dokter bevestig? {G2HIST2B}<Y>  
(Het die dokter gesê dit is longontsteking?) <N>

B. Hoe oud was jy toe jy dit vir die eerste keer gekry het? {G2HIST2C}##  
\_\_\_\_\_j

G2.3 Het jy al ooit hooikoors gehad? {G2HIST3A}<Y>  
<N>

Indien JA op G2.3 :

A. Was jy by 'n dokter wat gesê het dit is hooikoors? {G2HIST3B}<Y>  
<N>

B. Op watter ouderdom het dit begin? {G2HIST3C}##  
\_\_\_\_\_j

G2.4 Het jy al ooit enige sinus probleme gehad? {G2HIST4A}<Y>  
<N>

Indien JA op G2.4 :

A. Is dit deur 'n dokter bevestig? {G2HIST4B}<Y>  
<N>

B. Op watter ouderdom het dit begin? {G2HIST4C}##  
\_\_\_\_\_j

## G2.5 Longtuberkulose (T.B.)?

{G2HIST5A}<Y>  
<N>

Indien JA op G2.5:

- A. Is dit deur 'n dokter bevestig? {G2HIST5B}<Y>  
<N>
- B. Op watter ouderdom het dit begin? {G2HIST5C}##  
\_\_\_\_\_j
- C. Hoeveel maande lank het jy be-  
handeling gekry by 'n hospitaal  
en/of kliniek? {G2HIST5D}##  
\_\_\_\_\_m
- D. Is jy meer as een keer behandel  
vir tuberkulose ? {G2HIST5E}<Y>  
<N>
- E. Ontvang jy steeds behandeling  
vir tuberkulose? {G2HIST5F}<Y>  
<N>

## G2.6 Het jy al ooit asma gehad ?

{HISTG3A}<Y>  
<N>

Indien JA :

- A. Gebruik jy op die oomblik medisyne  
of behandeling (bv. 'n spuitpomp)  
vir asma? {HISTG3A}<Y>  
<N>
- B. Kry jy nog steeds asma? {HISTG3B}<Y>  
<N>

Indien NEE, gaan na F, indien JA:

- C. Het die dokter gesê dit is asma? {HISTG3C}<Y>  
<N>
- D. Op watter ouderdom het dit begin ? {HISTG3D} ##  
\_\_\_\_\_j
- E. Het jy gedurende die afgelope jaar  
'n asma-aanval gehad ? {HISTG3E}<Y>  
<N>
- F. Indien jy dit nie meer kry nie, op  
watter ouderdom het dit opgehou? {HISTG3F} ##  
\_\_\_\_\_j
- G. Kry enige ander familielide tans  
asma of het enigiemand in jou  
familie al voorheen asma gekry? {HISTG3G}<Y>  
<N>

Spesifiseer asseblief:

1. moeder {HISTG3G1} <Y>  
2. vader {HISTG3G2} <Y>  
3. broers of susters {HISTG3G3} <Y>  
4. kinders {HISTG3G4} <Y>  
5. ander {HISTG3G5} <Y>

G3. Het jy al ooit :

A. Enige ander borskwaal gehad ?

Indien JA spesifiseer asseblief:

---

---

{HISTG4A}

B. Enige bors-operasies gehad ?

Indien JA spesifiseer asseblief:

---

---

{HISTG4B}

C. Enige borsbeserings opgedoen ?

Indien JA spesifiseer asseblief:

---

---

{HISTG4C}

D. Enige ander siektes ?

Indien JA spesifiseer asseblief:

---

---

---

---

---

{HISTG4D}

**Appendix 2:**

**Lung Function Report Sheet**

Name: ID: P56 Date: 27-May-94  
Race: Caucasian Height: 171 cm Weight: 85.0 kg Sex: M  
Room: BSA: 1.97 Age: 30 yr  
Dr. : DR WHITE Technician: MANDI

PRE-BRONCH  
Actual Pred. %Pred.



POST-BRONCH  
Actual %Pred. %Chng

LUNG MECHANICS

|                |         |       |      |     |
|----------------|---------|-------|------|-----|
| VC             | (L)     | 4.45  | 4.73 | 94  |
| EV1            | (L)     | 3.93  | 3.99 | 99  |
| EV1/FVC        | (%)     | 88    | 84   |     |
| EF 25%         | (L/sec) | 10.17 | 8.00 | 127 |
| EF 50%         | (L/sec) | 5.42  | 5.20 | 104 |
| EF 75%         | (L/sec) | 2.63  | 2.34 | 112 |
| EF MAX         | (L/sec) | 11.09 | 9.36 | 118 |
| EF 25-75%      | (L/sec) | 4.94  | 4.73 | 105 |
| EF 75-85%      | (L/sec) | 1.67  |      |     |
| IVC            | (L)     | 4.74  |      |     |
| IF 50%         | (L/sec) | 10.34 | 5.50 | 188 |
| EF 50%/FIF 50% |         | 0.52  | 0.95 |     |

LUNG DIFFUSION


|                      |       |       |     |
|----------------------|-------|-------|-----|
| LCUnc(ml/min/mmHg)   | 34.40 | 32.80 | 105 |
| ALVEOLAR VOLUME (L)  | 6.25  | 6.36  | 98  |
| DL/VA(ml/min/mmHg/L) | 5.51  | 5.16  | 107 |





### **Appendix 3:**

**Examples of Saturation and  
Heart Traces recorded  
during exercise**

a) Example of "Interpretable" traces







**Appendix 4:**  
**Glossary of variables**

## APPENDIX 4 Glossary of variables

NOTE FOR ALL DICHOTOMOUS VARIABLES (DI) 1=YES; 2=NO UNLESS OTHERWISE SPECIFIED

### Variable:

### Definition:

#### General

|          |   |
|----------|---|
| BMI      | Body mass index (height/weight <sup>2</sup> ) |
| BSA      | Body surface area                             |
| HEIGHTCM | height (cm)                                   |
| IDX      | Study number                                  |
| DATE     | Survey date                                   |
| NAME     | Surname                                       |
| NAME1    | Name  |
| SCHOOL   | No of years attended school                   |
| WEIGHTKG | Weight (kg)                                   |

#### Respiratory Symptoms

##### coughing:

|         |   |
|---------|---|
| COUGHA1 | Coughing (DI)                           |
| COUGHA2 | Coughing > 4-6 per day; > 6 per wk (DI) |
| COUGHA3 | Coughing in morning (DI)                |
| COUGHA4 | Coughing in rest of the day (DI)        |
| COUGHA5 | Coughing > 3 mnths (DI)                 |
| COUGHA6 | no of yrs COUGHA5                       |
| COUGHA7 | Coughing > 2 yrs (DI)                   |

##### phlegm production:

|          |                                       |
|----------|---------------------------------------|
| PHLEGMB1 | Phlegm (DI)                           |
| PHLEGMB2 | Phlegm > 4-6 per day; > 6 per wk (DI) |
| PHLEGMB3 | Phlegm in morning (DI)                |
| PHLEGMB4 | Phlegm in rest of the day (DI)        |
| PHLEGMB5 | Phlegm > 3 mnths (DI)                 |
| PHLEGMB6 | no of yrs PHLEGMB5                    |
| PHLEGMB7 | Phlegm > 2 yrs (DI)                   |

##### Episodes of coughing and slime:

|         |                      |
|---------|----------------------|
| EPSDEC1 | > 3 wks (DI)         |
| EPSDEC2 | no yrs of EPSDEC1    |
| EPSDEC3 | EPSDEC1 > 2 yrs (DI) |

##### Wheezing:

|         |  |
|---------|--|
| WHEZDI  | Wheezing current year (DI)             |
| WHEZ1D1 | During cold (DI)                       |
| WHEZ2D1 | Wheezing when no cold (DI)             |
| WHEZ3D1 | Most days and nights (DI)              |
| WHEZ4D1 | Shortness of breath when wheezing (DI) |

|         |                                     |
|---------|-------------------------------------|
| WHEZ5D1 | Wheezing when no cold (DI)          |
| WHEZ6D1 | Awoke with tight chest (DI)         |
| WHEZ7D1 | Awoke short of breath (DI)          |
| WHEEZD2 | No of yrs of wheezing               |
| WHEEZD3 | attack of wheezing and shortness of |
|         | breath (DI)                         |
| WHEEZD4 | age of first wheezing               |
| WHEEZD5 | > 2 WHEEZD3 (DI)                    |
| WHEEZD6 | Treatment for wheezing (DI)         |
| WHEEZD7 | > 2 yrs wheezing (DI)               |

Shortness of breath (SOB):

|         |   |
|---------|---|
| BRETHE1 | Description of SOB                      |
| BRETHE2 | SOB during fast or incline walking (DI) |
| BRETHE3 | > SOB than age-group (DI)               |
| BRETHE4 | SOB during normal walking (DI)          |
| BRETHE5 | SOB after 100m walking (DI)             |
| BRETHE6 | SOB normal activity (DI)                |

Chest Colds:

|         |                                       |
|---------|---------------------------------------|
| CHESTF  | Cold in chest (DI)                    |
| CHESTF1 | Chest cold during past 3 yrs + absent |
|         | from work (DI)                        |
| CHESTF2 | Slime production (DI)                 |
| CHESTF3 | No of times in past 3 yrs             |

History of resp. illness:

|        |                              |
|--------|------------------------------|
| HISTG1 | Lung problems before 16 (DI) |
|--------|------------------------------|

(bronchitis)

|          |                           |
|----------|---------------------------|
| G2HIST1A | bronchitis (DI)           |
| G2HIST1B | medical confirmation (DI) |

(pneumonia)

|          |                           |
|----------|---------------------------|
| G2HIST2A | Pneumonia (DI)            |
| G2HIST2B | medical confirmation (DI) |

(hayfever)

|          |                           |
|----------|---------------------------|
| G2HIST3A | Hayfever (DI)             |
| G2HIST3B | medical confirmation (DI) |

(sinus)

|          |                           |
|----------|---------------------------|
| G2HIST4A | sinus (DI)                |
| G2HIST4B | medical confirmation (DI) |

(T.B)

|          |                            |
|----------|----------------------------|
| G2HIST5A | TB (DI)                    |
| G2HIST5B | med confirm. (DI)          |
| G2HIST5E | > 1 time TB treatment (DI) |
| G2HIST5F | Still TB treatment (DI)    |

(Asthma)

|          |                                      |
|----------|--------------------------------------|
| HISTG3A  | past asthma (DI)                     |
| HISTG3AM | currently using med. for asthma (DI) |
| HISTG3B  | still asthma (DI)                    |
| HISTG3C  | med confirm. of asthma (DI)          |
| HISTG3E  | asthma during current yr. (DI)       |

(relatives with asthma)

|          |                          |
|----------|--------------------------|
| HISTG3G1 | mother (DI)              |
| HISTG3G2 | father (DI)              |
| HISTG3G3 | brothers or sisters (DI) |
| HISTG3G4 | children (DI)            |
| HISTG3G5 | other relatives (DI)     |

HISTG3GN

(Other problems)

|         |                       |
|---------|-----------------------|
| HISTG4A | Other chest problems  |
| HISTG4B | chest operations (DI) |
| HISTG4C | chest injuries (DI)   |
| HISTG4D | other illnesses (DI)  |

Respiratory tests

|          |  |
|----------|--|
| ALV      | Alveolar volume (l)                    |
| ALV1     | predicted ALV                          |
| ALV2     | % predicted ALV                        |
| DLCOUN   | CO transfer factor (ml/min/mmHg)       |
| DLCOUN1  | predicted DLCOUN                       |
| DLCOUN2  | % predicted DLCOUN                     |
| DLVAMLM  | CO transfer factor/ALV (ml/min/mmHg ?) |
| DLVAMLM1 | predicted DLVAMLM                      |
| DLVAMLM2 | % predicted DLVAMLM                    |
| FEFMAX   | Maximum Forced expiratory (l/sec)      |
| FEFMAX1  | Predicted FEFMAX                       |
| FEFMAX2  | % predicted FEFMAX                     |
| FEV1FVC  | FEV1/FVC                               |
| FEV1FVC1 | FEV1/FVC predicted                     |
| FEV1FVC2 | FEV1/FVC % of predicted                |
| FEV1L    | FEV1 (l)                               |

|        |                           |
|--------|---------------------------|
| FEV1L1 | predicted FEV1 (1)        |
| FEV1L2 | % predicted FEV1          |
| FVCL   | Forced vital capacity (1) |
| FVCL1  | predicted FVC             |
| FVCL2  | % predicted FVC           |

Exercise:

continuous variables:

|          |  |
|----------|--|
| RESTHR   | Resting pulse rate (beats/min)                 |
| MAXHR    | Maximum heart rate during exercise (beats/min) |
| HRPRED   | Predicted maximum heart rate (beats/min)       |
| DIFFHR   | difference between MAXHR and RESTHR            |
| RESTSAT  | Resting saturation (%)                         |
| MAXSAT   | Saturation at maximum exercise                 |
| DIFFSAT  | difference between RESTSAT and MAXSAT          |
| MAXWL    | Maximum workload reached (kpm/min)             |
| WLPRED   | Predicted MAXWL                                |
| PERWLPRE | % of predicted MAXWL                           |
| VO2MAX   | Maximum Oxygen consumption (1)                 |
| VO2MAXP  | Predicted. VO2MAX                              |
| PERPREDV | % of predicted VO2MAX                          |

Oximetry:

categorical variables:

|        |                      |
|--------|----------------------|
| TRACE3 | DIFFSAT (DI); 1 ≥ 2% |
| TRACE4 | DIFFSAT (DI); 1 ≥ 3% |
| TRACE5 | DIFFSAT (DI); 1 ≥ 4% |
| TRACE6 | DIFFSAT (DI); 1 ≥ 5% |

Radiography:

continuous variable

|      |                           |
|------|---------------------------|
| PROF | Profusions (scale 0 - 10) |
|------|---------------------------|

categorical variable

|        |                           |
|--------|---------------------------|
| CPROF  | PROF (DI); 1 ≥ score of 0 |
| CPROF2 | PROF (DI); 1 ≥ score of 1 |

EXPOSURE

continuous variables:

|          |  |
|----------|--|
| HERBACE  | Total lifetime cumulative herbicide exposure |
| PARACE   | Total lifetime cumulative paraquat exposure  |
| SHERBACE | Short-term herbicide exposure                |
| SPARACE  | Short-term paraquat exposure                 |
| HERBINT  | lifetime average intensity of herbicide      |

|         |  |
|---------|--|
| PARINT  | exposure<br>lifetime average intensity of paraquat<br>exposure |
| PARACE2 | PARACE - SPARACE   |
| PARINT2 | PARACE2/no of jobyears   |

categorical variables:

|         |                                |
|---------|--------------------------------|
| EXPA0   | HERBACE (DI); 1 > 0            |
| EXPA50  | HERBACE (DI); 1 > 50 JEM days  |
| EXPA100 | HERBACE (DI); 1 > 100 JEM days |
| EXPA250 | HERBACE (DI); 1 > 250 JEM days |
| EXPA700 | HERBACE (DI); 1 > 700 JEM days |

|      |  |
|------|--|
| EXPP | short-term HERBACE (DI);<br>1 > 0 JEM days |
|------|--|

|          |                               |
|----------|-------------------------------|
| EXPPA0   | PARACE (DI); 1 > 0 JEM days   |
| EXPPA50  | PARACE (DI); 1 > 50 JEM days  |
| EXPPA100 | PARACE (DI); 1 > 100 JEM days |
| EXPPA250 | PARACE (DI); 1 > 250 JEM days |
| EXPPA700 | PARACE (DI); 1 > 700 JEM days |

|          |                                 |
|----------|---------------------------------|
| EXPINT13 | PARINT (DI); 1 > 13 JEM days/yr |
| EXPINT34 | PARINT (DI); 1 > 34 JEM days/yr |

|      |                              |
|------|------------------------------|
| EXPS | SPARACE (DI); 1 > 0 JEM days |
|------|------------------------------|

|        |  |
|--------|--|
| EXGRAD | Ordinal PARACE; 1 = JEM days, 2 > 0 and < 200<br>JEM days, 3 > 200 and < 516 JEM days, 4 > 516<br>JEM days |
|--------|--|

|          |   |
|----------|---|
| POISTOT2 | previous history of paraquat poisoning (DI) |
|----------|---|

SMOKING AND ALCOHOL

continuous variables:

|      |                          |
|------|--------------------------|
| ALC  | Alcohol consumption (kg) |
| NICX | 20 cig. pack-years       |

categorical variables:

|        |                 |
|--------|-----------------|
| NICCAT | ALC (DI); 1 > 0 |
| ETHCAT | ALC (DI); 1 > 0 |

**Appendix 5:**  
**Supplementary Results**



Appendix 5 Supplementary Results  
Appendix 5.1 Univariate results

TABLE 1 Continuous variables

| Outcome<br>(units)       | Median | Mean   | SD     | n   | Range        |
|--------------------------|--------|--------|--------|-----|--------------|
| FVCL (1)                 |        | 3.73   | 0.61   | 125 | 2.33 - 5.11  |
| FVCL2 (1)                |        | 89.24  | 12.41  | 125 | 67 - 130     |
| FEV1L (1)                |        | 3.06   | 0.57   | 125 | 1.38 - 4.39  |
| FEV1L2 (1)               |        | 86.11  | 14.07  | 125 | 48 - 137     |
| FEV1FVC                  | 84     | 82.03  | 9.84   | 125 | 52 - 97      |
| FEFMAX<br>(l/sec)        |        | 7.73   | 1.91   | 125 | 2.68 - 12.04 |
| FEFMAX2                  |        | 89.23  | 21.2   | 125 | 35 - 138     |
| DLCOUN<br>(ml/min/kPa    |        | 4.10   | 0.75   | 107 | 2.28 - 5.65  |
| DLCOUN2                  |        | 106.40 | 18.96  | 107 | 69 - 177     |
| ALV (1)                  |        | 5.29   | 0.75   | 107 | 3.6 - 7.06   |
| ALV2                     |        | 91.48  | 11.10  | 107 | 67 - 123     |
| DLVAMLM<br>(ml/min/kPa/l |        | 0.78   | 0.14   | 107 | 0.44 - 1.17  |
| DLVAMLM2                 | 114    | 117.12 | 22.35  | 107 | 70 - 209     |
| MAXWL<br>(Kpm/min)       |        | 1080.3 | 164.46 | 122 | 700 - 1500   |
| PERWLPRE                 |        | 103.45 | 19.80  | 122 | 59 - 170     |
| RESTSAT                  | 99     | 98.3   | 1.5    | 90  | 95 - 100     |
| MAXSAT                   | 96     | 95.8   | 2.7    | 90  | 86 - 100     |
| DIFFSAT (%)              | 2      | 2.54   | 2.36   | 90  | -1 - 10      |
| RESTHR<br>(beats/min)    | 65     | 68.8   | 15.2   | 122 | 60 - 120     |
| MAXHR<br>(beats/min)     | 170    | 168.7  | 12.2   | 122 | 137 - 200    |
| DIFFHR                   | 101.5  | 99.9   | 16.52  | 122 | 32 - 132     |
| PERPREDH                 |        | 89.6   | 6.65   | 122 | 73 - 104     |
| VO2MAX<br>(ml/min)       |        | 2357.9 | 335.6  | 122 | 1582 - 3210  |

| Exposure<br>(units)  | Median | Mean  | SD    | n   | Range         |
|----------------------|--------|-------|-------|-----|---------------|
| EYRTOT2 (yrs)        | 16.0   | 17.9  | 11.0  | 126 | 3.0 - 54.0    |
| HERBACE<br>(days)    | 154.4  | 436.9 | 763.2 | 76  | 1 - 5212      |
| HERBINT<br>(days/yr) | 12.81  | 27.0  | 37.3  | 76  | 0.07 - 192.36 |
| SHERBACE<br>(days)   | 40     | 47.3  | 39.3  | 48  | 0.7 - 135     |
| PARACE<br>(days)     | 190.3  | 456.4 | 794.9 | 68  | 1.8 - 5196    |
| PARINT<br>(days/yr)  | 13.45  | 27.90 | 38.49 | 68  | 0.17 - 192.36 |
| SPARACE<br>(days)    | 45.0   | 51.6  | 40.2  | 41  | 0.7 - 135     |

| Variables<br>(units) | Median | Mean  | SD   | n   | Range       |
|----------------------|--------|-------|------|-----|-------------|
| WEIGHTKG (Kg)        |        | 56.1  | 8.9  | 125 | 35 - 85     |
| BSA                  |        | 1.6   | 0.14 | 125 | 1.22 - 1.97 |
| HEIGHTCM (cm)        |        | 163.6 | 6.9  | 125 | 147 - 177   |
| AGE (years)          |        | 34.2  | 9.9  | 126 | 18 - 65     |
| ALC (Kg)             | 148.8  |       |      | 125 | 0 - 1298.7  |
| NICX<br>(packyears)  | 7.5    | 10.9  | 14.2 | 125 | 0 - 94.5    |

TABLE2 Categorical variables

## Respiratory symptom:

| Variable | n   | Prevalence (%) |
|----------|-----|----------------|
| COUGHA1  | 126 | 57.1           |
| COUGHA2  | 126 | 41.3           |
| COUGHA3  | 126 | 43.7           |
| COUGHA4  | 126 | 38.9           |
| COUGHA5  | 126 | 11.9           |
| COUGHA7  | 126 | 7.9            |
| PHLEGMB1 | 126 | 32.5           |
| PHLEGMB2 | 126 | 18.3           |
| PHLEGMB3 | 126 | 23.8           |
| PHLEGMB4 | 126 | 18.3           |
| PHLEGMB5 | 126 | 10.3           |
| PHLEGMB7 | 126 | 7.9            |
| EPSDEC1  | 126 | 23.8           |
| EPSDEC3  | 126 | 21.4           |
| WHEZD1   | 126 | 46.8           |
| WHEZ1D1  | 126 | 44.4           |
| WHEZ2D1  | 126 | 15.1           |
| WHEZ3D1  | 126 | 22.2           |
| WHEZ4D1  | 126 | 25.4           |
| WHEZ5D1  | 126 | 14.3           |
| WHEZ6D1  | 126 | 14.3           |
| WHEZ7D1  | 126 | 7.9            |
| WHEEZD3  | 126 | 8.7            |
| WHEEZD5  | 126 | 6.3            |
| WHEEZD6  | 126 | 2.4            |
| WHEEZD7  | 126 | 22.2           |
| BRETHER2 | 126 | 40.5           |
| BRETHER3 | 126 | 15.9           |
| BRETHER4 | 126 | 7.9            |
| BRETHER5 | 126 | 7.1            |

| Variable | n   | Prevalence (%) |
|----------|-----|----------------|
| BRETHE6  | 126 | 1.6            |
| CHESTF1  | 126 | 75.4           |
| CHESTF2  | 126 | 15.9           |
| CHESTF3  | 126 | 11.9           |
| HISTG1   | 126 | 9.5            |
| G2HIST1A | 126 | 16.7           |
| G2HIST1B | 126 | 14.3           |
| G2HIST2A | 126 | 21.4           |
| G2HIST2B | 126 | 20.6           |
| G2HIST3A | 126 | 14.3           |
| G2HIST3B | 126 | 4.0            |
| G2HIST4A | 126 | 19.0           |
| G2HIST4B | 126 | 7.1            |
| G2HIST5A | 126 | 7.9            |
| G2HIST5B | 126 | 7.9            |
| G2HIST5E | 126 | 0.8            |
| G2HIST5F | 126 | 0              |
| HISTG3A  | 126 | 2.4            |
| HISTG3AM | 126 | 0              |
| HISTG3B  | 126 | 0              |
| HISTG3C  | 126 | 0.8            |
| HISTG3E  | 3   | 0              |
| HISTG3G1 | 3   | 0              |
| HISTG3G2 | 3   | 0              |
| HISTG3G3 | 3   | 0              |
| HISTG3G4 | 3   | 66.7           |
| HISTG3G5 | 3   | 0              |
| HISTG3GN | 3   | 66.7           |
| HISTG4A  | 126 | 12.7           |
| HISTG4B  | 126 | 0.8            |
| HISTG4C  | 126 | 15.1           |
| HISTG4D  | 126 | 59.5           |

Other variables:

| Variable | n   | Prevalence (%) |
|----------|-----|----------------|
| EXPA0    | 126 | 60.3           |
| EXPB0    | 126 | 60.3           |
| EXPPA0   | 126 | 54.0           |
| EXPPB0   | 126 | 54.0           |
| EXPS     | 126 | 38.1           |
| EXPP     | 126 | 32.5           |
| NICCAT   | 125 | 84.8           |
| ETHCAT   | 126 | 92.9           |
| TRACE3   | 90  | 73.3           |
| TRACE4   | 90  | 44.4           |
| TRACE5   | 90  | 32.2           |

## APPENDIX 5.2 Significant Bivariate associations

(Level of significance = 5%;

Significant outcome relationships

### X - Square results

| OUTCOME  | VARIABLES ASSOCIATED (direction of association)                                    |
|----------|--|
| TRACE3   | EXPS (+) <sup>a</sup> ; EXPP (-)   |
| TRACE4   | EXPP (+) <sup>a</sup> ; NICCAT (-);  |
| TRACE5   | EXPA700 (+) <sup>a</sup> ; NICCAT (-)  |
| COUGHA1  | NICCAT (+) <sup>c</sup> ;  |
| COUGHA2  | NICCAT (+) <sup>c</sup> ;  |
| COUGHA3  | NICCAT (+) <sup>c</sup> ;  |
| COUGHA4  | NICCAT (+) <sup>c</sup> ;  |
| PHLEGMB2 | EXPA0 (+) <sup>b</sup> ; EXPA50 (+) <sup>b</sup>                                   |
| PHLEGMB4 | EXPPA0 (+) <sup>c</sup> ;  |
| EPSDEC1  | EXPA100 (+) <sup>b</sup> ; EXPPA100 (+) <sup>b</sup> ; EXPPA250 (+) <sup>b</sup> ; |
| EPSDEC3  | EXPPA250 (+) <sup>b</sup> ;  |
| WHEZ1D1  | NICCAT (+);  |
| WHEZ5D1  | EXPA0 (-)  |
| WHEZ6D1  | EXPA0 (-); EXPPA0 (-); EXPA50 (-)  |
| WHEEZD3  | EXPP (+);  |
| WHEEZD5  | EXPA700 (+) <sup>b</sup> ; EXPPA700 (+) <sup>b</sup>                               |
| CHESTF2  | NICCAT (-);  |
| CHESTF3  | NICCAT (-);  |
| HISTG1   | EXPA0 (+) ; EXPS (+); EXPP (+);  |
| G2HIST1B | EXPA0 (-)  |
| HISTG3A  | NICCAT (-);  |
| HISTG4A  | EXPA100 (+)  |
| HISTG4C  | EXPA700 (+)  |
| HISTG4D  | EXPS (-); EXPP (-)   |

### T-tests and Wilcoxon

|         |  |
|---------|--|
| TRACE3  | SPARACE(+) <sup>a</sup> ; SHERBACE (+) <sup>a</sup>    |
| DIFFSAT | EXPA700 (+) <sup>a</sup> ; EXPPA700 (+) <sup>a</sup> ; |
| DLCOUN  | EXPPA0 (+);  |
| FEFMAX  | EXPA700 (+); EXPPA700 (+);                             |
| FEFMAX2 | EXPPA700 (+)   |

### Spearman and Pearson correlations

|         |   |
|---------|---|
| FEV1L   | AGE (-) <sup>d</sup> ; HEIGHTCM (+) <sup>d</sup> ; WEIGHTKG (+) <sup>d</sup> ; NICK (-) |
| FVCL    | AGE (-) <sup>d</sup> ; HEIGHTCM (+) <sup>d</sup> ; WEIGHTKG (+) <sup>d</sup>            |
| FEV1FVC | AGE (-) <sup>d</sup>  |
| FEFMAX  | HEIGHTCM (+) <sup>d</sup> ; WEIGHTKG (+) <sup>d</sup>                                   |
| FEFMAX2 | WEIGHTKG (+) <sup>d</sup>   |
| DLCOUN  | AGE (-) <sup>d</sup> ; HEIGHTCM (+) <sup>d</sup> ; WEIGHTKG (+) <sup>d</sup> ; NICK (-) |
| DLCOUN2 | AGE (-) <sup>d</sup> ; WEIGHTKG (-) <sup>d</sup>  |
| ALV     | HEIGHTCM (+) <sup>d</sup> ; WEIGHTKG (+) <sup>d</sup>                                   |
| DLVAMLM | SPARACE AGE (-) <sup>d</sup>  |

Other significant associations

### T-tests and Wilcoxon's

ALC                    EXPPA250 (+)<sup>f</sup>; EXPPA700 (+)<sup>f</sup>;  
AGE                    EXPPA700 (+)<sup>a</sup>

### Spearman and Pearson correlations

AGE                    DIFFHR (-)  
HEIGHTCM              PERWLPRE (-)  
WEIGHTKG              PERWLPRE (-)  
NICK                   DIFFHR (-)

+ : positive association  
- : negative association

### Important associations

- "a" = Significant associations between exposure and exercise desaturation
- "b" = Significant associations between long-term exposure and reported health
- "c" = Significant associations between smoking and reported respiratory health
- "d" = Significant associations between lung function and age, weight, height
- "e" = Significant associations between long-term exposure and age
- "f" = Significant associations between long-term exposure and alcohol consumption

Appendix 5.3 Summary of linear regression analysis of the effect of total long-term accumulated paraquat exposure on radiology

Table 1. Full model

Outcome : Profusion score

| Predictor | Beta         | SE(beta)   | P-value | Partial<br>R <sup>2</sup> |
|-----------|--------------|------------|---------|---------------------------|
| AGE       | 0.008878     | 0.00657987 | 0.1799  | 0.0251                    |
| WEIGHTKG  | -0.007780    | 0.00802597 | 0.3344  | 0.0043                    |
| HEIGHTCM  | 0.007304     | 0.01013215 | 0.4724  | 0.0050                    |
| NICX      | 0.004219     | 0.00419708 | 0.3169  | 0.0068                    |
| ALC       | 0.000008267  | 0.00001558 | 0.5966  | 0.0023                    |
| PARACE    | -0.000099267 | 0.00009079 | 0.2765  | 0.0092                    |

Model R<sup>2</sup> : 0.0527



Appendix 5.4 Summary of logistic regression analysis of the effect of long-term total cumulative paraquat exposure on reported respiratory symptoms

Table 1. Full models describing the relationship between long-term accumulated paraquat and reported respiratory symptoms

Outcome COUGHA1

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0311   | 0.0263   | 0.2370  | 1.032 (0.980-1.086)   |
| HEIGHTCM  | -0.00208 | 0.0350   | 0.9527  | 0.998 (0.932-1.069)   |
| WEIGHTKG  | -0.0501  | 0.0282   | 0.0763  | 0.951 (0.900-1.005)   |
| NICX      | -0.00730 | 0.0143   | 0.6101  | 0.993 (0.965-1.021)   |
| ALC       | 0.000071 | 0.000061 | 0.2469  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.00927  | 0.0627   | 0.8826  | 1.009 (0.893-1.141)   |
| PARACE    | -0.00051 | 0.000361 | 0.1550  | 0.999 (0.999-1.000)   |

N = 124

Outcome COUGHA2

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.00658 | 0.0263   | 0.8025  | 0.993 (0.944-1.046)   |
| HEIGHTCM  | -0.0271  | 0.0359   | 0.4512  | 0.973 (0.907-1.044)   |
| WEIGHTKG  | -0.0531  | 0.0306   | 0.0824  | 0.948 (0.893-1.007)   |
| NICX      | 0.00573  | 0.0145   | 0.6919  | 1.006 (0.978-1.035)   |
| ALC       | 0.00009  | 0.000057 | 0.1163  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.0116  | 0.0639   | 0.8561  | 0.988 (0.872-1.120)   |
| PARACE    | -0.00031 | 0.000372 | 0.4106  | 1.000 (0.999-1.000)   |

N = 124

Outcome COUGHA3

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0363   | 0.0256   | 0.1565  | 1.037 (0.986-1.090)   |
| HEIGHTCM  | -0.00082 | 0.0347   | 0.9811  | 0.999 (0.933-1.069)   |
| WEIGHTKG  | -0.0465  | 0.0286   | 0.1043  | 0.955 (0.902-1.010)   |
| NICX      | -0.00082 | 0.0143   | 0.9541  | 0.999 (0.972-1.028)   |
| ALC       | 0.000027 | 0.000055 | 0.6190  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.0130  | 0.0625   | 0.8354  | 0.987 (0.873-1.116)   |
| PARACE    | -0.00054 | 0.000411 | 0.1899  | 0.999 (0.999-1.000)   |

N = 124

# Outcome COUGHA4

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.00927 | 0.0273   | 0.7338  | 0.991 (0.939-1.045)   |
| HEIGHTCM  | 0.0340   | 0.0375   | 0.3646  | 1.035 (0.961-1.113)   |
| WEIGHTKG  | -0.0859  | 0.0338   | 0.0111  | 0.918 (0.859-0.981)   |
| NICX      | 0.00229  | 0.0153   | 0.8806  | 1.002 (0.973-1.033)   |
| ALC       | 0.000125 | 0.000061 | 0.0419  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.0425  | 0.0660   | 0.5197  | 0.958 (0.842-1.091)   |
| PARACE    | -0.00028 | 0.000394 | 0.4829  | 1.000 (0.999-1.000)   |

N = 124 \*

# Outcome COUGHA5

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.00645  | 0.0367   | 0.8604  | 1.006 (0.937-1.082)   |
| HEIGHTCM  | -0.0144  | 0.0547   | 0.7920  | 0.986 (0.885-1.097)   |
| WEIGHTKG  | -0.0117  | 0.0435   | 0.7887  | 0.988 (0.908-1.076)   |
| NICX      | -0.0350  | 0.0370   | 0.3446  | 0.966 (0.898-1.038)   |
| ALC       | 0.000034 | 0.000077 | 0.6607  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.1077  | 0.0943   | 0.2534  | 0.898 (0.746-1.080)   |
| PARACE    | -0.00041 | 0.000711 | 0.5601  | 1.000 (0.998-1.001)   |

N = 124

# Outcome COUGHA7

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0220   | 0.0430   | 0.6084  | 1.022 (0.940-1.112)   |
| HEIGHTCM  | 0.0452   | 0.0686   | 0.5095  | 1.046 (0.915-1.197)   |
| WEIGHTKG  | -0.0211  | 0.0513   | 0.6804  | 0.979 (0.885-1.083)   |
| NICX      | -0.0609  | 0.0547   | 0.2661  | 0.941 (0.845-1.048)   |
| ALC       | 0.00004  | 0.00009  | 0.6551  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.1023  | 0.1161   | 0.3785  | 0.903 (0.719-1.134)   |
| PARACE    | -0.00015 | 0.000609 | 0.8038  | 1.000 (0.999-1.001)   |

N=124

# Outcome PHLEGMB1

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.00675 | 0.0274   | 0.8056  | 0.993 (0.941-1.048)   |
| HEIGHTCM  | 0.0493   | 0.0369   | 0.1814  | 1.051 (0.977-1.129)   |
| WEIGHTKG  | -0.0360  | 0.0301   | 0.2328  | 0.965 (0.909-1.023)   |
| NICX      | -0.0145  | 0.0194   | 0.4568  | 0.986 (0.949-1.024)   |
| ALC       | -0.00001 | 0.000059 | 0.8156  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.00876 | 0.0662   | 0.8948  | 0.991 (0.871-1.129)   |
| PARACE    | -0.00025 | 0.000414 | 0.5443  | 1.000 (0.999-1.001)   |

N=124

## Outcome PHLEGMB2

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0230  | 0.0362   | 0.5259  | 0.977 (0.910-1.049)   |
| HEIGHTCM  | 0.0788   | 0.0463   | 0.0885  | 1.082 (0.988-1.185)   |
| WEIGHTKG  | -0.0784  | 0.0418   | 0.0605  | 0.925 (0.852-1.003)   |
| NICX      | 0.0128   | 0.0212   | 0.5459  | 1.013 (0.972-1.056)   |
| ALC       | -0.00012 | 0.000101 | 0.2444  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.00473  | 0.0839   | 0.9551  | 1.005 (0.852-1.184)   |
| PARACE    | -0.00021 | 0.000685 | 0.7598  | 1.000 (0.998-1.001)   |

N=124

## Outcome PHLEGMB3

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.00315  | 0.0297   | 0.9157  | 1.003 (0.946-1.063)   |
| HEIGHTCM  | 0.0207   | 0.0398   | 0.6030  | 1.021 (0.944-1.104)   |
| WEIGHTKG  | -0.0374  | 0.0335   | 0.2646  | 0.963 (0.902-1.029)   |
| NICX      | -0.0172  | 0.0223   | 0.4411  | 0.983 (0.941-1.027)   |
| ALC       | -4.05E-7 | 0.000062 | 0.9948  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.00325 | 0.0729   | 0.9644  | 0.997 (0.864-1.150)   |
| PARACE    | -0.00015 | 0.000405 | 0.7189  | 1.000 (0.999-1.001)   |

N=124

## Outcome PHLEGMB4

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.00224  | 0.0324   | 0.9449  | 1.002 (0.941-1.068)   |
| HEIGHTCM  | 0.0620   | 0.0454   | 0.1724  | 1.064 (0.973-1.163)   |
| WEIGHTKG  | -0.0498  | 0.0380   | 0.1894  | 0.951 (0.883-1.025)   |
| NICX      | -0.00785 | 0.0230   | 0.7329  | 0.992 (0.948-1.038)   |
| ALC       | -0.00002 | 0.00007  | 0.8174  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.0294  | 0.0803   | 0.7144  | 0.971 (0.830-1.137)   |
| PARACE    | 0.000087 | 0.000382 | 0.8191  | 1.000 (0.999-1.001)   |

N=124

## Outcome PHLEGMB5

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0146   | 0.0428   | 0.7319  | 1.015 (0.933-1.103)   |
| HEIGHTCM  | 0.0215   | 0.0561   | 0.7014  | 1.022 (0.915-1.141)   |
| WEIGHTKG  | -0.0214  | 0.0457   | 0.6387  | 0.979 (0.895-1.070)   |
| NICX      | -0.00245 | 0.0248   | 0.9212  | 0.998 (0.950-1.047)   |
| ALC       | 4.079E-6 | 0.000082 | 0.9606  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.0643   | 0.1069   | 0.5472  | 1.066 (0.865-1.315)   |
| PARACE    | 0.000223 | 0.000388 | 0.5645  | 1.000 (0.999-1.001)   |

N=124

# Outcome PHLEGMB7

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0114  | 0.0472   | 0.8099  | 0.989 (0.901-1.084)   |
| HEIGHTCM  | 0.0911   | 0.0701   | 0.1935  | 1.095 (0.955-1.257)   |
| WEIGHTKG  | -0.0133  | 0.0518   | 0.7969  | 0.987 (0.892-1.092)   |
| NICX      | 0.0158   | 0.0243   | 0.5153  | 1.016 (0.969-1.066)   |
| ALC       | -0.00009 | 0.000125 | 0.4883  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.0563  | 0.1137   | 0.6202  | 0.945 (0.756-1.181)   |
| PARACE    | 0.000354 | 0.000492 | 0.4716  | 1.000 (0.999-1.001)   |

N=124

# Outcome EPDSDEC1

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0309   | 0.0322   | 0.3368  | 1.031 (0.968-1.099)   |
| HEIGHTCM  | 0.0372   | 0.0425   | 0.3804  | 1.038 (0.955-1.128)   |
| WEIGHTKG  | -0.0304  | 0.0340   | 0.3717  | 0.970 (0.907-1.037)   |
| NICX      | -0.0621  | 0.0334   | 0.0625  | 0.940 (0.880-1.003)   |
| ALC       | 0.000074 | 0.00006  | 0.2203  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.0687   | 0.0806   | 0.3941  | 1.071 (0.915-1.254)   |
| PARACE    | 0.000384 | 0.000361 | 0.2870  | 1.000 (1.000-1.001)   |

N=124

# Outcome EPSDEC3

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0291   | 0.0328   | 0.3746  | 1.030 (0.965-1.098)   |
| HEIGHTCM  | 0.0556   | 0.0454   | 0.2211  | 1.057 (0.967-1.156)   |
| WEIGHTKG  | -0.0582  | 0.0380   | 0.1254  | 0.943 (0.876-1.016)   |
| NICX      | -0.0483  | 0.0327   | 0.1395  | 0.953 (0.894-1.016)   |
| ALC       | 0.000071 | 0.000061 | 0.2448  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.0165   | 0.0827   | 0.8424  | 1.017 (0.864-1.195)   |
| PARACE    | 0.000417 | 0.000355 | 0.2410  | 1.000 (1.000-1.001)   |

N=124

## Outcome WHEZD1

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0274  | 0.0265   | 0.3011  | 0.973 (0.924-1.025)   |
| HEIGHTCM  | 0.0305   | 0.0357   | 0.3930  | 1.031 (0.961-1.106)   |
| WEIGHTKG  | -0.0621  | 0.0305   | 0.0415  | 0.940 (0.885-0.998)   |
| NICX      | 0.00650  | 0.0145   | 0.6545  | 1.007 (0.978-1.036)   |
| ALC       | 0.000111 | 0.000059 | 0.0592  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.0288  | 0.0628   | 0.6465  | 0.972 (0.859-1.099)   |
| PARACE    | -0.00007 | 0.000331 | 0.8293  | 1.000 (0.999-1.001)   |

N=124

## Outcome WHEZ1D1

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0285  | 0.0265   | 0.2823  | 0.972 (0.923-1.024)   |
| HEIGHTCM  | 0.0362   | 0.0358   | 0.3127  | 1.037 (0.967-1.112)   |
| WEIGHTKG  | -0.0643  | 0.0309   | 0.0375  | 0.938 (0.883-0.996)   |
| NICX      | 0.0128   | 0.0145   | 0.3744  | 1.013 (0.985-1.042)   |
| ALC       | 0.000067 | 0.000054 | 0.2161  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.0223  | 0.0626   | 0.7220  | 0.978 (0.865-1.106)   |
| PARACE    | 0.000049 | 0.000315 | 0.8776  | 1.000 (0.999-1.001)   |

N=124

## Outcome WHEZ2D1

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0360  | 0.0452   | 0.4254  | 0.965 (0.883-1.054)   |
| HEIGHTCM  | 0.1173   | 0.0519   | 0.0237  | 1.124 (1.016-1.245)   |
| WEIGHTKG  | -0.1003  | 0.0469   | 0.0324  | 0.905 (0.825-0.992)   |
| NICX      | 0.0311   | 0.0206   | 0.1309  | 1.032 (0.991-1.074)   |
| ALC       | -0.00011 | 0.00011  | 0.3048  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.1112   | 0.1011   | 0.2711  | 1.118 (0.917-1.362)   |
| PARACE    | 0.000306 | 0.000483 | 0.5259  | 1.000 (0.999-1.001)   |

N=124

## Outcome WHEZ3D1

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0412  | 0.0343   | 0.2303  | 0.960 (0.897-1.026)   |
| HEIGHTCM  | -0.00297 | 0.0426   | 0.9443  | 0.997 (0.917-1.084)   |
| WEIGHTKG  | -0.0458  | 0.0387   | 0.2363  | 0.955 (0.885-1.030)   |
| NICX      | 0.000076 | 0.0189   | 0.9968  | 1.000 (0.964-1.038)   |
| ALC       | 0.000092 | 0.000062 | 0.1353  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.0281  | 0.0759   | 0.7110  | 0.972 (0.838-1.128)   |
| PARACE    | -0.00016 | 0.000452 | 0.7301  | 1.000 (0.999-1.001)   |

N=124

## Outcome WHEZ4D1

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.00067 | 0.0302   | 0.9822  | 0.999 (0.942-1.060)   |
| HEIGHTCM  | 0.0323   | 0.0394   | 0.4121  | 1.033 (0.956-1.116)   |
| WEIGHTKG  | -0.0408  | 0.0335   | 0.2241  | 0.960 (0.899-1.025)   |
| NICX      | 0.0187   | 0.0150   | 0.2108  | 1.019 (0.989-1.049)   |
| ALC       | 0.000103 | 0.000061 | 0.0910  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.0704   | 0.0723   | 0.3302  | 1.073 (0.931-1.236)   |
| PARACE    | -0.00041 | 0.000474 | 0.3836  | 1.000 (0.999-1.001)   |

N=124

## Outcome WHEZ5D1

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0304  | 0.0416   | 0.4646  | 0.970 (0.894-1.052)   |
| HEIGHTCM  | 0.1037   | 0.0506   | 0.0406  | 1.109 (1.004-1.225)   |
| WEIGHTKG  | -0.0765  | 0.0446   | 0.0865  | 0.926 (0.849-1.011)   |
| NICX      | 0.0190   | 0.0203   | 0.3499  | 1.019 (0.979-1.060)   |
| ALC       | -0.00001 | 0.000086 | 0.9031  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.0451   | 0.0927   | 0.6266  | 1.046 (0.872-1.255)   |
| PARACE    | -0.00049 | 0.000807 | 0.5445  | 1.000 (0.998-1.001)   |

N=124

## Outcome WHEZ6D1

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0364   | 0.0389   | 0.3498  | 1.037 (0.961-1.119)   |
| HEIGHTCM  | -0.0150  | 0.0504   | 0.7658  | 0.985 (0.893-1.087)   |
| WEIGHTKG  | -0.0846  | 0.0487   | 0.0821  | 0.919 (0.835-1.011)   |
| NICX      | -0.0154  | 0.0258   | 0.5504  | 0.985 (0.936-1.036)   |
| ALC       | 0.00013  | 0.000066 | 0.0475  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.0783   | 0.0995   | 0.4311  | 1.081 (0.890-1.314)   |
| PARACE    | -0.00022 | 0.000463 | 0.6361  | 1.000 (0.999-1.001)   |

N=124 \*

## Outcome WHEZ7D1

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0504  | 0.0544   | 0.3545  | 0.951 (0.855-1.058)   |
| HEIGHTCM  | 0.1257   | 0.0682   | 0.0654  | 1.134 (0.992-1.296)   |
| WEIGHTKG  | -0.1303  | 0.0666   | 0.0505  | 0.878 (0.770-1.000)   |
| NICX      | -0.0207  | 0.0481   | 0.6667  | 0.980 (0.891-1.076)   |
| ALC       | 0.000091 | 0.000093 | 0.3302  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.0906  | 0.1209   | 0.4537  | 0.913 (0.721-1.158)   |
| PARACE    | 0.000331 | 0.00052  | 0.5238  | 1.000 (0.999-1.001)   |

N=124

## Outcome WHEEZD3

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0169  | 0.0555   | 0.7605  | 0.983 (0.882-1.096)   |
| HEIGHTCM  | 0.0334   | 0.0606   | 0.5817  | 1.034 (0.918-1.164)   |
| WEIGHTKG  | -0.0166  | 0.0497   | 0.7384  | 0.984 (0.892-1.084)   |
| NICX      | -0.0431  | 0.0486   | 0.3755  | 0.958 (0.871-1.054)   |
| ALC       | 0.000059 | 0.000094 | 0.5264  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.1413   | 0.1291   | 0.2736  | 1.152 (0.894-1.483)   |
| PARACE    | 0.000406 | 0.000388 | 0.2949  | 1.000 (1.000-1.001)   |

N=124

## Outcome WHEEZD6

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0461   | 0.0950   | 0.6273  | 1.047 (0.869-1.261)   |
| HEIGHTCM  | 0.0405   | 0.1044   | 0.6980  | 1.041 (0.849-1.278)   |
| WEIGHTKG  | 0.0300   | 0.0691   | 0.6638  | 1.030 (0.900-1.180)   |
| NICX      | -0.0559  | 0.0916   | 0.5417  | 0.946 (0.790-1.132)   |
| ALC       | -0.00013 | 0.000274 | 0.6341  | 1.000 (0.999-1.000)   |
| SCHOOL    | 0.4247   | 0.3325   | 0.2015  | 1.529 (0.797-2.934)   |
| PARACE    | -0.00360 | 0.00540  | 0.5047  | 0.996 (0.986-1.007)   |

N=124

## Outcome WHEEZD5

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0723  | 0.0718   | 0.3133  | 0.930 (0.808-1.071)   |
| HEIGHTCM  | 0.1144   | 0.0774   | 0.1397  | 1.121 (0.963-1.305)   |
| WEIGHTKG  | -0.0592  | 0.0651   | 0.3633  | 0.943 (0.830-1.071)   |
| NICX      | -0.0113  | 0.0474   | 0.8110  | 0.989 (0.901-1.085)   |
| ALC       | 0.000118 | 0.000103 | 0.2523  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.0383   | 0.1453   | 0.7919  | 1.039 (0.782-1.381)   |
| PARACE    | 0.000701 | 0.000451 | 0.1198  | 1.001 (1.000-1.002)   |

N=124

## Outcome WHEEZD7

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0312  | 0.0320   | 0.3292  | 0.969 (0.910-1.032)   |
| HEIGHTCM  | 0.0397   | 0.0426   | 0.3514  | 1.040 (0.957-1.131)   |
| WEIGHTKG  | -0.0541  | 0.0377   | 0.1511  | 0.947 (0.880-1.020)   |
| NICX      | 0.00526  | 0.0178   | 0.7675  | 1.005 (0.971-1.041)   |
| ALC       | 0.000045 | 0.000061 | 0.4662  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.0675  | 0.0742   | 0.3632  | 0.935 (0.808-1.081)   |
| PARACE    | 0.000071 | 0.000379 | 0.8516  | 1.000 (0.999-1.001)   |



## Outcome BRETHER2

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.00682  | 0.0289   | 0.8136  | 1.007 (0.951-1.066)   |
| HEIGHTCM  | 0.1148   | 0.0423   | 0.0067  | 1.122 (1.032-1.219)   |
| WEIGHTKG  | -0.1404  | 0.0392   | 0.0003  | 0.869 (0.805-0.938)   |
| NICX      | 0.00174  | 0.0159   | 0.9133  | 1.002 (0.971-1.034)   |
| ALC       | 0.000157 | 0.000068 | 0.0217  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.0129  | 0.0692   | 0.8524  | 0.987 (0.862-1.131)   |
| PARACE    | -0.00036 | 0.000449 | 0.4165  | 1.000 (0.999-1.001)   |

N=124 \*

## Outcome BRETHER3

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0127   | 0.0334   | 0.7037  | 1.013 (0.949-1.081)   |
| HEIGHTCM  | 0.0777   | 0.0510   | 0.1274  | 1.081 (0.978-1.194)   |
| WEIGHTKG  | -0.0766  | 0.0438   | 0.0805  | 0.926 (0.850-1.009)   |
| NICX      | 0.00965  | 0.0178   | 0.5883  | 1.010 (0.975-1.046)   |
| ALC       | 0.000122 | 0.000067 | 0.0688  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.0678  | 0.0848   | 0.4235  | 0.934 (0.791-1.103)   |
| PARACE    | -0.00036 | 0.000542 | 0.5050  | 1.000 (0.999-1.001)   |

N=124

## Outcome BRETHER4

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0515  | 0.0527   | 0.3280  | 0.950 (0.857-1.053)   |
| HEIGHTCM  | 0.000356 | 0.0716   | 0.9960  | 1.000 (0.869-1.151)   |
| WEIGHTKG  | -0.0162  | 0.0606   | 0.7886  | 0.984 (0.874-1.108)   |
| NICX      | -0.0336  | 0.0503   | 0.5037  | 0.967 (0.876-1.067)   |
| ALC       | 0.000259 | 0.000092 | 0.0046  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.1632  | 0.1168   | 0.1623  | 0.849 (0.676-1.068)   |
| PARACE    | -0.00386 | 0.00323  | 0.2318  | 0.996 (0.990-1.002)   |

N=124 \*



## Outcome BRETHE5

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0320   | 0.0550   | 0.5605  | 1.033 (0.927-1.150)   |
| HEIGHTCM  | -0.0557  | 0.0723   | 0.4405  | 0.946 (0.821-1.090)   |
| WEIGHTKG  | -0.1096  | 0.0756   | 0.1470  | 0.896 (0.773-1.039)   |
| NICX      | 0.0217   | 0.0233   | 0.3506  | 1.022 (0.976-1.070)   |
| ALC       | 0.000148 | 0.000083 | 0.0731  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.1457   | 0.1412   | 0.3020  | 1.157 (0.877-1.526)   |
| PARACE    | -0.00087 | 0.00106  | 0.4146  | 0.999 (0.997-1.001)   |

N=124

## Outcome BRETHE6

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0231   | 0.0305   | 0.4483  | 1.023 (0.964-1.086)   |
| HEIGHTCM  | -0.0475  | 0.0399   | 0.2342  | 0.954 (0.882-1.031)   |
| WEIGHTKG  | 0.0227   | 0.0326   | 0.4866  | 1.023 (0.960-1.091)   |
| NICX      | -0.0304  | 0.0162   | 0.0607  | 0.970 (0.940-1.001)   |
| ALC       | 0.000111 | 0.000082 | 0.1778  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.00925 | 0.0722   | 0.8982  | 0.991 (0.860-1.142)   |
| PARACE    | 0.000805 | 0.000825 | 0.3293  | 1.001 (0.999-1.002)   |

N=124

## Outcome CHESTF2

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.00999 | 0.0378   | 0.7915  | 0.990 (0.919-1.066)   |
| HEIGHTCM  | 0.0179   | 0.0476   | 0.7064  | 1.018 (0.927-1.118)   |
| WEIGHTKG  | 0.0465   | 0.0355   | 0.1901  | 1.048 (0.977-1.123)   |
| NICX      | 0.0218   | 0.0165   | 0.1859  | 1.022 (0.990-1.056)   |
| ALC       | -0.00005 | 0.000085 | 0.5727  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.1022   | 0.0899   | 0.2554  | 1.108 (0.929-1.321)   |
| PARACE    | 0.000075 | 0.000448 | 0.8671  | 1.000 (0.999-1.001)   |

N=124

## Outcome CHESTF3

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0431  | 0.0475   | 0.3649  | 0.958 (0.873-1.051)   |
| HEIGHTCM  | -0.0188  | 0.0551   | 0.7326  | 0.981 (0.881-1.093)   |
| WEIGHTKG  | 0.0720   | 0.0417   | 0.0843  | 1.075 (0.990-1.166)   |
| NICX      | 0.0319   | 0.0184   | 0.0834  | 1.032 (0.996-1.070)   |
| ALC       | -0.00006 | 0.000112 | 0.5964  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.0802   | 0.1034   | 0.4380  | 1.084 (0.885-1.327)   |
| PARACE    | -0.00009 | 0.000693 | 0.8976  | 1.000 (0.999-1.001)   |

N=124

## Outcome HISTG1

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0874  | 0.0507   | 0.0845  | 0.916 (0.830-1.012)   |
| HEIGHTCM  | 0.0156   | 0.0669   | 0.8150  | 1.016 (0.891-1.158)   |
| WEIGHTKG  | -0.0570  | 0.0645   | 0.3768  | 0.945 (0.832-1.072)   |
| NICX      | -0.0127  | 0.0456   | 0.7814  | 0.987 (0.903-1.080)   |
| ALC       | -0.00013 | 0.000149 | 0.3764  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.3193  | 0.1131   | 0.0047  | 0.727 (0.582-0.907)   |
| PARACE    | 0.000313 | 0.000659 | 0.6343  | 1.000 (0.999-1.002)   |

N=124

## Outcome G2HIST1A

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.00720 | 0.0314   | 0.8188  | 0.993 (0.934-1.056)   |
| HEIGHTCM  | -0.00316 | 0.0470   | 0.9464  | 0.997 (0.909-1.093)   |
| WEIGHTKG  | -0.0134  | 0.0374   | 0.7198  | 0.987 (0.917-1.062)   |
| NICX      | -0.0176  | 0.0247   | 0.4761  | 0.983 (0.936-1.031)   |
| ALC       | 0.000015 | 0.000067 | 0.8176  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.1461  | 0.0803   | 0.0690  | 0.864 (0.738-1.011)   |
| PARACE    | 0.000015 | 0.000399 | 0.9693  | 1.000 (0.999-1.001)   |

N=124

## Outcome G2HIST1B

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0112  | 0.0329   | 0.7325  | 0.989 (0.927-1.055)   |
| HEIGHTCM  | 0.0292   | 0.0521   | 0.5750  | 1.030 (0.930-1.140)   |
| WEIGHTKG  | -0.0368  | 0.0426   | 0.3875  | 0.964 (0.887-1.048)   |
| NICX      | -0.00940 | 0.0246   | 0.7019  | 0.991 (0.944-1.039)   |
| ALC       | 0.000011 | 0.000072 | 0.8782  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.1993  | 0.0872   | 0.0222  | 0.819 (0.691-0.972)   |
| PARACE    | 8.508E-6 | 0.000463 | 0.9853  | 1.000 (0.999-1.001)   |

N=124

## Outcome G2HIST2A

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.00550 | 0.0294   | 0.8519  | 0.995 (0.939-1.054)   |
| HEIGHTCM  | 0.0587   | 0.0435   | 0.1768  | 1.060 (0.974-1.155)   |
| WEIGHTKG  | -0.0292  | 0.0344   | 0.3962  | 0.971 (0.908-1.039)   |
| NICX      | 0.00520  | 0.0195   | 0.7896  | 1.005 (0.968-1.044)   |
| ALC       | -0.00005 | 0.000071 | 0.5138  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.1384  | 0.0754   | 0.0665  | 0.871 (0.751-1.009)   |
| PARACE    | -0.00188 | 0.00126  | 0.1343  | 0.998 (0.996-1.001)   |

N=124

# Outcome G2HIST2B

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.00365 | 0.0297   | 0.9023  | 0.996 (0.940-1.056)   |
| HEIGHTCM  | 0.0536   | 0.0438   | 0.2215  | 1.055 (0.968-1.150)   |
| WEIGHTKG  | -0.0277  | 0.0347   | 0.4249  | 0.973 (0.909-1.041)   |
| NICX      | 0.00246  | 0.0203   | 0.9035  | 1.002 (0.963-1.043)   |
| ALC       | -0.00004 | 0.000071 | 0.5735  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.1321  | 0.0761   | 0.0826  | 0.876 (0.755-1.017)   |
| PARACE    | -0.00192 | 0.00130  | 0.1389  | 0.998 (0.996-1.001)   |

N=124

# Outcome G2HIST3A

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0716   | 0.0383   | 0.0616  | 1.074 (0.997-1.158)   |
| HEIGHTCM  | -0.0275  | 0.0501   | 0.5836  | 0.973 (0.882-1.073)   |
| WEIGHTKG  | -0.0333  | 0.0412   | 0.4190  | 0.967 (0.892-1.049)   |
| NICX      | -0.1452  | 0.0578   | 0.0120  | 0.865 (0.772-0.969)   |
| ALC       | 0.000022 | 0.000076 | 0.7720  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.0833   | 0.0999   | 0.4045  | 1.087 (0.894-1.322)   |
| PARACE    | -0.00004 | 0.000357 | 0.9014  | 1.000 (0.999-1.001)   |

N=124 \*

# Outcome G2HIST3B

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0118   | 0.0915   | 0.8976  | 1.012 (0.846-1.211)   |
| HEIGHTCM  | 0.0901   | 0.1007   | 0.3713  | 1.094 (0.898-1.333)   |
| WEIGHTKG  | -0.00133 | 0.0718   | 0.9853  | 0.999 (0.868-1.150)   |
| NICX      | -0.2352  | 0.1305   | 0.0715  | 0.790 (0.612-1.021)   |
| ALC       | 0.000352 | 0.000181 | 0.0517  | 1.000 (1.000-1.001)   |
| SCHOOL    | 0.6107   | 0.3372   | 0.0701  | 1.842 (0.951-3.566)   |
| PARACE    | -0.00218 | 0.00157  | 0.1635  | 0.998 (0.995-1.001)   |

N=124

# Outcome G2HIST4A

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.00091 | 0.0316   | 0.9772  | 0.999 (0.939-1.063)   |
| HEIGHTCM  | 0.0159   | 0.0416   | 0.7030  | 1.016 (0.936-1.102)   |
| WEIGHTKG  | -0.00534 | 0.0335   | 0.8735  | 0.995 (0.931-1.062)   |
| NICX      | 0.00579  | 0.0173   | 0.7383  | 1.006 (0.972-1.041)   |
| ALC       | 0.000024 | 0.000063 | 0.7056  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.0294   | 0.0774   | 0.7037  | 1.030 (0.885-1.199)   |
| PARACE    | -0.00149 | 0.00108  | 0.1655  | 0.999 (0.996-1.001)   |

N=124

# Outcome G2HIST4B

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.000122 | 0.0492   | 0.9980  | 1.000 (0.908-1.101)   |
| HEIGHTCM  | 0.0631   | 0.0680   | 0.3533  | 1.065 (0.932-1.217)   |
| WEIGHTKG  | 0.0344   | 0.0460   | 0.4542  | 1.035 (0.946-1.133)   |
| NICX      | -0.00536 | 0.0287   | 0.8517  | 0.995 (0.940-1.052)   |
| ALC       | 0.000084 | 0.000083 | 0.3120  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.0198   | 0.1178   | 0.8664  | 1.020 (0.810-1.285)   |
| PARACE    | -0.00072 | 0.000993 | 0.4702  | 0.999 (0.997-1.001)   |

N=124

# Outcome G2HIST5A

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0482  | 0.0461   | 0.2958  | 0.953 (0.871-1.043)   |
| HEIGHTCM  | 0.0878   | 0.0802   | 0.2733  | 1.092 (0.933-1.278)   |
| WEIGHTKG  | -0.0791  | 0.0701   | 0.2590  | 0.924 (0.805-1.060)   |
| NICX      | 0.0366   | 0.0291   | 0.2077  | 1.037 (0.980-1.098)   |
| ALC       | 0.000089 | 0.000083 | 0.2842  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.3288  | 0.1235   | 0.0078  | 0.720 (0.565-0.917)   |
| PARACE    | -0.00519 | 0.00362  | 0.1513  | 0.995 (0.998-1.002)   |

N=124 \*

# Outcome G2HIST5B

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0482  | 0.0461   | 0.2958  | 0.953 (0.871-1.043)   |
| HEIGHTCM  | 0.0878   | 0.0802   | 0.2733  | 1.092 (0.933-1.278)   |
| WEIGHTKG  | -0.0791  | 0.0701   | 0.2590  | 0.924 (0.805-1.060)   |
| NICX      | 0.0366   | 0.0291   | 0.2077  | 1.037 (0.980-1.098)   |
| ALC       | 0.000089 | 0.000083 | 0.2842  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.3288  | 0.1235   | 0.0078  | 0.720 (0.565-0.917)   |
| PARACE    | -0.00519 | 0.00362  | 0.1513  | 0.995 (0.988-1.002)   |

N=124 \*

# Outcome G2HIST5E

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.1095   | 0.0970   | 0.2588  | 1.116 (0.923-1.349)   |
| HEIGHTCM  | -0.0629  | 0.1280   | 0.6231  | 0.939 (0.731-1.207)   |
| WEIGHTKG  | -0.2293  | 0.1521   | 0.1317  | 0.795 (0.590-1.071)   |
| NICX      | -0.0398  | 0.0773   | 0.6066  | 0.961 (0.826-1.118)   |
| ALC       | -0.00008 | 0.000198 | 0.6849  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.0311   | 0.2405   | 0.8970  | 1.032 (0.644-1.653)   |
| PARACE    | -0.00320 | 0.00465  | 0.4906  | 0.997 (0.988-1.006)   |

N=124

# Outcome HISTG3C

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | 0.0468   | 0.0413   | 0.2573  | 1.048 (0.966-1.136)   |
| HEIGHTCM  | -0.0628  | 0.0498   | 0.2071  | 0.939 (0.852-1.035)   |
| WEIGHTKG  | 0.0226   | 0.0391   | 0.5635  | 1.023 (0.947-1.104)   |
| NICX      | -0.0128  | 0.0224   | 0.5682  | 0.987 (0.945-1.032)   |
| ALC       | 0.000016 | 0.000078 | 0.8417  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.2263   | 0.1111   | 0.0417  | 1.254 (1.009-1.559)   |
| PARACE    | -0.00044 | 0.00064  | 0.4914  | 1.000 (0.998-1.001)   |

N=124

# Outcome HISTG4B

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.0484  | 0.0398   | 0.2241  | 0.953 (0.881-1.030)   |
| HEIGHTCM  | 0.0137   | 0.0507   | 0.7875  | 1.014 (0.918-1.120)   |
| WEIGHTKG  | -0.00134 | 0.0413   | 0.9742  | 0.999 (0.921-1.083)   |
| NICX      | 0.0118   | 0.0175   | 0.4983  | 1.012 (0.978-1.047)   |
| ALC       | 0.000124 | 0.000066 | 0.0581  | 1.000 (1.000-1.000)   |
| SCHOOL    | -0.0672  | 0.0842   | 0.4249  | 0.935 (0.793-1.103)   |
| PARACE    | 0.000374 | 0.000341 | 0.2717  | 1.000 (1.000-1.001)   |

N=124

# Outcome HISTG4D

| Predictor | Beta     | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|----------|----------|---------|-----------------------|
| AGE       | -0.00226 | 0.0250   | 0.9278  | 0.998 (0.950-1.048)   |
| HEIGHTCM  | -0.0270  | 0.0343   | 0.4313  | 0.973 (0.910-1.041)   |
| WEIGHTKG  | 0.0189   | 0.0273   | 0.4879  | 1.019 (0.966-1.075)   |
| NICX      | -0.00907 | 0.0139   | 0.5147  | 0.991 (0.964-1.018)   |
| ALC       | 0.000046 | 0.000054 | 0.4007  | 1.000 (1.000-1.000)   |
| SCHOOL    | 0.00641  | 0.0612   | 0.9166  | 1.006 (0.893-1.135)   |
| PARACE    | -0.00013 | 0.000304 | 0.6724  | 1.000 (0.999-1.000)   |

\* Model p-value < 0.05

# Appendix 5.5 Summary of linear regression analysis of the effect of total long-term cumulative paraquat exposure on respiratory function

Table1 Models describing the relationship between long-term accumulated paraquat exposure and respiratory function

Outcome: FEV1L, full model

| Predictor | Beta        | SE(beta)   | Stand. Beta | P-value | Partial R <sup>2</sup> |
|-----------|-------------|------------|-------------|---------|------------------------|
| AGE       | -0.030557   | 0.00488539 | -0.53800672 | 0.0001  | 0.2506                 |
| HEIGHTCM  | 0.016363    | 0.00752287 | 0.19709139  | 0.0316  | 0.0389                 |
| WEIGHTKG  | 0.018390    | 0.00595908 | 0.28893941  | 0.0025  | 0.0753                 |
| NICX      | -0.002029   | 0.00311623 | -0.05093601 | 0.5163  | 0.0036                 |
| ALC       | 0.000012840 | 0.00001156 | 0.09150987  | 0.2692  | 0.0104                 |
| PARACE    | 0.000046939 | 0.00006741 | 0.05202026  | 0.4876  | 0.0041                 |

Model R-square 0.3922 \*

Outcome: FVCL, full model

| Predictor | Beta         | SE(beta)   | Stand. Beta | P-value | Partial R <sup>2</sup> |
|-----------|--------------|------------|-------------|---------|------------------------|
| AGE       | -0.019442    | 0.00528658 | -0.32055642 | 0.0004  | 0.1036                 |
| HEIGHTCM  | 0.037939     | 0.00814065 | 0.42794012  | 0.0001  | 0.1566                 |
| WEIGHTKG  | 0.009432     | 0.00644844 | 0.13877921  | 0.1462  | 0.0180                 |
| NICX      | -0.003208    | 0.00337213 | -0.07542408 | 0.3434  | 0.0077                 |
| ALC       | 0.000002831  | 0.00001251 | 0.01889198  | 0.8214  | 0.0004                 |
| PARACE    | -0.000022848 | 0.00007295 | -0.02371271 | 0.7547  | 0.0008                 |

Model R-square 0.3758 \*

Outcome: DLCOUN, full model

| Predictor | Beta      | SE(beta)  | Stand. Beta | P-value | Partial R <sup>2</sup> |
|-----------|-----------|-----------|-------------|---------|------------------------|
| AGE       | -0.041524 | 0.0076933 | -0.54965180 | 0.0001  | 0.2273                 |
| HEIGHTCM  | 0.018571  | 0.0110218 | 0.17236190  | 0.0952  | 0.0279                 |
| WEIGHTKG  | 0.025018  | 0.0087698 | 0.30356085  | 0.0053  | 0.0760                 |
| NICX      | -0.002910 | 0.0044119 | -0.05737864 | 0.5113  | 0.0044                 |
| ALC       | 0.000037  | 0.0000169 | 0.20853946  | 0.0296  | 0.0469                 |
| PARACE    | 0.000074  | 0.0000940 | 0.06537023  | 0.4336  | 0.0062                 |

Model R-square 0.3646 \*

Outcome: DLVAMLM, full model

| Predictor | Beta        | SE(beta)  | Stand. Beta | P-value | Partial<br>R <sup>2</sup> |
|-----------|-------------|-----------|-------------|---------|---------------------------|
| AGE       | -0.007456   | 0.0015586 | -0.54506957 | 0.0001  | 0.1876                    |
| HEIGHTCM  | -0.002357   | 0.0022335 | -0.12082394 | 0.2939  | 0.0111                    |
| WEIGHTKG  | 0.001266    | 0.0017771 | 0.08481193  | 0.4781  | 0.0051                    |
| NICX      | 0.000510    | 0.0008941 | 0.05555204  | 0.5698  | 0.0033                    |
| ALC       | 0.000005510 | 0.0000034 | 0.17197642  | 0.1070  | 0.0260                    |
| PARACE    | 0.000002412 | 0.0000191 | 0.01205595  | 0.8972  | 0.0002                    |

Model R-square 0.2041 \*

Outcome: FEFMAX, full model

| Predictor | Beta        | SE(beta)   | Stand. Beta | P-value | Partial<br>R <sup>2</sup> |
|-----------|-------------|------------|-------------|---------|---------------------------|
| AGE       | -0.055908   | 0.01783648 | -0.29387386 | 0.0022  | 0.0775                    |
| HEIGHTCM  | 0.030962    | 0.02746588 | 0.11133838  | 0.2619  | 0.0107                    |
| WEIGHTKG  | 0.087250    | 0.02175653 | 0.40926860  | 0.0001  | 0.1208                    |
| NICX      | -0.001584   | 0.01137731 | -0.01187078 | 0.8895  | 0.0002                    |
| ALC       | 0.000044104 | 0.00004222 | 0.09384480  | 0.2984  | 0.0092                    |
| PARACE    | 0.000471    | 0.00024611 | 0.15585044  | 0.0581  | 0.0304                    |

Model R-square 0.2778 \*

Outcome: FEFMAX, forward selection model

| Predictor | Beta        | SE(beta)   | Stand. Beta | P-value | Partial<br>R <sup>2</sup> |
|-----------|-------------|------------|-------------|---------|---------------------------|
| AGE       | -0.05234435 | 0.01550276 | -0.27514392 | 0.0010  | 0.0580                    |
| WEIGHTKG  | 0.09985086  | 0.01715390 | 0.46837796  | 0.0001  | 0.1740                    |
| PARACE    | 0.00052384  | 0.00024058 | 0.17331976  | 0.0314  | 0.0292                    |

Model R-square 0.2612 \*

\* Model p-value < 0.05

Appendix 5.6 Summary of linear regression analysis of the effect of long-term total cumulative paraquat exposure on the maximum workload achieved in exercise testing (MAXWL).

Table1 Full model and model with lowest CIA criterion.

Outcome: MAXWL (full model)

| Predictor | Beta       | SE(beta)   | Stand. Beta | P-value | Partial R <sup>2</sup> |
|-----------|------------|------------|-------------|---------|------------------------|
| AGE       | -5.943452  | 1.63491649 | -0.34849142 | 0.0004  | 0.1307                 |
| WEIGHTKG  | 7.032828   | 1.85095246 | 0.38321098  | 0.0002  | 0.0810                 |
| HEIGHTCM  | -4.194959  | 2.37415961 | -0.17499029 | 0.0800  | 0.0079                 |
| NICX      | -1.054923  | 0.95491531 | -0.09266777 | 0.2716  | 0.0074                 |
| ALC       | 0.00002969 | 0.00003796 | 0.07001668  | 0.4358  | 0.0150                 |
| DIFFHR    | 3.474230   | 0.80871262 | 0.35066556  | 0.0001  | 0.1422                 |
| RESTSAT   | -3.693665  | 6.82791875 | -0.04280552 | 0.5896  | 0.0026                 |
| PARACE    | -0.007571  | 0.02070686 | -0.02933506 | 0.7153  | 0.0012                 |

Model R<sup>2</sup>: 0.3414

Outcome: MAXWL (forward selection model)

| Predictor | Beta     | SE(beta) | Stand. Beta | P-value | Partial R <sup>2</sup> |
|-----------|----------|----------|-------------|---------|------------------------|
| AGE       | -5.93201 | 1.39258  | -0.34782035 | 0.0001  | 0.1858                 |
| WEIGHTKG  | 6.47271  | 1.78731  | 0.35269050  | 0.0004  | 0.0668                 |
| HEIGHTCM  | -3.82188 | 2.29211  | -0.15942765 | 0.0981  | 0.0617                 |
| DIFFHR    | 3.57833  | 0.78939  | 0.36117316  | 0.0001  | 0.0160                 |

Model R<sup>2</sup>: 0.3303



Appendix 5.7 Correlation matrix of variables in the model describing the relationship between total average lifetime paraquat exposure to exercise oxygen desaturation

| VARIABLES | INTERCEP | AGE     | WEIGHTKG | NICK    |
|-----------|----------|---------|----------|---------|
| INTERCEP  | 1.0000   | -0.4404 | -0.4619  | 0.0507  |
| AGE       | -0.4404  | 1.0000  | -0.2279  | -0.1823 |
| WEIGHTKG  | -0.4619  | -0.2279 | 1.0000   | -0.1410 |
| NICK      | 0.0507   | -0.1823 | -0.1410  | 1.0000  |
| ALC       | 0.0996   | -0.4194 | 0.0752   | -0.0923 |
| DIFFHR    | -0.7570  | 0.3173  | -0.1020  | 0.0681  |
| PARINT    | 0.0215   | 0.1720  | -0.0550  | 0.0011  |
| VARIABLES | ALC      | DIFFHR  | PARINT   |         |
| INTERCEP  | 0.0996   | -0.7570 | 0.0215   |         |
| AGE       | -0.4194  | 0.3173  | 0.1720   |         |
| WEIGHTKG  | 0.0752   | -0.1020 | -0.0550  |         |
| NICK      | -0.0923  | 0.0681  | 0.0011   |         |
| ALC       | 1.0000   | -0.0982 | -0.3100  |         |
| DIFFHR    | -0.0982  | 1.0000  | -0.1067  |         |
| PARINT    | -0.3100  | -0.1067 | 1.0000   |         |

Appendix 5.8 Multivariate analysis of the effect of paraquat exposure on exercise oxygen desaturation.

Table 1 Multiple linear regression analysis of the relationship between paraquat exposure and exercise oxygen desaturation using a number of exposure variables.

a) Full models

b) Model selected by stepwise and  $C_p$  procedures (lowest  $C_p$ )

a) Outcome: DIFFSAT

| Predictor | $\beta$      | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial $R^2$ |
|-----------|--------------|---------------|----------------|---------|---------------|
| AGE       | 0.026108     | 0.03021703    | 0.111          | 0.3901  | 0.0007        |
| WEIGHTKG  | -0.060853    | 0.02785492    | -0.239         | 0.0318  | 0.0431        |
| NICX      | 0.006971     | 0.01804779    | 0.043          | 0.7003  | 0.0012        |
| ALC       | -0.000001098 | 0.00000168    | -0.085         | 0.5158  | 0.0026        |
| DIFFHR    | 0.015721     | 0.01769700    | 0.100          | 0.3770  | 0.0140        |
| PARACE    | 0.001141     | 0.00056445    | 0.243          | 0.0464  | 0.0474        |

Model  $R^2$ : 0.1055 ( $p=0.154$ )

b) Outcome: DIFFSAT

| Predictor | $\beta$   | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial $R^2$ |
|-----------|-----------|---------------|----------------|---------|---------------|
| WEIGHTKG  | -0.052885 | 0.02622634    | -0.20782560    | 0.0469  | 0.0431        |
| PARACE    | 0.001067  | 0.00048382    | 0.22721595     | 0.0302  | 0.0464        |

Model  $R^2$ : 0.0894 ( $p=0.0178$ )

a) Outcome: DIFFSAT

| Predictor | $\beta$      | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial $R^2$ |
|-----------|--------------|---------------|----------------|---------|---------------|
| AGE       | 0.034968     | 0.03033325    | 0.148          | 0.2523  | 0.0007        |
| WEIGHTKG  | -0.062021    | 0.02760924    | -0.243         | 0.0274  | 0.0431        |
| NICX      | 0.006676     | 0.01787788    | 0.041          | 0.7098  | 0.0012        |
| ALC       | -0.000000674 | 0.00000155    | -0.052         | 0.6656  | 0.0026        |
| DIFFHR    | 0.014989     | 0.01753500    | 0.095          | 0.3951  | 0.0140        |
| PARINT    | 0.019419     | 0.00811618    | 0.264          | 0.0190  | 0.0652        |

Model  $R^2$ : 0.122 ( $p=0.0902$ )

b) Outcome: DIFFSAT

| Predictor | $\beta$ | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial $R^2$ |
|-----------|---------|---------------|----------------|---------|---------------|
|-----------|---------|---------------|----------------|---------|---------------|

|          |           |            |             |        |        |
|----------|-----------|------------|-------------|--------|--------|
| WEIGHTKG | -0.051420 | 0.02601466 | -0.20206899 | 0.0513 | 0.0408 |
| PARINT   | 0.018563  | 0.00750381 | 0.25290945  | 0.0153 | 0.0611 |

Model R<sup>2</sup>: 0.1019 (p=0.010)

a) Outcome: DIFFSAT

| Predictor | $\beta$      | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial R <sup>2</sup> |
|-----------|--------------|---------------|----------------|---------|------------------------|
| AGE       | 0.031615     | 0.03115917    | 0.134          | 0.3133  | 0.0007                 |
| WEIGHTKG  | -0.061969    | 0.02826237    | -0.243         | 0.0312  | 0.0431                 |
| NICX      | 0.000701     | 0.01870944    | 0.004          | 0.9702  | 0.0012                 |
| ALC       | -0.000000618 | 0.00000169    | -0.047         | 0.7152  | 0.0026                 |
| DIFFHR    | 0.015958     | 0.01796931    | 0.101          | 0.3771  | 0.0140                 |
| SPARACE   | 0.011981     | 0.00825626    | 0.179          | 0.1506  | 0.0250                 |

Model R-2 0.0844 (p=0.2851)

b) Outcome: DIFFSAT

| Predictor | $\beta$   | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial |
|-----------|-----------|---------------|----------------|---------|---------|
| WEIGHTKG  | -0.053979 | 0.02661255    | -0.212         | 0.0456  | 0.03795 |
| SNDPT     | 0.011685  | 0.00696639    | 0.175          | 0.0971  | 0.03167 |

Model R-2 0.0685 (p=0.0412)

a) Outcome: DIFFSAT

| Predictor | $\beta$      | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial R <sup>2</sup> |
|-----------|--------------|---------------|----------------|---------|------------------------|
| AGE       | 0.027814     | 0.03021759    | 0.118          | 0.3600  | 0.0007                 |
| WEIGHTKG  | -0.059930    | 0.02778871    | -0.235         | 0.0340  | 0.0431                 |
| NICX      | 0.006663     | 0.01801505    | 0.0412         | 0.7124  | 0.0012                 |
| ALC       | -0.000001150 | 0.00000168    | -0.089         | 0.4954  | 0.0026                 |
| DIFFHR    | 0.017798     | 0.01758673    | 0.113          | 0.3145  | 0.0140                 |
| HERBACE   | 0.001169     | 0.00055748    | 0.249          | 0.0391  | 0.0508                 |

Model R<sup>2</sup>: 0.1087 (p=0.1398)

b) Outcome: DIFFSAT

| Predictor | $\beta$   | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partia R <sup>2</sup> |
|-----------|-----------|---------------|----------------|---------|-----------------------|
| WEIGHTKG  | -0.051693 | 0.02619007    | -0.203         | 0.0516  | 0.0412                |
| HERBACE   | 0.001071  | 0.00048211    | 0.228          | 0.0289  | 0.0490                |

Model R-2 0.0902 (p=0.0371)

a) Outcome: DIFFSAT

| Predictor | $\beta$      | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial $R^2$ |
|-----------|--------------|---------------|----------------|---------|---------------|
| AGE       | 0.036433     | 0.03044884    | 0.155          | 0.2349  | 0.0007        |
| WEIGHTKG  | -0.061118    | 0.02759370    | -0.240         | 0.0295  | 0.0431        |
| NICX      | 0.006415     | 0.01787975    | 0.039          | 0.7207  | 0.0012        |
| ALC       | -0.000000669 | 0.00000155    | -0.051         | 0.6680  | 0.0026        |
| DIFFHR    | 0.016655     | 0.01747620    | 0.106          | 0.3434  | 0.0140        |
| HERBINT   | 0.019370     | 0.00810713    | 0.263          | 0.0192  | 0.0650        |

Model R-2 0.0123 (p=0.0907)

b) Outcome: DIFFSAT

| Predictor | $\beta$   | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial $R^2$ |
|-----------|-----------|---------------|----------------|---------|---------------|
| WEIGHTKG  | -0.050234 | 0.02603662    | -0.197         | 0.0570  | 0.0379        |
| HERBINT   | 0.018300  | 0.00753406    | 0.249          | 0.0172  | 0.0642        |

Model R-2 0.0997 (p=0.0109)

a) Outcome: DIFFSAT

| Predictor | $\beta$      | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial $R^2$ |
|-----------|--------------|---------------|----------------|---------|---------------|
| AGE       | 0.025286     | 0.03022219    | 0.107          | 0.4052  | 0.0007        |
| WEIGHTKG  | -0.060548    | 0.02787290    | -0.237         | 0.0327  | 0.0431        |
| NICX      | 0.007551     | 0.01806819    | 0.046          | 0.6771  | 0.0012        |
| ALC       | -0.000001019 | 0.00000167    | -0.079         | 0.5438  | 0.0026        |
| DIFFHR    | 0.015996     | 0.01770109    | 0.102          | 0.3688  | 0.0140        |
| PARACE2   | 0.001161     | 0.00058466    | 0.237          | 0.0504  | 0.0458        |

Model R<sup>2</sup> 0.104 (P=0.1616)

b) Outcome: DIFFSAT

| Predictor | $\beta$   | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial $R^2$ |
|-----------|-----------|---------------|----------------|---------|---------------|
| WEIGHTKG  | -0.052569 | 0.02623902    | -0.206         | 0.0483  | 0.0426        |
| PARACE2   | 0.001098  | 0.00050507    | 0.224          | 0.0325  | 0.0455        |

Model R<sup>2</sup>: 0.0881 (p=0.019)

a) Outcome: DIFFSAT

| Predictor | $\beta$      | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial R <sup>2</sup> |
|-----------|--------------|---------------|----------------|---------|------------------------|
| AGE       | 0.033884     | 0.03032109    | 0.144          | 0.2670  | 0.0007                 |
| WEIGHTKG  | -0.062197    | 0.02765706    | -0.244         | 0.0272  | 0.0431                 |
| NICX      | 0.007047     | 0.01790570    | 0.043          | 0.6949  | 0.0012                 |
| ALC       | -0.000000635 | 0.00000155    | -0.049         | 0.6841  | 0.0026                 |
| DIFFHR    | 0.015520     | 0.01754263    | 0.099          | 0.3789  | 0.0140                 |
| PARINT2   | 0.019840     | 0.00848977    | 0.257          | 0.0219  | 0.0624                 |

Model R<sup>2</sup>: 0.120 (p=0.099)

b) Outcome: DIFFSAT

| Predictor | $\beta$     | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial R <sup>2</sup> |
|-----------|-------------|---------------|----------------|---------|------------------------|
| WEIGHTKG  | -0.05170960 | 0.02605384    | -0.203         | 0.0504  | 0.0412                 |
| PARINT2   | 0.01909271  | 0.00787878    | 0.248          | 0.0175  | 0.0582                 |

Model R<sup>2</sup>: 0.100 (p=0.011)

a) Outcome: DIFFSAT

| Predictor | $\beta$      | SE( $\beta$ ) | Stand. $\beta$ | P-value <sub>2</sub> | Partial R <sup>2</sup> |
|-----------|--------------|---------------|----------------|----------------------|------------------------|
| AGE       | 0.029191     | 0.03098453    | 0.124          | 0.3445               | 0.0007                 |
| WEIGHTKG  | -0.061908    | 0.02806421    | -0.243         | 0.0302               | 0.0431                 |
| NICX      | 0.004571     | 0.01876367    | 0.028          | 0.8082               | 0.0012                 |
| ALC       | -0.000001299 | 0.00000174    | -0.100         | 0.4569               | 0.0026                 |
| DIFFHR    | 0.014885     | 0.01785821    | 0.095          | 0.4070               | 0.0140                 |
| SPARACE   | 0.004750     | 0.00955987    | 0.071          | 0.6206               | 0.0250                 |
| PARACE    | 0.000972     | 0.00066124    | 0.207          | 0.1453               | 0.0260                 |

Model R<sup>2</sup>: 0.110 (p=0.215)

b) Outcome: DIFFSAT

| Predictor | $\beta$   | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial R <sup>2</sup> |
|-----------|-----------|---------------|----------------|---------|------------------------|
| WEIGHTKG  | -0.052885 | 0.02622634    | -0.20782560    | 0.0469  | 0.0431                 |
| PARACE    | 0.001067  | 0.00048382    | 0.22721595     | 0.0302  | 0.0464                 |

Model R<sup>2</sup>: 0.0894 (p=0.0178)

a) Outcome: DIFFSAT

| Predictor | $\beta$      | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial $R^2$ |
|-----------|--------------|---------------|----------------|---------|---------------|
| AGE       | 0.036120     | 0.03077473    | 0.153          | 0.2440  | 0.0007        |
| WEIGHTKG  | -0.062564    | 0.02783154    | -0.245         | 0.0273  | 0.0431        |
| NICX      | 0.005342     | 0.01858607    | 0.033          | 0.7745  | 0.0012        |
| ALC       | -0.000000837 | 0.00000167    | -0.065         | 0.6165  | 0.0026        |
| DIFFHR    | 0.014524     | 0.01771053    | 0.092          | 0.4146  | 0.0140        |
| SPARACE   | 0.002690     | 0.00950157    | 0.040          | 0.7778  | 0.0250        |
| PARINT    | 0.018022     | 0.00953921    | 0.245          | 0.0624  | 0.0422        |

Model  $R^2$ : 0.123 (p=0.141)

b) Outcome: DIFFSAT

| Predictor | $\beta$   | SE( $\beta$ ) | Stand. $\beta$ | P-value | Partial $R^2$ |
|-----------|-----------|---------------|----------------|---------|---------------|
| WEIGHTKG  | -0.051420 | 0.02601466    | -0.20206899    | 0.0513  | 0.0408        |
| PARINT    | 0.018563  | 0.00750381    | 0.25290945     | 0.0153  | 0.0611        |

Model  $R^2$ : 0.1019 (p=0.010)

Table 2 Multiple Logistic Regression analysis of the effects of paraqu. exposure on exercise desaturation dichotomised at various cut-offs using a number of exposure indices. (Full models)

| Predictor | Beta       | SE(beta)  | P-value | Odds Ratio and 95% CI |                 |
|-----------|------------|-----------|---------|-----------------------|-----------------|
| AGE       | 0.0377     | 0.0284    | 0.1840  | 1.038                 | (0.984 - 1.093) |
| WEIGHTKG  | -0.0378    | 0.0281    | 0.1777  | 0.964                 | (0.916 - 1.016) |
| NICX      | -0.0112    | 0.0205    | 0.5825  | 0.989                 | (0.950 - 1.029) |
| ALC       | -0.0000017 | 0.0000016 | 0.2707  | 1.000                 | (1.000 - 1.000) |
| DIFFHR    | 0.00052    | 0.0170    | 0.9752  | 1.001                 | (0.970 - 1.028) |
| EXPINT13  | 0.7361     | 0.5469    | 0.1783  | 2.088                 | (0.715 - 6.098) |

N = 90

Outcome TRACE5

| Predictor | Beta       | SE(beta)  | P-value | Odds Ratio and 95% CI |                  |
|-----------|------------|-----------|---------|-----------------------|------------------|
| AGE       | 0.0436     | 0.0293    | 0.1364  | 1.045                 | (0.985 - 1.109)  |
| WEIGHTKG  | -0.0409    | 0.0289    | 0.1563  | 0.960                 | (0.910 - 1.020)  |
| NICX      | -0.0230    | 0.0233    | 0.3231  | 0.977                 | (0.934 - 1.023)  |
| ALC       | -0.0000032 | 0.0000017 | 0.0863  | 1.000                 | (1.000 - 1.000)  |
| DIFFHR    | -0.00868   | 0.0176    | 0.6254  | 0.991                 | (0.958 - 1.026)  |
| EXPINT34  | 1.5305     | 0.6970    | 0.0282  | 4.621                 | (1.178 - 18.128) |

N = 90

| Predictor | Beta       | SE(beta)  | P-value | Odds Ratio and 95% CI |                 |
|-----------|------------|-----------|---------|-----------------------|-----------------|
| AGE       | 0.0377     | 0.0284    | 0.1840  | 1.038                 | (0.982 - 1.098) |
| WEIGHTKG  | -0.0378    | 0.0281    | 0.1777  | 0.963                 | (0.911 - 1.017) |
| NICX      | -0.0112    | 0.0204    | 0.5825  | 0.989                 | (0.950 - 1.029) |
| ALC       | -0.0000017 | 0.0000016 | 0.2707  | 1.000                 | (1.000 - 1.000) |
| DIFFHR    | 0.00053    | 0.0170    | 0.9752  | 1.001                 | (0.968 - 1.034) |
| EXPA250   | 0.9566     | 0.5832    | 0.1010  | 2.604                 | (0.830 - 8.197) |

N = 90

Outcome TRACE5

| Predictor | Beta       | SE(beta)  | P-value | Odds Ratio and 95% CI |                  |
|-----------|------------|-----------|---------|-----------------------|------------------|
| AGE       | 0.0437     | 0.0294    | 0.1365  | 1.045                 | (0.986 - 1.107)  |
| WEIGHTKG  | -0.0409    | 0.0289    | 0.1565  | 0.960                 | (0.907 - 1.016)  |
| NICX      | -0.0230    | 0.0233    | 0.3231  | 0.977                 | (0.934 - 1.023)  |
| ALC       | -0.0000031 | 0.0000018 | 0.0867  | 1.000                 | (1.000 - 1.000)  |
| DIFFHR    | -0.00858   | 0.0176    | 0.6254  | 0.991                 | (0.958 - 1.026)  |
| EXPA700   | 2.5201     | 0.9497    | 0.0080  | 12.430                | (1.932 - 79.954) |

N = 90

## Outcome TRACE5

| Predictor | Beta       | SE(beta)  | P-value | Odds Ratio and 95% CI |
|-----------|------------|-----------|---------|-----------------------|
| AGE       | 0.0470     | 0.0297    | 0.1135  | 1.048 (0.989 - 1.111) |
| WEIGHTKG  | -0.0388    | 0.0285    | 0.1724  | 0.962 (0.910 - 1.017) |
| NICX      | -0.0111    | 0.0227    | 0.6235  | 0.983 (0.946 - 1.034) |
| ALC       | -0.0000035 | 0.0000019 | 0.0723  | 1.000 (1.000 - 1.000) |
| DIFFHR    | 0.000681   | 0.0173    | 0.9686  | 1.001 (0.967 - 1.035) |
| HERBACE   | 0.00155    | 0.000604  | 0.0105  | 1.002 (1.000 - 1.003) |

N = 90

## Outcome TRACE5

| Predictor | Beta       | SE(beta)  | P-value | Odds Ratio and 95% CI |
|-----------|------------|-----------|---------|-----------------------|
| AGE       | 0.0567     | 0.0300    | 0.0592  | 1.058 (0.998 - 1.122) |
| WEIGHTKG  | -0.0393    | 0.0285    | 0.1682  | 0.961 (0.909 - 1.017) |
| NICX      | -0.0118    | 0.0231    | 0.6105  | 0.988 (0.944 - 1.034) |
| ALC       | -0.0000026 | 0.0000175 | 0.1319  | 1.000 (1.000 - 1.000) |
| DIFFHR    | -0.00133   | 0.0175    | 0.9394  | 0.999 (0.965 - 1.034) |
| HERBINT   | 0.0260     | 0.0106    | 0.0137  | 1.026 (1.005 - 1.048) |

N = 90

## Outcome TRACE3

| Predictor | Beta       | SE(beta)  | P-value | Odds Ratio and 95% CI |
|-----------|------------|-----------|---------|-----------------------|
| AGE       | 0.0433     | 0.0293    | 0.1389  | 1.044 (0.986 - 1.106) |
| WEIGHTKG  | -0.0394    | 0.0284    | 0.1647  | 0.982 (0.909 - 1.016) |
| NICX      | -0.0106    | 0.0223    | 0.6352  | 0.989 (0.947 - 1.034) |
| ALC       | -0.0000033 | 0.0000019 | 0.0872  | 1.000 (1.000 - 1.000) |
| DIFFHR    | -0.00226   | 0.0174    | 0.8968  | 0.998 (0.964 - 1.032) |
| PARACE    | 0.00143    | 0.000597  | 0.0166  | 1.001 (1.000 - 1.003) |

N = 90

## Outcome TRACE4

| Predictor | Beta    | SE(beta) | P-value | Odds Ratio and 95% CI |
|-----------|---------|----------|---------|-----------------------|
| AGE       | 0.0487  | 0.0295   | 0.0989  | 1.050 (0.991 - 1.112) |
| WEIGHTKG  | -0.0401 | 0.0282   | 0.1543  | 0.961 (0.909 - 1.015) |
| NICX      | -0.0185 | 0.0215   | 0.3886  | 0.982 (0.941 - 1.024) |



|         |            |           |        |                       |
|---------|------------|-----------|--------|-----------------------|
| ALC     | -0.0000023 | 0.0000016 | 0.1684 | 1.000 (1.000 - 1.000) |
| DIFFHR  | -0.00143   | 0.0170    | 0.9333 | 0.999 (0.966 - 1.033) |
| SPARACE | 0.0142     | 0.00797   | 0.0743 | 1.014 (0.999 - 1.030) |

N = 90

#### Outcome TRACE5

| Predictor | Beta       | SE(beta)  | P-value | Odds Ratio and 95% CI  |
|-----------|------------|-----------|---------|------------------------|
| AGE       | 0.0355     | 0.0290    | 0.2218  | 1.036 (0.979 - 1.097)  |
| WEIGHTKG  | -0.0405    | 0.0287    | 0.1586  | 0.960 (0.908 - 1.016)  |
| NICX      | -0.0147    | 0.0209    | 0.4837  | 0.985 (0.946 - 1.027)  |
| ALC       | -0.0000023 | 0.0000016 | 0.1765  | 1.000 (1.000 - 1.000)  |
| DIFFHR    | -0.00286   | 0.0172    | 0.8680  | 0.997 (0.964 - 1.031)  |
| EXPPA516  | 1.6826     | 0.7445    | 0.0238  | 5.376 (1.250 - 23.256) |

N = 90

#### Outcome TRACE3

| Predictor | Beta       | SE(beta)  | P-value | Odds Ratio and 95% CI |
|-----------|------------|-----------|---------|-----------------------|
| AGE       | 0.0533     | 0.0297    | 0.0723  | 1.055 (0.995 - 1.118) |
| WEIGHTKG  | -0.0401    | 0.0285    | 0.1594  | 0.961 (0.908 - 1.016) |
| NICX      | -0.0114    | 0.0229    | 0.6193  | 0.989 (0.945 - 1.034) |
| ALC       | -0.0000026 | 0.0000017 | 0.1404  | 1.000 (1.000 - 1.000) |
| DIFFHR    | -0.00359   | 0.0177    | 0.8396  | 0.996 (0.962 - 1.032) |
| PARINT    | 0.0248     | 0.0103    | 0.0166  | 1.025 (1.005 - 1.046) |

N = 90

#### Outcome TRACE4

|          |                          |                         |        |                       |
|----------|--------------------------|-------------------------|--------|-----------------------|
| AGE      | -0.00103                 | 0.0273                  | 0.9700 | 0.999 (0.947 - 1.054) |
| WEIGHTKG | -0.0323                  | 0.0263                  | 0.2187 | 0.968 (0.920 - 1.019) |
| NICX     | 0.00828                  | 0.0165                  | 0.6170 | 1.008 (0.976 - 1.042) |
| ALC      | -6.79 X 10 <sup>-7</sup> | 1.43 X 10 <sup>-6</sup> | 0.6354 | 1.000 (1.000 - 1.000) |
| DIFFHR   | 0.00963                  | 0.0160                  | 0.5475 | 1.010 (0.978 - 1.042) |
| EXPPA516 | 0.9993                   | 0.6944                  | 0.1501 | 2.717 (0.696 - 10.64) |

N = 90

#### Outcome TRACE3

| Predictor | Beta       | SE(beta)  | P-value | Odds Ratio and 95% CI |
|-----------|------------|-----------|---------|-----------------------|
| AGE       | 0.00505    | 0.0303    | 0.8676  | 1.005 (0.947 - 1.067) |
| WEIGHTKG  | -0.0440    | 0.0290    | 0.1298  | 0.957 (0.904 - 1.013) |
| NICX      | 0.0254     | 0.0274    | 0.3536  | 1.026 (0.972 - 1.082) |
| ALC       | -0.0000027 | 0.0000022 | 0.1809  | 1.000 (1.000 - 1.000) |
| DIFFHR    | 0.0330     | 0.0188    | 0.0791  | 1.034 (0.996 - 1.072) |

# Outcome TRACE3

| Predictor | Beta       | SE(beta)  | P-value | Odds Ratio and 95% CI |
|-----------|------------|-----------|---------|-----------------------|
| AGE       | 0.00505    | 0.0303    | 0.8676  | 1.005 (0.947 - 1.067) |
| WEIGHTKG  | -0.0440    | 0.0290    | 0.1298  | 0.957 (0.904 - 1.013) |
| NICX      | 0.0254     | 0.0274    | 0.3536  | 1.026 (0.972 - 1.082) |
| ALC       | -0.0000027 | 0.0000022 | 0.1809  | 1.000 (1.000 - 1.000) |
| DIFFHR    | 0.0330     | 0.0188    | 0.0791  | 1.034 (0.996 - 1.072) |
| EXPPA516  | 1.2725     | 1.1322    | 0.2610  | 3.571 (0.388 - 3.333) |

N = 90